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 SUMMARY 
Lipocalin 2 (LCN2) is a member of the lipocalin family, which has diverse 
roles in infections, iron homeostasis, apoptosis, tumourigenesis, inflammation, renal 
physiology and pathology. Yet, little is known about the functions of LCN2 in the 
central nervous system (CNS). In view of recent studies that showed an association 
of LCN2 with apoptosis via LCN2R, the present study investigates the role of LCN2 
in kainate (KA)-induced neurodegeneration. Intracerebroventricular injection of KA in 
rats induces neuronal loss in the hippocampal formation. Therefore, the KA model 
was used as a neurodegeneration model to elucidate the role of LCN2 in 
neurodegeneration in the hippocampus.  
Despite microarray studies reporting substantial upregulation of LCN2 mRNA 
expression after some forms of brain insults, the expression and localisation of LCN2 
had not been characterised physiologically. Thus, LCN2’s tissue distribution and 
expression were analysed in the normal rat brain. High LCN2 expression in the 
olfactory bulb, cerebellum and brainstem suggested that these brain regions may be 
potential routes of entry for microorganisms since LCN2 is known as a bacteriostatic 
agent. After KA injury, LCN2 was highly upregulated and expressed in the astrocytes 
in the lesioned hippocampal region. 
Since the interaction of LCN2 with its receptor (LCN2R) has been suggested 
to have an effect on apoptosis via Bim, a pro-apoptotic protein, it was important to 
examine LCN2R’s cellular localisation. LCN2R was expressed in the hippocampal 
pyramidal neurons physiologically. After KA injury, LCN2R neuronal expression was 
reduced, but upregulated in the activated microglia. Coincidentally, Bim was also 
upregulated in activated microglia after KA treatment, but these microglia were not 
apoptotic. Only at 1 day post-KA injection, selective neurons with high Bim 
   vii 
 
 expression were apoptotic. However, it is unclear if the upregulation of Bim was an 
effect of the interaction between LCN2 and LCN2R. 
The effect of LCN2 on Bim-mediated apoptosis in neurons was further 
examined when primary hippocampal neurons were treated with recombinant LCN2 
(rLCN2, apo-LCN2), and rLCN2:iron:enterochelin (holo-LCN2) to mimic the 
substantial LCN2 release after KA injury. Both treatments interacted with the LCN2R 
expressed on the neurons and were internalised into the neuronal cell bodies. Apo-
LCN2 had no effect on apoptosis, while upregulation of Bim and decreased cell 
survival were detected in holo-LCN2-treated neurons, indicating the pro-apoptotic 
effect of holo-LCN2. It is possible that holo-LCN2 may import iron into the neurons, 
where it increases intracellular free iron to promote ROS production, thus increasing 
their vulnerability to oxidative stress and apoptosis. 
The present study addressed the expression and localisation of LCN2 and its 
receptor, LCN2R, in the hippocampus after KA injury and their association with Bim-
mediated apoptosis. Besides Bim, the apoptotic role of LCN2 was also dependent on 
its iron status as only iron-loaded LCN2 produced a pro-apoptotic effect. This pro-
apoptotic effect of iron-loaded LCN2 may account for a select population of cell 
demise in KA-induced neurodegeneration. Elucidation of the role of LCN2 in the KA-
induced neurodegeneration model could serve as a stepping stone to understand the 
role of LCN2 in other neurodegenerative diseases as interventions can be targeted at 
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1. Neurodegeneration 
 Neurodegeneration refers to any pathological condition that primarily affects 
the neurons. Neurodegenerative diseases represent a group of neurological 
disorders with heterogeneous clinical and pathological expressions, such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and 
amyotrophic lateral sclerosis (ALS), effecting specific subsets of neurons in various 
functional anatomic systems (Calne et al., 1992; Przedborski et al., 2003).  
 
1.1 Causes of neurodegeneration 
Different neurodegenerative disorders have their own risk factors specific to 
the disease. However, the common risk factors for developing degenerative 
disorders are: increasing age, genetics and environmental factors (Jellinger, 2003, 
2009, 2010; Przedborski et al., 2003). As many of these diseases have late-onset, it 
suggests the involvement of neurons gradually losing their function with age. Some 
neurodegenerative diseases have clear familial occurrence, which suggests a 
genetic basis. For instance, in HD, the disease runs as an autosomal dominant trait 
among the affected families (Przedborski et al., 2003). Even for PD, AD and ALS, 
about 10% of all cases are familial with specific genetic defect(s) that are identifiable 
and inheritable (Cho, 2010; Przedborski et al., 2003). From genetic linkage studies 
and molecular work, some genetic alterations were observed, such as mutations in 
the amyloid precursor protein (APP), presenilin 1 and 2 genes to alter amino acid β-
amyloid (Aβ) peptide production in AD (Elder et al., 2010; Schaeffer et al., 2011); 
mutations of α-synuclein gene in PD (Beal, 2001; Shimohama et al., 2003); and 
mutations in SOD1 in ALS (Gruzman et al., 2007). However, most neurodegenerative 
diseases are sporadic, which can be a result of environmental and genetic risks 
Chapter 1: Introduction 
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combined together. Genetically determined components that confer further 
susceptibility to an environmental factor could initiate neurodegenerative processes 
(Calne et al., 1992), as some neurodegenerative conditions arise in geographic or 
temporal clusters due to exposure to toxic compounds (Przedborski et al., 2003). 
 
1.2. Models of many neurodegenerative disorders 
 To understand more about the basis of the pathophysiology in 
neurodegenerative diseases, many models have been used. For instance, for AD: 
transgenic mouse models with APP, presenilin or Tau mutations or Aβ-induced 
neurodegeneration (Elder et al., 2010; Schaeffer et al., 2011); and for PD: in vivo 
neurotoxin models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 6-
hydroxydopamine (6-OHDA) and rotenone and transgenic animals of Drosophila and 
murine α-synuclein overexpression (Beal, 2001; Shimohama et al., 2003). However, 
these models are designed to exhibit hallmarks of the actual clinical or pathological 
condition of the disease, not models of neurodegeneration in general. Although many 
hypotheses were discussed to explain neuronal death in neurodegeneration, it is 
known that excitotoxicity is an underlying cause of neuronal damage in cerebral 
ischaemia, epilepsy, PD, and AD (Doble, 1999; Meldrum, 2000; Wang et al., 2005). 
Therefore, to investigate the role of lipocalin 2 (LCN2) in neurodegeneration in 
general, the administration of excitotoxins (such as excitatory amino acids) will serve 
as a better tool in the present study as they can produce neuronal damage with some 
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1.3. Excitotoxin models for neurodegeneration  
 In many neurodegenerative diseases, neurodegeneration of the hippocampus 
is of particular concern as it affects learning and memory (Price, 1986). Excitotoxins 
that are often used for hippocampal lesioning studies include, ibotenic acid (IBO), N-
methyl-D-aspartate (NMDA), kainate (KA) and quisqualate (Jarrard, 2002). IBO was 
not used in this study as it results in nonspecific patterns of cell loss of the 
hippocampus (dentate gyrus, hilar cells, CA1-CA3 pyramidal neurons) in the rat 
(Jarrard, 2002; Kohler et al., 1979). The high density of NMDA receptors on the CA1 
pyramidal neurons may account for the selectivity of NMDA-induced lesions for CA1 
(Greenamyre et al., 1985). In both IBO and NMDA lesioning models, no secondary 
damage was observed outside the hippocampus (Jarrard, 2002; Kohler et al., 1979). 
In contrast, KA results in selective cell loss at CA3, hilar cells and CA1 region and 
produces secondary damage in extrahippocampal structures (Patel et al., 1986). KA-
induced excitotoxic neurodegeneration is often accompanied with excess calcium 
influx, inflammation, glia activation, oxidative stress (due to generation of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS)), apoptotic and necrotic 
cell death (Wang et al., 2005; Zheng et al., 2011). These characteristics are similar to 
the pathological conditions in most neurodegenerative diseases. Therefore, KA-
induced neurodegeneration was applied as a model of neurodegeneration in the 
present study. 
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2. Kainate-induced neurodegeneration 
2.1. Kainate (KA) 
Kainate, or kainic acid (KA) (2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic 
acid), an acidic pyrolidine isolated from the seaweed Digenea simplex (Coyle, 1987), 
is an analogue of the excitatory amino acid L-glutamate. Glutamate, the major 
excitatory amino acid transmitter in the CNS, exerts its action by binding to glutamate 
receptors (GluRs). GluRs include the ionotropic receptors (iGluRs) and metabotropic 
receptors (mGluRs). In response to synaptically released glutamate, iGluRs generally 
provide rapid postsynaptic depolarisations and play major roles in neural 
transmission, synaptic plasticity, and learning and memory. There are three major 
subtypes of iGluRs: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA), and kainate (KA) receptors (Bloss and Hunter, 2010; 
Meldrum, 2000). KA is a non-degradable analogue of glutamate and is 30 times more 
potent in neurotoxicity than glutamate (Bleakman and Lodge, 1998). 
 
2.2. Receptors that bind KA 
KA is a potent agonist at AMPA and kainate classes of glutamate receptors in 
the CNS (Berger et al., 1986; Bleakman and Lodge, 1998). Both AMPARs and KARs, 
often collectively referred as non-NMDA receptors can bind KA, but KARs have 
about 1000-fold higher affinity for KA (Bloss and Hunter, 2010; Herb et al., 1992). 
 
2.3. KA-induced excitotoxicity 
KA is often used to induce excitotoxicity: stimulation of the non-NMDA 
receptors can result in rapid increase of free intracellular calcium (Ca2+). Ca2+ 
Chapter 1: Introduction 
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overload can damage the neurons in various ways, such as activation of Ca2+-
dependent enzymes (e.g. phospholipase A2, C, protein kinase C, endonucleases) 
and generation of ROS. With excessive Ca2+ and ROS, mitochondrial membrane 
potential collapses and results in the opening of mitochondrial permeability transition 
pores, releasing cytochrome-c and apoptotic-inducing factor (AIF), leading to 
activation of caspases and apoptosis (Wang et al., 2005). Overload of Ca2+ can also 
directly cause mitochondrial swelling and damage, reduction in ATP, increase in 
ROS, oxidising proteins, lipids and DNA, resulting in necrosis (Wang et al., 2005). 
Notably, KA-induced neuronal cell death bears hallmarks of both necrosis and 
apoptosis (Filipkowski et al., 1994; Kaminska et al., 1994; Pollard et al., 1994a; 
1994b). 
 
2.4. KA on the hippocampus 
2.4.1. Select vulnerability in the hippocampus to KA 
KA administration to rodents has been often used as an animal model to 
study mechanisms of neurodegenerative pathways. The hippocampus is especially 
sensitive to the excitatory and neurotoxic insult of KA (Suzuki et al., 1995) and is 
most affected by KA compared to other structures in the brain (Ben-Ari et al., 1981). 
KA can be administered into the rodents to induce neuronal loss in select 
regions of the brain, depending on the method of administration - systemic or 
intracerebral injections of KA. Systemic administration includes subcutaneous, 
intraperitoneal or intravenous administrations of KA which cause neuronal death in 
the CA4, CA3 and CA1 subfields, but to a lesser extent in the CA2 subfield (Sperk et 
al., 1983; Sperk, 1994). Since very little (a few percent) of the systematically injected 
KA can reach the receptors in the brain (Berger et al., 1986; Nadler et al., 1980b), the 
Chapter 1: Introduction 
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low bioavailability contributes to the variation in the response to KA (Sperk, 1994). 
Intracerebral injections have included intra-amygdala, intra-hippocampal and 
intracerebroventricular injections of KA (Sperk, 1994). Pyramidal cells of the CA3 and 
CA4 regions were most sensitive to intra-hippocampal injection of KA (Kohler et al., 
1979), while intra-amygdala KA injection results in pronounced cell death within CA3 
subfields (Ben-Ari et al., 1980; Pollard et al., 1994b). In contrast, 
intracerebroventricular (icv) administration of KA causes greatest cellular damage in 
the CA3 subfield ipsilateral to the injection, and lesser damage to the CA1 subfield 
(Nadler et al., 1978; 1980a; Schwob et al., 1980). It also produces more consistent 
hippocampal lesions compared to systemic KA injections (Ong et al., 1996; 1999). 
Across all routes of administration, the dentate gyrus (DG) and the CA2 are usually 
unaffected by the KA-induced excitotoxicity (Sperk, 1994). 
The selective vulnerability of neurons to KA is largely contributed by the 
heterogeneous distribution of low and high affinity KA binding sites in the brain. 
Within the hippocampus, the highest density of high affinity KA receptors is around 
the mossy fibre terminals in the CA3 region of the hippocampus (Malva et al., 1998; 
Patel et al., 1986), while high densities of NMDA and AMPA receptors were detected 
at the basal and apical dendrites of the CA1 pyramidal neurons (Greenamyre et al., 
1985). This suggests why CA3 pyramidal neurons are most vulnerable to KA-induced 
excitotoxicity.  
In the present study, icv injection of KA was performed in order to study KA-
induced neurodegeneration on the hippocampus as it produces consistent 
hippocampal lesions (Ong et al., 1999) and an orderly hierarchy of degeneration, 
which can mimic the pathology in neurodegenerative diseases (McGeer and McGeer, 
1982). Intrahippocampal injection may be too invasive as it can cause physical injury 
to the hippocampus. The additional tissue injury at the lesioned site may induce 
Chapter 1: Introduction 
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unnecessary upregulation of LCN2, confounding the effects of physical injury with 
KA-induced neuronal injury. On the other hand, icv KA injection permits exposure of 
hippocampal cells over the broad anterior-posterior surface of the hippocampus 
bordering on the lateral ventricles (McGeer and McGeer, 1982). Therefore, the effect 
observed would be a consequence of KA, the excitotoxin, rather than physical injury. 
Unilateral injection was performed at the right lateral ventricle so that 
neurodegeneration could be observed at the ipsilateral site of injection, while saline-
injected animals served as control.  
 
2.4.2. Glial activation 
KA-induced neurodegeneration is accompanied with reactive gliosis - the 
response of endogenous glial cells reacting to the signals from the injured neurons 
(Streit et al., 1999). Activation of astrocytes and microglia (Jorgensen et al., 1993; 
Mitchell et al., 1993; Wang et al., 2005) and increases in expression of inflammatory 
cytokines were observed in lesioned areas (Ravizza et al., 2005; Rizzi et al., 2003). 
After icv injection of KA, upregulation of activated microglia peaked at one 
month and declined thereafter (Jorgensen et al., 1993; Mitchell et al., 1993). 
Normally, microglia exist as ramified microglia (resting microglia), with small (5-
10μm) oval cell bodies, with nuclei filling most of the soma, and numerous processes 
radiating from the soma. During neuronal injury, microglia become activated, with 
enlarged cell bodies and shorter, stouter processes, which appear to be spherical, 
rod-shaped and pleomorphic or amoeboid-like, unlike the ramified morphology. 
Finally, the activated microglial cells become phagocytic microglia (Streit et al., 1999; 
Streit, 2000). 
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In response to KA injury, astrocytes are activated and undergo reactive 
astrocytosis. Reactive astrocytes are characterised by their large cytoplasmic mass 
(hypertrophy), long, thick processes and increased expression of glial fibrillary acidic 
protein (GFAP) (Bendotti et al., 2000). Hence, GFAP is a well-known marker for 
reactive astrocytosis (Ding et al., 2000). Upregulation of GFAP was observed in the 
CA3 and CA1 subfields of the lesioned hippocampus as early as one day after KA 
administration and peaked at one month after the injection (Jorgensen et al., 1993; 
Mitchell et al., 1993).  
 
2.4.3. Other models of KA-induced injury  
Due to its wide-ranging effects on the hippocampus and extrahippocampal 
tissue, neuronal damage induced by KA also results in repeated temporal lobe 
seizures (Ben-Ari et al., 1984; Ben-Ari, 1985; Gruenthal et al., 1986; Sater and 
Nadler, 1988), cerebral ischaemia-reperfusion (Dykens et al., 1987) and production 
of oxidative stress (Candelario-Jalil et al., 2001). Therefore, besides being a model of 
neurodegeneration, KA has also been widely used as a model for ischaemic 
damage, temporal lobe epilepsy and oxidative damage (Benavides et al., 1990; 
Gluck et al., 2000; Groticke et al., 2008; Ratte and Lacaille, 2006). 
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3. Lipocalin 2 (LCN2) 
3.1. Lipocalin family 
Lipocalin 2 (LCN2) is a member of the lipocalin protein family, which is a large 
group of small extracellular proteins. These proteins have a large degree of diversity 
at the sequence level, but they have a highly conserved three-dimensional structure 
that is comprised of a single eight-stranded continuously hydrogen-bonded 
antiparallel beta-barrel, enclosing an internal ligand-binding site (Flower, 1996). They 
are characterised by a range of different molecular-recognition properties: 1) The 
ability to bind a range of small hydrophobic molecules, 2) binding to specific cell-
surface receptors and 3) the formation of complexes with soluble macromolecules. 
They have a variety of different functions, including retinol transport, cryptic 
colouration, olfaction, pheromone transport, enzymatic synthesis of prostaglandins, 
regulation of immune responses, and mediation of cell homeostasis (Flower et al., 
1993; Flower, 1994, 1996). 
Most lipocalins share three characteristic conserved sequence motifs, 
corresponding to the three main structurally conserved regions of the lipocalin fold 
and are known as kernel lipocalins, such as the retinol binding protein (RBP), 
apolipoprotein D (apoD), prostaglandin D synthase (PGDS) and LCN2 (Flower et al., 
1991). The more divergent family members, the outlier lipocalins, share two or less of 
the three motifs and are more diverse, such as the odorant-binding protein (OBP), 
von Ebner’s-gland protein and α1-acid glycoproteins (Flower et al., 1993).  
 
3.2. History of Lipocalin 2  
LCN2, is a 25kDa protein, also known as 24p3 (murine orthologue), 
neutrophil gelatinase-associated lipocalin (NGAL, human orthologue), α-2-
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microglobulin-related protein (rat orthologue), 24-kDa superinducible protein (SIP24), 
uterocalin and siderocalin. The cDNA of the rat orthologue was fortuitously isolated 
during screening of a cDNA library for other purposes and GeneBank revealed the 
protein to be related to rat α-2-microglobulin. Hence it was named “α-2-microglobulin-
related protein” (Chan et al., 1988).  
Mouse 24p3 protein, the product of the single gene, 24p3, was first noted due 
to its increase in mRNA expression in cultured mouse kidney cells infected by SV40 
and polyoma virus (Hraba-Renevey et al., 1989). Following that, from motif matching, 
high global homology, especially to rat α-2-microglobulin-related protein, and its 
consistency with the size and pattern of cysteine residues with other family members, 
mouse 24p3 was identified as a member of the lipocalin family (Flower et al., 1991). 
Isolation of a protein named “SIP24” secreted from Balb/c 3T3 mouse fibroblasts 
stimulated with fibroblast growth factor (FGF) and cycloheximide, an inhibitor of 
protein synthesis, which was shown later to be identical to mouse 24p3 (Davis et al., 
1991; Liu and Nilsen-Hamilton, 1995). “SIP24” was then known as “superinducible 
protein”, due to the enhanced synthesis by cells and “24” due to its molecular weight 
estimated from SDS-PAGE (Davis et al., 1991; Hamilton et al., 1985; Nilsen-Hamilton 
et al., 1982).  
In 1993, the human orthologue of LCN2 was identified as a protein of 
unknown function associated with 92kDa gelatinase/MMP9 in human neutrophils. 
Through immunoblotting and immunoprecipitation, a 135kDa form of gelatinase was 
found to be a complex of the 92kDa gelatinase and an “unknown” 25kDa protein. 
Sequence homology revealed a high degree of similarity with rat α-2-microglobulin-
related protein and mouse 24p3 protein, suggesting the 25kDa “unknown” protein to 
be the human orthologue of 24p3, hence it was named “neutrophil gelatinase-
associated lipocalin (NGAL)” (Kjeldsen et al., 1993). NGAL could exist as a 
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monomer, homodimer or as a heterodimer with gelatinase and was stored in specific 
granules within the neutrophils (Kjeldsen et al., 1994). 
Among all three orthologues of LCN2, on the amino acid level, rat α-2-
microglobulin-related protein and mouse 24p3 protein are 80% identical, while NGAL 
is 63.5% identical to α-2-microglobulin-related protein, and 62% identical to 24p3 
(Kjeldsen et al., 1993; 2000). The high degree of identity at the cDNA level further 
validates that rat α-2-microglobulin-related protein and mouse 24p3 protein are 
homologues of NGAL (Bundgaard et al., 1994).  
With the characterisation and identification of this novel lipocalin member, 
lipocalin 2 (LCN2), many studies were performed to understand its distribution and 
expression in normal and pathological cells and tissues, in order to elucidate its 
biological function. 
Two decades from the first time LCN2 was isolated, LCN2 has now been 
shown to have diverse roles in infections, iron transport, inflammation, apoptosis, 
tumourigenesis, renal physiology, hematopoiesis and reproductive biology. In this 
thesis, only a few aspects that are relevant to the possible roles and functions of 
LCN2 in KA-induced excitotoxicity will be covered in detail. Due to the immense body 
of work done on different orthologues of LCN2 and various aspects of its functions, 
LCN2 has been named differently. In this thesis, since rat animal models were used, 
the rat orthologue of lipocalin 2 will be addressed as “LCN2”. In addition, lipocalin 2 in 
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3.3. Ligands of LCN2 
LCN2, like most lipocalins, was thought to bind ligands and interact with 
specific cell-surface receptors to modulate cellular processes. Hence, by X-ray 
crystallography, atomic absorption and X-ray fluorescence analysis, mouse and 
human orthologues of LCN2 were reported to bind specifically and with high affinity 
to bacterial catecholate-type ferric siderophores (Coles et al., 1999; Goetz et al., 
2000; Goetz et al., 2002). It was the structure of NGAL (human orthologue of LCN2) 
that led to the inference of its ligand. Similar to other lipocalins of the lipocalin family, 
LCN2 has an eight-stranded anti-parallel β barrel, enclosing a ligand binding site 
(calyx), with short 310-helix at the N-terminus and α-helix at the C-terminus. Unlike 
most lipocalin calyces, which have distinct hydrophobic linings, the calyx of LCN2 is 
lined with polar and positively-charged residues and is shallower and broader than 
most lipocalin calyces (Coles et al., 1999; Goetz et al., 2000). 
When NGAL (human orthologue of LCN2) was expressed in bacteria, it was 
co-purified with a red chromophore, which was tightly associated but not covalently 
bound with the purified NGAL. The heavy atom of the chromophore was identified as 
iron by atomic absorption and X-ray fluorescence spectroscopy (Goetz et al., 2002). 
Binding and analytical studies then identified the red chromophore as ferric 
enterochelin (Fe:Ent) with a net charge of -3 (Raymond et al., 2003). Complex 
structural analyses reveal that LCN2 binds Fe:Ent by intercalating the positively 
charged side chains of the three protein residues (Arg 81, Lys 125 and Lys 134) 
between the three catecholate rings of Fe:Ent, creating a novel hybrid of ionic and 
cation-π interactions (Clifton et al., 2009; Goetz et al., 2002). Despite the additional 
stabilising van der Waals and hydrogen bonds, the Fe:Ent does not fill all of the calyx 
sub-pockets completely (Goetz et al., 2002). This suggests that the LCN2 calyx may 
be optimised for other ligands (Coles et al., 1999; Goetz et al., 2000; 2002). An 
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interesting point to note was NGAL:iron:enterochelin was in a 1:1:1 stoichiometry 
(Goetz et al., 2002). 
Enterochelin (Ent, enterobactin) is a siderophore of many enteric bacteria. 
Siderophores are low molecular weight (500-1500Da) compounds produced by 
bacteria, fungi graminaceous plants with high affinity for iron (Fe3+) to scavenge iron 
from the environment. Siderophores can be categorised into three board classes 
based on the chemistry of chelation: hydroxamates, phenolates/catecholates or α-
hydroxycarboxylates (Braun and Killmann, 1999; Hider and Kong, 2010). However, 
qualitative binding assays reveal that LCN2 binds with catecholate-type ferric 
siderophores (e.g. parabactin and cepabactin), but not hydroxamate-type ferric 
siderophores (e.g. aerobactin, ferrichrome, and desferrioxamine B) (Goetz et al., 
2002). Before the elucidation of mammalian siderophores in 2010, ferric enterochelin 
was often used as a surrogate to investigate LCN2’s role on iron delivery in 
mammalian cells. 
Hence with the ability to scavenge iron from bacteria, LCN2 was later studied 
to be a bacteriostatic agent in bacterial infection which will be discussed later in 
Section 3.5.1.  
 
3.4. Receptors of LCN2 
 Like other lipocalin family members, LCN2 has a receptor binding patch, 
suggesting it has receptors (Flower, 1996). Two cell surface receptors of different 
molecular structure have been identified: 1) Megalin, a multi-ligand receptor and 2) 
24p3R, receptor for 24p3, the murine orthologue of LCN2 (Devireddy et al., 2005; 
Hvidberg et al., 2005). 
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3.4.1. Megalin 
Megalin, also known as gp330 or low density lipoprotein-related protein 2 
(LRP2), is a multi-ligand, endocytic receptor with significant physiological functions. 
The name “megalin” was suggested due to its large size of 600kDa (Saito et al., 
1994). Megalin is a 4,600-amino acid transmembrane protein with a large amino-
terminal extracellular domain, a single transmembrane domain and a short carboxy-
terminal cytoplasmic tail (Saito et al., 1994). The protein belongs to the low-density 
lipoprotein receptor (LDLR) family. Other mammalian receptors include the LDL 
receptor, the very-low-density lipoprotein (VLDL) receptor, the LDLR-related protein 
and the apolipoprotein E receptor 2 (ApoER2) (Gliemann, 1998). 
Megalin is expressed in many absorptive epithelia facing transcellular fluids, 
such as the small intestine, epididymis, thyroid cells, epithelium of the eye and the 
choroid plexus (Kounnas et al., 1994; Zheng et al., 1994). It is also localised in the 
apical endocytic pathway of the renal proximal tubule and in the glomeruli (Kerjaschki 
and Farquhar, 1982, 1983). Its endocytic scavenger receptor function in the kidney 
proximal-tubule epithelium (Kerjaschki and Farquhar, 1983; Kerjaschki et al., 1984) 
where low molecular weight proteins are reabsorbed into the tubules from the 
glomerular filtrate, has been widely discussed. Being a promiscuous receptor, it 
interacts with lactoferrin (Willnow et al., 1992) and has a large number of ligands, 
including other lipocalins, such as vitamin-binding proteins (vitamin D- and retinol-
binding proteins) (Nykjaer et al., 1999), apolipoproteins (apoB, apoE and apoH), and 
other low molecular weight peptides and hormones (insulin, epidermal growth factor, 
prolactin and lysozyme) (Christensen and Birn, 2001, 2002).  
Megalin-deficient mice showed defective tubular reabsorption and increased 
urinary excretion of low molecular weight proteins including LCN2 (Leheste et al., 
1999), which suggests that megalin is required for re-uptake of LCN2. With surface 
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plasmon resonance, megalin was reported as a cellular receptor for NGAL and binds 
with it with high affinity, mediating its cellular uptake (Hvidberg et al., 2005).  
 
3.4.2. 24p3R (murine orthologue) 
A receptor for 24p3 (murine orthologue of LCN2), 24p3R, was first discovered 
in leukocytic cell lines as a cell surface receptor mediating the apoptotic effect of 
24p3 (Devireddy et al., 2001; Devireddy et al., 2005). It is a highly conserved protein 
also known as brain type organic cation transporter (BOCT), belonging to the organic 
cation transporter family (OCT, SLC22) made up of ATP-independent facilitative 
transporters that are responsible for the uptake, reabsorption and excretion of drugs, 
nutrients and metabolites. OCTs are characterised by 12 putative transmembrane 
domains (TMDs), a large extracellular loop with multiple glycosylation sites between 
TMDs 6 and 7 and intracellular N and C-terminal (Koepsell et al., 1998). 24p3R, also 
known as SLC22A17, BOCT1, shares sequence similarity with the other BOCT 
proteins from TM2 to TM12. 24p3R has a shorter N-terminus than other members 
and is without a comparable TM1 domain, indicating that the N-terminus is 
extracellular (Bennett et al., 2011). 
Northern blot results reveal 24p3R expression to be highest in the brain and 
kidney, intermediate expression in the liver, low expression in the heart, stomach and 
testis, and absent in the muscles (Bennett et al., 2011). The tissue expression of 
24p3R suggests its importance in the brain and kidney, where LCN2 has also been 
expressed (Chia et al., 2011; Yang et al., 2002b). Among brain and brain-derived 
cells, the choroid plexus had the highest expression of 24p3R, followed by primary 
neurons, whole brain, NG108 neuroblastoma, C6 astroglioma and the primary 
astrocytes had the lowest expression (Bennett et al., 2011). Therefore, 24p3R may 
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be involved in functions in the brain and blood brain barrier as LCN2 was shown to 
be upregulated at the choroid plexus after peripheral inflammation (Marques et al., 
2008). 24p3R protein expression was also widely expressed in heart, lung, liver, 
kidney, stomach, small intestine, testis, uterus, ovary and placenta tissues from mice 
(Devireddy et al., 2005). Since in this thesis, in vivo studies were performed in the rat 
animal model, 24p3R will be referred as “LCN2R”.  
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3.5. Roles of LCN2 in various aspects 
Since the isolation of LCN2 in 1988, many studies were done on different 
orthologues of LCN2. Therefore, due to diverse roles of LCN2, this thesis will focus 
on a few aspects in which LCN2 plays a major role, such as in renal physiology, 
kidney injuries, tumourigenesis, and aspects of LCN2 that are relevant to its possible 
role in KA-induced neurodegeneration, such as its role in bacterial infections, iron 
transport and apoptosis will be covered in detail.  
 
3.5.1. Infections and innate immunity 
 LCN2 is rapidly upregulated in many models of infection, including infections 
involving Escherichia coli, Klebsiella pneumonia (Fischbach et al., 2006; Flo et al., 
2004; Wu et al., 2010), Chlamydia pneumonia (Rodriguez et al., 2007), Salmonella 
typhimurium (Godinez et al., 2008; Nairz et al., 2007; Raffatellu et al., 2009), and 
Mycobacteria (Halaas et al., 2010; Martineau et al., 2007; Saiga et al., 2008), which 
indicates an important function of LCN2 as a bacteriostatic agent (Li and Chan, 
2011). As mentioned earlier, due to its ability to bind bacterial catecholate-type ferric 
siderophore with specificity and affinity, it can interfere with iron acquisition by 
bacteria.  
Under aerobic conditions, iron is primarily in the ferric (Fe3+) oxidation state 
and forms insoluble complexes readily. Although iron is essential for cell survival, 
levels of free iron (Fe2+) must be kept in check as it can be potentially toxic, either by 
catalysing the generation of free radicals, or by promoting the growth of bacteria. 
Therefore, in the human body, the majority of iron is sequestered by iron-binding 
proteins. Most iron is bound by haemoglobulin; transferrin transports iron between 
cells and is usually 30-40% saturated in the serum; ferritin sequesters free iron 
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intracellularly (Harrison and Arosio, 1996; Ponka et al., 1998); and lactoferrin is 
released from neutrophils at sites of inflammation with a bacteriostatic effect (Ellison, 
1994; Jurado, 1997).  
As bacteria require iron for growth, they release bacterial siderophore 
proteins, such as enterochelin (enterobactin, Ent) that bind ferric iron with an 
extraordinary high affinity, which is greater than that of the above mentioned 
mammalian iron-binding proteins (Barasch and Mori, 2004; Flo et al., 2004; Goetz et 
al., 2002). Bacteria express receptors for the bacterial siderophore to facilitate iron 

























Fig. 1.1. Schematic diagram of the function of LCN2 in bacterial infection. (1) 
Bacteria (orange) release bacterial siderophore (blue). (2) Bacterial siderophore 
binds iron (red) with higher affinity than competing iron-binding proteins expressed by 
the mammalian host (purple) e.g. transferrin. (3) Bacteria express siderophore 
receptors (green) to bind the iron-bacterial siderophore complex. (4) The iron is 
subsequently internalised into the bacterium. (5) Mammalian host LCN2 (light blue) 
binds to the iron-bacterial siderophore complex with similar affinity to the bacterial 
siderophore receptor, thus preventing bacteria from capturing iron from mammalian 
hosts. Not drawn to scale. 
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stimulate the transcription, translation and secretion of LCN2 by the host. Secreted 
LCN2 then binds the bacterial siderophore-iron complex, forms a tricomplex, to be 
taken into the host cells. Since LCN2 binds siderophore with similar affinity to the 
siderophore receptor of the bacteria, it competes with bacteria for the siderophore-
iron complex and inhibits bacterial growth (Flo et al., 2004; Goetz et al., 2002) (Fig. 
1.1).  
LCN2 is thus an important component of innate immunity against bacterial 
infection, and LCN2-deficient mice showed increased susceptibility to bacterial 
infection due to failure of iron sequestration by LCN2 (Berger et al., 2006; Flo et al., 
2004). It is also interesting to note that another lipocalin, LCN1, also known as tear 
lipocalin, is able to bind a broader spectrum of siderophores, exhibiting anti-microbial 




Other than LCN2’s involvement in bacterial infection, marked increases in the 
local and systemic expression of LCN2 have been reported in various inflammatory 
conditions in affected tissues of the respiratory, gastro-enteric, and renal structures 
(Alpizar-Alpizar et al., 2009; Dittrich et al., 2010; Grigoryev et al., 2008).  
In 1995, LCN2 was identified as an acute phase protein due to the rapid 
elevation of its mRNA and protein expression in mouse serum and liver during the 
acute phase response induced by turpentine injection (Liu and Nilsen-Hamilton, 
1995). This further emphasised its role in inflammation as acute phase proteins are 
defined as proteins with at least 25% change in plasma concentration at the 
beginning of the inflammatory process (Ceciliani et al., 2002; Gabay and Kushner, 
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1999; Morley and Kushner, 1982). An example of an acute phase protein is C-
reactive protein (CRP), which was detected in the plasma of patients during the acute 
phase of pneumococcal infection (Tillett and Francis, 1930).  
Similarly, LCN2 has been reported as a choroid plexus acute phase protein in 
peripheral inflammation induced by systemic lipopolysaccharide (LPS) (Marques et 
al., 2008). LCN2 was also upregulated in inflammatory salivary tissues (Woo et al., 
2007), livers in acute and chronic experimental liver injury (Borkham-Kamphorst et 
al., 2011) and lung tissues with airway inflammation (Dittrich et al., 2010). Authors 
had also suggested a protective role for LCN2 in allergic airway disease, as blocking 
of LCN2 increased inflammation and reduced apoptosis (Dittrich et al., 2010). The 
upregulation of LCN2 after inflammation indicates its possible involvement in 
inflammation, as the purpose of acute phase proteins is to restore homeostasis as 
soon as possible. 
LCN2 has also been associated with obesity (Wang et al., 2007; Yan et al., 
2007) and its related metabolic conditions, such as insulin-resistance (Wang et al., 
2007; Yan et al., 2007) and hyperglycemia (Wang et al., 2007) due to their 
increasingly recognition as inflammatory conditions. As LCN2 was highly expressed 
in the adipose tissues in vivo and in vitro, it is also known as an adipokine (Yan et al., 
2007; Zhang et al., 2008). As an adipokine, LCN2 has been reported to have an anti-
inflammatory effect by inducing PPARγ expression, antagonising TNFα effects in 
adipocytes and suppressing LPS stimulation on cytokine expression in macrophages 
(Zhang et al., 2008). 
 
3.5.3. Tumourigenesis and other biological processes 
3.5.3.1. Cancer and tumourigenesis 
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Other than inflammation, LCN2 has recently been widely studied in 
tumourigenesis. LCN2 was elevated in several human cancers, including leukaemia 
(Kaneta et al., 2003; Villalva et al., 2008) and breast (Bauer et al., 2008; Fernandez 
et al., 2005), gastric (Kubben et al., 2007), colorectal (Conrotto et al., 2008; Madoz-
Gurpide et al., 2006), ovarian (Lim et al., 2007; Santin et al., 2004) and pancreatic 
(Furutani et al., 1998; Han et al., 2002) cancers, suggesting its involvement in 
cancer.  
Matrix metallopeptidase-9 (MMP-9) complexes with LCN2 were found in 
about 90% of the urine samples of breast cancer patients, which were absent from 
healthy women, indicating the use of LCN2/MMP9 as potential biomarker for 
diagnosis (Fernandez et al., 2005). Furthermore, elevated LCN2 strongly correlated 
with a poor prognosis in human primary breast cancer (Bauer et al., 2008). LCN2 
was suggested to promote cell metastasis, as it induced epithelial to mesenchymal 
transition (EMT) via the estrogen receptor α/Slug axis, and increased migration and 
invasion. The formation of complexes of LCN2 with MMP9 protected the latter from 
degradation, resulting in promotion of breast tumourigenesis (Yang et al., 2009). The 
upregulation or presence of LCN2/MMP9 complex has also been observed in 
cerebral tumours (Smith et al., 2008), gastric carcinoma tissue (Kubben et al., 2007), 
and biopsy samples of oesophageal squamous cell carcinoma (ESCC) (Zhang et al., 
2007).  
On the other hand, LCN2 levels were observed in benign and well-
differentiated ovarian and pancreatic carcinomas respectively, but were absent in 
high-grade carcinomas (Lim et al., 2007; Tong et al., 2008). Hence, LCN2 may have 
dual roles in promoting tumourigenesis and inhibiting the transition of neoplasias 
(cancerous tissues) towards more advanced grades of malignancy (Bolignano et al., 
2010b). In vitro, after induction of EMT by EGF in ovarian carcinoma models, LCN2 
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levels were reduced and LCN2 overexpression in colon carcinoma, pancreatic 
carcinoma, and mouse mammary mesenchymal tumour cell lines resulted in 
reduction of adhesion, invasion and angiogenesis (Gupta et al., 2001; Hanai et al., 
2005; Li and Chan, 2011; Tong et al., 2008), possibly suggesting an anti-
angiogenesis or anti-metastatic function of LCN2. 
In view of the conflicting studies on LCN2, the actual role of LCN2 in 
tumourigenesis remains to be elucidated, and LCN2 appears to have different effects 
on different type or grades of carcinoma, which could be either anti- or pro-
tumourigenic. 
 
3.5.3.2. Other biological processes 
Other than its role in tumourigenesis, LCN2 has been implicated in other 
biological processes in the body. LCN2 may be involved in kidney development and 
differentiation as it promotes differentiation and structural organisation of renal 
epithelial cells (Yang et al., 2002a; 2002b). LCN2 has also been shown to be 
involved in the pathophysiological process of chronic renal disease, such as 
polycystic kidney disease and glomerulonephritis (Bolignano et al., 2008). Due to its 
high elevation in the serum and urine in renal injuries, and correlation with severity of 
renal impairment, LCN2 has been suggested as a biomarker or real-time indicator for 
detection of various renal injuries (Bolignano et al., 2008; Schmidt-Ott et al., 2006; 
2007; Yang et al., 2003).  
Other than in renal pathophysiology, LCN2 can also play a protective role in 
thermal dysregulation, where LCN2 is induced in the liver, heart and kidney in vivo 
with cold and heat stress. In vitro data have revealed that ectopic expression of 
LCN2 can protect cells against cold stress, while exogenous LCN2 administration 
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can enhance the toxicity of heat stress (Roudkenar et al., 2009). LCN2 is also 
involved in hematopoiesis as LCN2 suppresses red blood cell production in an 
autocrine manner and the growth of erythroid and monocyte/macrophage lineages in 
vitro (Bolignano et al., 2010a; 2005; Miharada et al., 2008). In addition, LCN2 is 
involved in reproductive biology (Chu et al., 2000; Elangovan et al., 2004; Lee et al., 
2003; 2005). 
 
3.5.4. Iron transport 
Since LCN2 sequesters iron from bacterial cells during infection, many 
studies asked if it could traffic iron (with the help of a cofactor/mammalian 
siderophore) in or out of cells physiologically. In 2002, in the same journal that 
identified ferric enterochelin as a ligand of NGAL (human orthologue of LCN2) (Goetz 
et al., 2002), NGAL/24p3 (human and mouse orthologues of LCN2) was reported to 
deliver radioactive iron (59Fe) to the cytoplasm of kidney cell lines (Yang et al., 
2002b). NGAL/24p3 delivered iron into the cells via receptor-mediated endocytosis 
independent of the transferrin iron delivery pathway as the addition of transferrin did 
not block the entry of labelled NGAL/24p3 into the cells. Secondly, NGAL/24p3 and 
transferrin did not colocalise, as transferrin had a perinuclear staining while 
NGAL/24p3 was localised throughout the cytoplasm and close to the periphery of 
transferrin’s localisation (Yang et al., 2002b). Instead, NGAL/24p3 colocalised with 
DMT1 iron transporters, which were found in late endosomes (Tabuchi et al., 2000).  
Similar to lactoferrin, LCN2 trafficked iron to late endosomes and released 
iron at low pH (Abergel et al., 2008; Birgens et al., 1988; Nicholson et al., 1997). Late 
endosomes are more acidic than the early recycling vesicles and the low pH allows 
the conversion of ferric-catecholate to ferric salicylate, a substrate for reduction by 
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NADH or NADPH coupled ferrireductase (Ward et al., 1999). Hence, the bound ferric 
state (Fe3+) is reduced to ferrous state (Fe2+) and released (Abergel et al., 2008; 
Ward et al., 1999). In addition, the strong acidification degrades the siderophore 
(Abergel et al., 2008), but not LCN2 which can be recycled after iron release (Yang et 
al., 2002b). In other words, low pH in the late endosomes can result in the release of 
iron and degradation of the siderophore, and LCN2 has been postulated to be 
exported out of the cell for recycling.  
Iron-loaded LCN2 increased cytoplasmic iron and regulated iron-responsive 
genes (by enhancing translation or promoting degradation of the mRNA), such as 
upregulation of ferritin and downregulation of transferrin receptor 1 (Yang et al., 
2002b), and decreased levels of iron-regulatory protein IRP2 and conversion of IRP1 
to cytosolic aconitase (Devireddy et al., 2010).  
The biological function of LCN2 transporting iron was demonstrated by 
LCN2:Enterochelin (Ent) delivery of 55Fe to the kidney proximal tubule in vivo. 
LCN2:Fe:Ent protected the kidney from ischaemic-reperfusion injury (ATN) in mice 
while iron-free LCN2 could only partially protect it (Mori et al., 2005), indicating 
Fe:Ent as the main component in holo-LCN2’s protective effect. Holo-LCN2 also 
induced heme oxygenase-1 (HO-1), an important regulator of proximal tubule viability 
and for recovery from ATN (Mori et al., 2005).   
This indicates that the iron-trafficking function of LCN2 may be protective as it 
can also protect kidneys from ATN by regulating other protective factors (Mishra et 
al., 2004; Mori et al., 2005). The protective effect of iron-loaded LCN2 was also 
observed in 24p3R-expressing HeLa cells, in which iron-loaded LCN2 increased 
intracellular iron and inhibited apoptosis (Devireddy et al., 2005).  
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3.5.5. Apoptosis 
Besides the protective effect of LCN2 observed in iron delivery, LCN2 has 
been implicated in many pro- and anti-apoptotic functions, depending on the tissues, 
cell lines, pathological or physiological conditions.  
24p3 (murine orthologue of LCN2) has been reported to be pro-apoptotic as 
the conditioned medium from interleukin-3 (IL-3) deprived FL5.12 cells (mouse pro-B 
lymphocytic cell line) contained 24p3, which induced apoptosis in naive FL5.12 cells 
with IL-3 present (Devireddy et al., 2001). In the same cell line, LCN2 mRNA and 
protein expression was upregulated in MK886-induced apoptosis. When the cells 
were stably transfected with antisense cDNA of 24p3, apoptosis was reduced, 
suggesting that 24p3 was pro-apoptotic (Tong et al., 2003). Overexpression of 24p3 
increased the proportion of apoptotic epithelial cells by 3- to 4-fold in mammary 
epithelial cells (Bong et al., 2004). In vitro, LCN2 overexpression and LCN2 treatment 
increased the sensitivity of microglia, astrocytes and neurons to cytotoxic stimuli, 
which was abolished with the knockdown of LCN2 (Lee et al., 2007; 2009; 2011). 
The pro-apoptotic characteristic of LCN2 was further supported by its upregulation in 
13-cis-retinoic acid-induced apoptosis in human sebaceous gland cells and the 
silencing of LCN2 inhibited apoptosis (Nelson et al., 2008).  
On the other hand, LCN2 was also shown to be anti-apoptotic. Excessive 
amounts of purified recombinant LCN2 were not toxic to human lung 
adenocarcinoma A549 and Jurkat cells and LCN2 overexpressing cells had no 
abnormalities. Silencing of LCN2 enhanced the pro-apoptotic activity of celecoxib-
related compounds, indicating the anti-apoptotic function of LCN2 (Tong et al., 2005). 
Although LCN2 is greatly upregulated in post-ischaemic kidneys, intravenous 
administration of LCN2 in mice before, during and after ischaemia, ameliorated the 
histopathological damage and apoptotic effects (Mishra et al., 2004)  
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Recently, LCN2’s role in apoptosis has been associated with its ability to 
transport iron. LCN2 knockdown resulted in decreased iron content in human 
anaplastic thyroid carcinoma cells (FRO), which induced apoptosis under serum 
deprivation, but was abolished with the addition of iron or iron-loaded LCN2. The 
presence of LCN2 in FRO cells served as a pro-survival factor by binding and 
transporting iron in the cells (Iannetti et al., 2008). As discussed in the previous 
Section 3.5.4, endocytic delivery of LCN2:Fe:siderophore complex protects the 
kidney from ischaemia-reperfusion injury by upregulating HO-1, a protective enzyme, 
mitigating cell death (Mori et al., 2005). These are in agreement with the model 
proposed by Devireddy et al. (2005); holo-LCN2 (iron-loaded) has been suggested to 
inhibit apoptosis, while apo-LCN2 (iron-lacking) promotes apoptosis. 
Until now, it is not clear if LCN2 is pro- or anti-apoptotic, as its functions vary 
from cell line to cell line and from in vitro to in vivo conditions. The varied roles of 
LCN2 in apoptosis could also be attributed to the differences in the orthologues of 
LCN2 (Kehrer, 2010; Klausen et al., 2005). For instance, 24p3 (mouse orthologue) 
was implicated in apoptosis of myeloid cells, but not NGAL (human orthologue) and 
NGAL was not an acute phase protein unlike 24p3 (Klausen et al., 2005). 
Furthermore, as opposed to murine and rat orthologues of LCN2, NGAL has an 
additional cysteine so NGAL can undergo homodimerisation and is able to 
heterodimerise with gelatinase unlike the rodent orthologues of LCN2 (Kjeldsen et 
al., 2000). Despite the diverging literature, it is clear that LCN2’s involvement in iron 
transport and apoptosis are associated.  
Despite the roles postulated for LCN2 in the periphery as mentioned in the 
previous sections, LCN2-deficient mice produced by two independent groups raised 
in specific pathogen-free facilities showed no defects in apoptosis, iron metabolism, 
kidney development and reproduction, arguing against an obligatory role for LCN2 in 
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these biological processes (Berger et al., 2006; Flo et al., 2004). It is possible that 
there are compensatory mechanisms that can substitute LCN2 in these processes, 
which may obscure LCN2’s potential biological roles as discussed by many. 
Most of the work reviewed in this thesis is not exhaustive of the roles and 
functions of LCN2, as the lipocalin has diverse roles. To help understand the role of 
LCN2 in KA-induced neurodegeneration, it would be most relevant to study LCN2’s 
role in brain-derived cells (Section 3.6). With the increase in iron and apoptosis in 
neurodegeneration, the association of LCN2 with apoptosis and iron transport will 
also be covered in greater details in the following section (Section 3.7). 
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3.6. Role of LCN2 in brain-derived cells  
 Despite diverse studies in the periphery, little is known about LCN2 in the 
CNS. Lee, Suk and colleagues (2007, 2009, and 2011) are the first group to establish 
the pro-apoptotic effect of LCN2 in brain-derived cells - microglial, astrocytic, 
neuronal and glioblastoma cells (Lee et al., 2007; 2009; 2011; Zheng et al., 2009). 
These in vitro studies will be very useful for postulating LCN2’s role in the brain.  
Stable expression of LCN2 and treatment of LCN2 protein increased the 
sensitivity of primary microglia and BV-2 murine microglial cell lines to nitric oxide 
(NO)-induced apoptosis, which was abolished with the knockdown of LCN2. 
Furthermore, LCN2 treatment induced deramification of microglia to form the 
amoeboid morphology (Lee et al., 2007).  
 Similar to their previous study in 2007, Lee and colleagues showed that 
LCN2 sensitised primary astrocytes to cell death, which was negated with the 
silencing of LCN2. LCN2 also induced phenotypic change of astrocytes (reactive 
















Fig. 1.2. Schematic diagram of LCN2’s role in apoptosis and morphological 
changes in astrocytes and microglia in vitro. LCN2 is induced by inflammatory 
stimuli and acts on the receptors to induce pro-apoptotic effects and morphological 
changes on these cells in an autocrine manner. Apo-LCN2 has a pro-apoptotic effect 
on cells. Diagram adapted from Lee et al. (2007). Not drawn to scale. 
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Since LCN2 was induced in primary microglia, BV-2 microglial cells, primary 
astrocytes and C6 glioma cells upon inflammatory stimuli, the presence of 24p3R 
mRNA on these cells suggests that LCN2 acts in an autocrine manner to induce cell 
death sensitisation and morphological changes (Lee et al., 2007; 2009) (Fig. 1.2). 
Furthermore, LCN2 induced cell death sensitisation effects on B35 rat neuroblastoma 
and mice primary cortical neurons, and accelerated neuronal mobility and process 
extension, suggesting that LCN2 could regulate neuronal cell death, migration and 
morphology (Lee et al., 2011). 
Interestingly, cell death sensitisation effects of LCN2 on C6 glioma and B35 
neuroblastoma was abolished with the addition of iron:siderophore complex, a 
phenomenon which was similarly observed in the BV-2 microglial cells. Furthermore, 
LCN2-treated C6 glioma and B35 neuroblastoma cells had upregulated Bim 
expression, but upon Bim knockdown, the cell death sensitisation effect of LCN2 was 
abolished. The evidence strongly suggests the involvement of iron and Bim in the cell 
death sensitising effect of LCN2 in the astrocytic and neuronal cells. Despite this, the 
pro-apoptotic effect of LCN2 on BV-2 microglia was not Bim-mediated, suggesting 
that LCN2 may have other ways of inducing apoptosis (Lee et al., 2007; 2009; 2011) 
The pro-apoptotic effect of LCN2 was also observed in human glioblastoma 
cells (U87MG, U373MG and T98G cells), as the addition of LCN2 significantly 
increased the sensitivity of the cells to anti-cancer drugs in a dose-dependent 
manner (Zheng et al., 2009). 
Results from the brain-derived cells show that LCN2 is likely to be pro-
apoptotic and could either sensitise cells to cytotoxic stimuli or directly cause cell 
death at a high concentration (50 µg/ml) (in glioblastoma cells). Also, the presence of 
iron appears to affect the cell death sensitising effects of LCN2. Discrepancies in the 
involvement of Bim in the LCN2-induced cell sensitisation between the microglia, and 
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the neurons and astrocytes in vitro, serve as a cautionary signal not to assume the 
same mechanism for different cell types when examining LCN2-mediated apoptosis 
in vivo. The pro-apoptotic effect of LCN2 and the anti-apoptotic effect of LCN2 with 
the iron:siderophore is consistent with the model proposed by Devireddy et al. 
(2005), which will be discussed in detail in the following Section 3.7. 
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3.7. Association between LCN2, LCN2R and apoptosis 
Recently, an association between LCN2, iron transport and apoptosis was 
made with the isolation of a cell surface receptor for 24p3 (murine orthologue of 
LCN2), i.e., 24p3R (Devireddy et al., 2005). 24p3R expressing-HeLa cells could bind 
and internalise both iron-free 24p3 (apo-24p3) and iron-loaded 24p3 (holo-24p3). 
Holo-24p3 increased intracellular iron, and did not induce apoptosis. In contrast, apo-
24p3 treatment decreased intracellular iron and upregulated the pro-apoptotic 
protein, Bim. Bim shRNA reduced apo-24p3-induced apoptosis, indicating that the 
apoptosis was, at least in part, Bim-mediated. 
Devireddy and colleagues’ observations led to a proposed model expanded 
upon by Richardson (2005) in an influential review in Cell. The effects of LCN2 in iron 
uptake or apoptosis was dependent on its iron status. Holo-24p3 transports iron into 
cells via endosomes and releases iron at low pH (Abergel et al., 2008; Yang et al., 
2002b). This increases intracellular iron and inhibits apoptosis. In contrast, 
internalised apo-24p3 binds to intracellular iron-siderophore complex to form holo-
24p3, to be exported from the cell. Depletion of intracellular iron induces the 
expression of Bim, which leads to apoptosis (Devireddy et al., 2005; Richardson, 
2005). This model postulates the presence of endogenous intracellular mammalian 
siderophore(s) (Devireddy et al., 2005) (Fig. 1.3). 
This proposed mechanism led to a search for endogenous mammalian 
siderophores. Finally in June 2010, the same group, Devireddy, Green, and 
colleagues (2010), isolated the iron-binding moiety of the mammalian siderophore 
2,5-dihydroxybenzoic acid (2,5-DHBA), similar to 2,3-DHBA, the iron-binding moiety 
of the bacterial enterochelin (Raymond et al., 2003). The murine enzyme responsible 
for the synthesis of 2,5-DHBA was identified as BDH2, the murine homologue of 
bacterial EntA, catalysing the synthesis of 2,3-DHBA (Liu et al., 1989). The human 
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Fig. 1.3. Schematic diagram of the hypothesised association between LCN2, 
iron transport and apoptosis, mediated by LCN2R, in mammalian cells. In holo-
LCN2 (left panel), LCN2 forms a tricomplex with iron:siderophore to bind to the 
receptor, LCN2R. Internalisation of holo-LCN2 is mediated by LCN2R, and transports 
iron into the cell. This leads to an increase in intracellular iron, which reduces Bim 
expression and inhibits apoptosis. A concomitant reduction in transferrin receptor 1 
(TfR1) expression and rise in ferritin expression also occurs. In the absence of 
iron:siderophore complex (right panel), LCN2 alone is internalised and reduces the 
intracellular iron stores, triggering an increase in Bim expression and stimulating 
apoptosis. This is facilitated by novel mammalian siderophores which form 
complexes with intracellular iron to bind apo-LCN2 to form holo-LCN2 to be exported 
via exocytosis, thus transporting iron out of the cell. Intracellular iron levels can also 
induce changes in iron-regulated proteins/genes such as iron regulatory protein 1 
and 2. Diagrams adapted from Richardson (2005). Not drawn to scale. 
 
homologue of BDH2 was identified as a short-chain dehydrogenase/reductase family 
member originally called DHRS6 and now known as BDH2 (Guo et al., 2006).  
Previously, they postulated that the internalisation of apo-24p3 led to cellular 
iron efflux via an intracellular mammalian siderophore (Devireddy et al., 2005). 
Interestingly, in BDH2 knockdown (KD) cells, no 55Fe was detected in the 
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extracellular medium upon apo-24p3 treatment. BDH2 KD cells had increased 
cytoplasmic iron levels (as indicated by colourimetric, fluorescence assays, iron-
regulated (ferritin and transferrin receptor 1) and iron-regulatory proteins (IRP1 and 
IRP2)), ROS production and sensitivity to oxidative stress-induced apoptosis. 
Therefore, the knockdown effects of BDH2 were consistent with their previous 
hypothesis because, with the depletion of intracellular siderophores, intracellular iron 
levels are elevated without iron efflux, which in turn increase ROS production, 
enhancing the sensitivity of cells to oxidative stress (Devireddy et al., 2010). In 
contrast, in BDH2 KD cells, mitochondria iron stores were depleted and zebrafish 
embryos failed to synthesise heme, indicating the requirement of BDH2 in 
mitochondrial iron homeostasis as well (Devireddy et al., 2010).  
Likewise in June 2010, another group led by Bao, Strong, Barash and 
colleagues (2010) identified catechols as ligands of LCN2 from mouse and human 
urine samples with kidney injuries or disease. LCN2 and catechol:Fe3+ were injected 
into mice separately, but the complex was found in many organs, the kidney, lung 
and liver, while unbound catechols were rapidly cleared. This indicates LCN2 was 
able to bind catechol:Fe3+ in vivo, delivering iron to the kidney. LCN2 was reported to 
bind catechols with poor affinity, but the presence of Fe3+ increases the binding 
affinity by a 100-fold. As proposed by Goetz et al. (2002), the LCN2:catechol:iron 
was internalised via receptor-mediated endocytosis and trafficked into late 
endosomes, in which the LCN2:catechol:iron complex releases iron upon 
acidification at pH 6.0. In vivo, autoradiography revealed that LCN2:catechol:iron 
complex delivered iron to the proximal tubules of the kidney, and after glomerular 
filtration of the tricomplex, iron transported by endocytosis at the apical membrane 
was suggested to be mediated by the LCN2 receptors (24p3R or megalin) (Bao et 
al., 2010). 
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The proposed mechanism of apo- and holo-LCN2’s effects on iron transport 
and apoptosis, together with the elucidation of the novel endogenous mammalian 
siderophores, leads to the question of whether LCN2 has similar roles in the CNS 
and if mammalian siderophres are present. In vitro, apo-24p3 induced Bim-mediated 
apoptosis in primary astrocytes and neurons, which was abolished by the addition of 
iron:siderophore (Lee et al., 2009; 2011) supporting Devirddy et al. (2005)’s 
proposed mechanism. However, the same cannot be assumed in vivo, and the role 
of LCN2 in neurodegeneration, specifically KA-induced neurodegeneration, remains 
to be identified.  
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4. Hypothesis and Aim 
LCN2 has been widely studied in the periphery, and with the mounting 
evidence of roles of LCN2 in the periphery, little is known about it in the CNS. 
Therefore, this thesis aims to bridge this gap of knowledge. The studies most 
relevant to the CNS involved the expression of LCN2 in brain-derived cells - primary 
astrocytes and microglia upon inflammatory stimuli. Lee, Suk and colleagues (2007, 
2009) suggest LCN2 acts in an autocrine manner to mediate apoptosis by inducing 
cell death sensitisation and morphological changes of microglia and astrocytes. Pro-
apoptotic effects of LCN2 in the primary astrocytes and C6 glioma cells were 
mediated by Bim and iron. This supports the proposed mechanism by Devireddy et 
al. (2005), which showed that iron-lacking LCN2 mediated by its receptor, LCN2R, 
decreased intracellular iron levels, and induced upregulation of Bim to trigger 
apoptosis. Although many studies have reported LCN2’s involvement in apoptosis 
and LCN2 as an iron trafficking protein, this proposed mechanism helps to associate 
LCN2, iron transport and apoptosis via LCN2R.  
Apoptosis and iron are both associated with neurodegeneration, as apoptosis 
is a major cause of neuronal death and excess iron is a feature of many 
neurodegenerative diseases as iron levels increase in brain regions that are affected 
by Alzheimer’s and Parkinson’s disease (Zecca et al., 2004). In consideration of 
LCN2’s possible role in apoptosis in neurodegeneration, it can be hypothesised that 
LCN2 has a role in KA-induced neurodegeneration. Intracerebroventricular injection 
of KA in rats induces neuronal loss in select regions of the brain, in particular the 
hippocampal formation via excitotoxicity-mediated cell death (Nadler et al., 1978). 
Since damage to the hippocampus is a main concern in neurodegeneration as it 
affects memory and learning, the neuronal injury model adopted in this thesis is 
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targeted at the hippocampus. Three main areas will be discussed, namely 1) LCN2, 
2) its receptor, LCN2R, and 3) the possible effects due to their interaction.  
Although LCN2 has been detected in vitro, its expression is still unclear in the 
intact hippocampus. Therefore, to ascertain if LCN2 is present in the CNS, the first 
part of the thesis aims to analyse LCN2’s distribution and cellular localisation in the 
normal rat brain and its expression and localisation changes after KA-induced 
neurodegeneration. Next, since LCN2 is reported to bind to its receptor LCN2R 
(Devireddy et al., 2005), it is crucial to elucidate LCN2R’s cellular localisation before 
and after KA injury as it can give an indication of the role of LCN2. For instance, the 
presence of LCN2R in primary astrocytes and microglia indicates that LCN2 may act 
in an autocrine manner to sensitise the cells to self-regulatory apoptosis (Lee et al., 
2007; 2009). 
Since LCN2 has been reported to induce Bim-mediated apoptosis (Devireddy 
et al., 2005; Lee et al., 2009; 2011), the expression and cellular localisation of Bim 
after KA injury will be examined in the third chapter. Lastly, the findings from LCN2, 
LCN2R and Bim after KA-induced neurodegeneration will be analysed so as to 
postulate a possible mechanism for LCN2’s role in apoptosis in the neurons during 
KA-induced neurodegeneration. 
Elucidation of the role of LCN2 in the KA-induced neurodegeneration model 
will serve as a stepping stone for others to study LCN2 in other neurodegenerative 
diseases. Interventions can also be targeted at the interaction between LCN2 and 
LCN2R to ameliorate neurodegeneration.  
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2.1. INTRODUCTION 
 Although LCN2 has been reported in a wide variety of tissues, especially in 
the kidney and tumourigenic tissues, little is known about its distribution, expression 
and cellular localisation in the CNS. Through several microarray analysis studies of 
various types of brain insults or injuries, LCN2 was detected in the CNS: Genome-
wide expression profiling showed LCN2 to be upregulated in mouse brain tissues 
after focal cerebral ischaemia (MacManus et al., 2004) and, closer to the scope of 
the present study, LCN2 gene expression was reported as the second highest 
upregulated gene in the cerebral cortex and hippocampus 24 hours post-
intracerebroventricular lipopolysaccharide (LPS) injection in mice (Bonow et al., 
2009). In the choroid plexus, high LCN2 mRNA and protein expression and 
localisation of LCN2 at the choroid epithelial were observed after peripheral 
administration of LPS in mice (Marques et al., 2008).  
Despite reports on significant increases in expression of LCN2 after some 
forms of brain insult, no reports characterised LCN2’s expression and localisation in 
the normal brain. LCN2 was expressed in primary astrocytes and microglia upon 
inflammatory stimuli (Lee et al., 2007; Lee et al., 2009). Hence it would be intriguing 
to find out if the same could be observed in vivo. This gap of knowledge will be 
addressed in this chapter with the detection of LCN2 mRNA and protein expression 
in various parts of the brain of normal rats and characterisation of the cellular 
localisation of LCN2. Further analysis will be done in the KA-induced 
neurodegeneration model to detect changes in LCN2 expression and cellular 
localisation.  
In this KA-induced neurodegeneration model, the changes in LCN2 and 
related proteins in the hippocampus will be the main focus since the hippocampus is 
extremely vulnerable to numerous stressors, including excitotoxicity and oxidative 
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stress (Jellinger, 2009, 2010). With an important role in memory and learning, it is 
also the primary region of concern in many neurodegenerative diseases. For 
instance, for Alzheimer’s disease, the hippocampus is often one of the earliest and 
most severely involved areas, as it is particularly vulnerable to oxidative damage 
(Reed et al., 2009). 
KA is used in this thesis as a neurotoxin to induce excitotoxicity and 
neurodegeneration in CA3 and CA1 pyramidal neurons in the hippocampus. 
Intracerebroventricular (icv) injection of KA was chosen as the route of administration 
as it would not cause direct mechanical injury to the hippocampus, which might 
induce LCN2 expression unnecessarily (for explanation on the choice of neurotoxin 
and route of administration, refer to Introduction, Sections 1.3 and 2.4.1). KA was 
injected unilaterally into the right ventricle so that more pronounced effects of 
neurodegeneration can be observed at the ipsilateral site of injection, while saline-
injected animals served as control.  
To examine the role of LCN2 in the progression of acute to chronic 
neurodegeneration, timepoints 1 day, 3 days and 2 weeks post-KA injection were 
investigated. 1 day post-KA injection (abbreviated as KA1d) will illustrate the acute 
changes in the hippocampus; while at 3 days post-KA injection (abbreviated as 
KA3d), neuronal death is more prominent; and, since activation of glia was most 
significant at 2 weeks post-KA injection (abbreviated as KA2wk), this timepoint will 
help elucidate changes in gliosis after neurodegeneration (McGeer and McGeer, 
1982; Nadler et al., 1978; 1980a).  
This chapter aims to bridge the gap of knowledge between the vast literature 
of LCN2 in the periphery and in the CNS by examining the distribution and 
expression of LCN2 in normal and KA-lesioned brains. 
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2.2. MATERIALS AND METHODS 
2.2.1. Animals and kainate (KA) injections 
Male Wistar rats weighing approximately 200 g each were anaesthetised by 
intraperitoneal injection of ketamine (75 mg/kg) and xylazine (10 mg/kg). KA (1.2 µl 
of 1 mg/ml) was stereotaxically injected into the right lateral ventricle (coordinates: 
1.0 mm caudal to bregma, 1.5 mm lateral to the midline, 4.5 mm from the surface of 
the cortex) using a microlitre syringe (5 μl Hamilton syringe, Model no.: 88000, 24 
gauge needle, outer diameter of needle: 0.57 mm, inner diameter of needle: 0.31 
mm). Experimental control rats were injected with 1.2 µl of normal saline instead of 
KA. All procedures involving animals were approved by the Institutional Animal Care 
and Use Committee, National University of Singapore (NUS). 
 
2.2.2. Real-time RT-PCR 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals were sacrificed at 1 day, 3 days and 2 weeks after injection. 
Three animals were also sacrificed to study the tissue distribution of LCN2 in the 
normal brain. Tissues were freshly dissected from the brain and immersed into 
RNAlater (Ambicon, CA, USA), flash frozen and kept at -80°C until analysis. Total 
RNA was isolated using TRIzol reagent (Invitrogen, CA, USA) according to the 
manufacturer’s protocol, and RNeasy Mini Kit (Qiagen Inc., CA, USA) was used to 
purify the RNA. The samples were reverse transcribed using High-Capacity cDNA 
Reverse Transcription Kits (Applied Biosystems, CA, USA). The reaction conditions 
were 25°C for 10 min, 37°C for 120 min and 85°C for 5 min. Real-time RT-PCR 
amplification was carried out using the 7500 Real-time RT-PCR system (Applied 
Biosystems, CA, USA) with Taq-Man Universal PCR Master Mix (Applied 
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Biosystems, CA, USA) and gene-specific primers and probes according to 
manufacturer’s protocols (Assay ID: LCN2 (Rn00590612_m1); apoD 
(Rn00562832_m1); Rbp4 (Rn01451318_m1); LCN5 (Rn00577120_m1); PGDS 
(Rn00564605_m1)). β-actin (Part no: 4352340E) was used as an internal control. All 
primers and probes were synthesised by Applied Biosystems. The PCR conditions 
were: an initial incubation of 50°C for 2 min and 95°C for 10 min followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min. All reactions were carried out in 
triplicates. The threshold cycle, CT, which correlates inversely with the levels of 
target mRNA, was measured as the number of cycles at which the reporter 
fluorescence emission exceeds the preset threshold level. The amplified transcripts 
were quantified using the comparative CT method (Livak and Schmittgen, 2001), with 
the formula for relative fold change = 2–∆∆CT. The mean was calculated, and possible 
significant differences were analysed using Student’s t-test. p < 0.05 was considered 
significant. RT-PCR was conducted on rat hippocampal tissues using specific 
primers to LCN2 transcript (Applied Biosystems, Assay ID: Rn00590612_m1). DNA 
gel electrophoresis was performed to separate the PCR products in a 1.5% agarose 
gel. The DNA bands were stained with ethidium bromide and visualised under UV 
irradiation.  
 
2.2.3. Western blotting 
Three KA-injected rats and three saline-injected control animals were 
sacrificed at 1 day, 3 days and 2 weeks after injection. Three normal rats were also 
sacrificed to analyse LCN2 protein levels in the untreated rat brain. The rats were 
anaesthetised by intraperitoneal injection of ketamine and xylazine and decapitated. 
The tissues were quickly removed and homogenised in cold lysis buffer containing 
Tris–HCl, pH 7.4, 10 mM EDTA, 150 mM NaCl, 0.5% Triton X-100 with protease 
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inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and placed on the 
shaker for 1 hr at 4°C. After centrifugation at 12,000g for 30 min, the supernatant was 
collected, and protein concentration was determined using the BCA protein assay kit 
(Pierce Biotechnology, Rockford, IL, USA). Prior to gel electrophoresis, the protein 
lysates were denatured by heating the sample in the presence of SDS and DTT for 
10 min at 95-100°C.  
Total protein (60 µg) was resolved in 12% SDS-polyacrylamide gel under 
reducing conditions and electro-transferred to a nitrocellulose membrane (Biorad, 
CA, USA). Non-specific binding sites on the membrane were blocked by incubation 
with 5% non-fat milk for 1 hr. The membrane was then incubated overnight with 
polyclonal goat anti-LCN2 antibody at 1:200 (AF3508, R&D systems, Minneapolis, 
MN, USA). Specificity of the LCN2 antibody was verified by pre-incubating 10 µg/ml 
(10x) and 20 µg/ml (20x) of recombinant rat LCN2 (R&D systems, Minneapolis, MN, 
USA) with 1 µg/ml of LCN2 antibody overnight. After washing with 0.1% Tween-20 in 
TBS, the membrane was incubated with horseradish peroxidase-conjugated mouse 
anti-goat immunoglobulin lgG (1:10,000; Thermo Fisher Scientific, Rockford, IL, USA) 
for 1 hr at room temperature. The protein was visualised with SuperSignal West Pico 
chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL, USA) according 
to the manufacturer’s instructions. Blots were treated with stripping buffer (Restore 
Western Blot Stripping Buffer, Thermo Fisher Scientific, Rockford, IL, USA) at room 
temperature for 10 min before reprobing of membrane with antibody to β-actin 
(Sigma, St. Louis, MO, USA). Exposed films were scanned with at least 300 dpi and 
the mean optical density of the protein bands of LCN2 was analysed by densitometry 
using ImageJ (NIH, Maryland, USA), and normalised to β-actin.  The mean was 
calculated, and possible significant differences were analysed using Student’s t-test. 
p < 0.05 was considered significant. 
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2.2.4. Immunohistochemistry 
Three KA-injected rats and three saline-injected rats were sacrificed at 2 
weeks. Rats were deeply anaesthetised and perfused through the left ventricle with 
4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brains were removed 
and blocks containing the hippocampus sectioned in the coronal plane at 100 µm 
thickness using a vibrating microtome. One set of free-floating sections was mounted 
on gelatinised slides and stained with cresyl fast violet (Nissl stain). Another set was 
washed for 3 hr in phosphate buffered saline (PBS; pH 7.4) to remove traces of 
fixative, quenched with 0.3% H2O2 and blocked with 5% rabbit serum in PBS-0.3% 
Triton X-100 and incubated overnight with polyclonal goat anti-LCN2 antibody at 1:50 
(AF3508, R&D systems, Minneapolis, MN, USA). This was followed by washing and 
incubation for 1 hr in a 1:200 dilution of biotinylated rabbit anti-goat IgG (Vector, 
Burlingame, CA, USA), and reaction with an avidin-biotinylated horseradish 
peroxidase complex (Vector, Burlingame, CA, USA). The reaction was visualised by 
treatment in 0.05% 3,3-diaminobenzidine tetrahydrochloride (DAB) solution in Tris 
buffer containing 0.05% hydrogen peroxide for 1.5 min. Sections were mounted on 
gelatin-coated slides and counterstained with methyl green before coverslipping.  
 
2.2.5. Double immunofluorescence labelling 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals each were sacrificed at 1 day, 3 days and 2 weeks after 
injection to study the effect of KA lesions. Three untreated rats were used to study 
the cellular localisation of LCN2 in the normal brain. The rats were anaesthetised by 
intraperitoneal injection of anaesthetic comprising ketamine and xylazine and 
transcardially perfused with Ringer solution, followed by 4% paraformaldehyde in 
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0.1M phosphate buffer (pH 7.4). The brains were dissected out, and blocks 
containing the KA- or saline-treated hippocampus were sectioned coronally at 20 µm 
using a freezing microtome. Some sections were stained with cresyl fast violet (Nissl 
stain) to visualise the hippocampal lesions. Sections from the olfactory bulb to the 
brainstem were collected for the three normal brains for detection of LCN2. Sections 
were soaked in phosphate buffered saline (PBS) for 30 min to remove traces of 
sucrose and permeabilised with PBS-0.3% Triton X-100 for 10 min. They were then 
blocked with 5% donkey serum in PBS-0.3% Triton X-100 for 1 hr, followed by 
incubation with goat polyclonal antibody to LCN2 at 1:200 (AF3508, R&D systems, 
MN, USA), rabbit polyclonal antibody to glial fibrillary acidic protein (GFAP, 1:1000, 
DakoCytomation, Glostrup, Denmark), or mouse monoclonal antibody to OX-42 
(1:200, Chemicon, Temecula, CA, USA) overnight at 4°C. Specificity of the LCN2 
antibody was verified by pre-incubating 20 µg/ml (20x) of recombinant rat LCN2 
(R&D systems, Minneapolis, MN, USA) with 1 µg/ml of LCN2 antibody overnight. The 
sections were washed in PBS, and incubated for 1 hr at room temperature in 1:200 
dilution of donkey anti-goat lgG (H+L) Alexa Fluor 555 and donkey anti-rabbit or 
donkey anti-mouse IgG (H+L) Alexa Fluor 488 (Invitrogen, CA, USA). The sections 
were then washed and mounted with ProLong® Gold antifade reagent with DAPI 
(Invitrogen, Carlsbad, CA, USA) and captured using a fluorescence microscope 
(Olympus BX51; Olympus Corporation, Tokyo, Japan) and a laser scanning confocal 
microscope (LSM 510, Carl Zeiss Göttingen, Germany). Colocalisation was 
established by analysing the overlap between the different labels by orthogonal 
reconstruction throughout the entire z-stack (LSM 510, Carl Zeiss Göttingen, 
Germany). 
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2.3. RESULTS 
2.3.1. Expression of LCN2 in the normal brain 
2.3.1.1. Tissue distribution of LCN2 mRNA levels in normal rat brain 
Little is known about the distribution of LCN2 in the normal brain in vivo, thus 
the mRNA expression of LCN2 was detected with real-time RT-PCR analysis in 
different parts of the untreated rat brain, including the olfactory bulb, striatum, 
hippocampus, frontal cortex, somatosensory cortex, thalamus, hypothalamus, 
cerebellum and brainstem. The values are presented as fold difference relative to the 
lowest level among the different brain regions, i.e. the hippocampus. Highest levels 
of LCN2 mRNA was found in the olfactory bulb (7-fold relative to the hippocampus), 
followed by the brainstem, cerebellum, thalamus and hypothalamus (3- to 4-fold 
relative to the hippocampus). Low levels of LCN2 mRNA were detected in the 
striatum, frontal cortex and somatosensory cortex. The hippocampus has the lowest 
level of LCN2 mRNA. Both the left and right sides of the brain revealed a similar 
trend in the distribution of LCN2 mRNA expression (analysed by Student’s t-test, not 
significant) (Fig. 2.1). 
 
2.3.1.2. Tissue distribution of LCN2 protein levels in normal rat brain 
With the knowledge that LCN2 mRNA is present in the brain, western blot 
analysis was performed to confirm the presence of LCN2 protein in the brain. A 
single band at approximately 25kDa in homogenates from different regions of the 
right side of normal rat brain was detected (Fig. 2.2A), consistent with the expected 
molecular weight of LCN2 (Kjeldsen et al., 1993; 2000).The highest level of LCN2 
protein was found in the olfactory bulb, followed by the brainstem and the cerebellum  
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Fig. 2.1. Distribution of LCN2 mRNA expression in normal rat brain. Real-time 
RT-PCR analysis on all parts of the normal brains, both left and right sides. Olf: 
Olfactory bulb, Str: Striatum, HC: Hippocampus, FCX: Frontal cortex, SCX: 
Somatosensory cortex, TH: Thalamus, HT: Hypothalamus, CB: Cerebellum, BS: 
Brainstem. Olfactory bulb has the highest LCN2 mRNA levels, followed by the 
brainstem, cerebellum, hypothalamus and thalamus. Hippocampus has the lowest 
LCN2 mRNA expression. All data have been normalised for levels of β-actin mRNA 
expression within the same sample and was expressed relative to hippocampal 
LCN2 mRNA expression levels. Data are expressed as mean ± SEM, n = 3. 
 
(Fig. 2.2B). Low LCN2 protein expression was observed in other parts of the brain, 
such as the striatum, frontal and somatosensory cortex. Among all the parts of the 
brain analysed, the hippocampus had the lowest level of LCN2 protein expression 
(Fig. 2.2B) consistent with the mRNA expression detected in Figure 2.1. The 
discrepancy between the mRNA levels and protein levels of LCN2 in the frontal 
cortex may be due to higher translational efficiency in this region. 
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LCN2 Protein Expression in Normal Rat Brain
B  
Fig. 2.2. Distribution of LCN2 protein expression in normal rat brain. (A) 
Western blot analysis of various parts of the right side of normal rat brain. Olf: 
Olfactory bulb, Str: Striatum, HC: Hippocampus, FCX: Frontal cortex, SCX: 
Somatosensory cortex, TH: Thalamus, HT: Hypothalamus, CB: Cerebellum, BS: 
Brainstem. The antibody to LCN2 detected a single band between 20 to 25kDa. (B) 
Densitometric analysis of LCN2 protein expression of various parts of the right side of 
the brain from three normal animals, normalised to β-actin, and again normalised to 
the hippocampus of each individual animal, as the hippocampus has the lowest 
protein expression. The olfactory bulb has the highest LCN2 protein expression, 
followed by the brainstem and cerebellum. Data are expressed as mean ± SEM, n = 
3.  
2.3.1.3. Immunoreactivity of LCN2 in normal rat brain 
 Understanding the distribution of LCN2 mRNA and protein levels in different 
regions of the normal rat brain, LCN2 immunostaining was performed on three brain 
structures with high LCN2 expression: the olfactory bulb, brainstem and cerebellum. 
LCN2 labelling was observed in the glomerular layer of the olfactory bulb (Fig. 2.3A) 
and in the lateral olfactory tract of the olfactory bulb. Immunoreactivity was also 
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detected in the cerebellar cortex (Fig. 2.3D) and different parts of the brainstem 
including the spinal trigeminal tract, ventral spinocerebellar tract, and the pyramidal 
tract (Fig. 2.3G). The LCN2 immunopositive cells in the olfactory bulb, cerebellum 
and brainstem were double-labelled with GFAP (Fig. 2.3B, E and H) indicating that 












Fig. 2.3. Confocal micrographs of LCN2-positive cells in various parts of the 
normal rat brain. LCN2-positive cells at the (A) olfactory bulb, (D) cerebellum and 
(G) brainstem colocalised with the (B, E and H) GFAP-positive cells. (C, F and I) 
LCN2 colocalised with GFAP in the olfactory bulb (OLF), cerebellum (CB) and 
brainstem (BS). Scale=20 μm. Scale in insert=5 μm. 
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2.3.1.4. LCN2 mRNA and protein expression in the hippocampus  
 RT-PCR of the total RNA from normal hippocampus amplified a 88bp PCR 
product indicating that LCN2 mRNA was present in the normal hippocampus (Fig. 
2.4A). Western blot analysis of the right hippocampi of three normal rats indicated 
faint protein bands around 25kDa (Fig. 2.4B). This weak expression of LCN2 
corresponds with the previous data that LCN2 mRNA and protein expression in the 













Fig. 2.4. LCN2 mRNA and protein expression in the right hippocampus of 
normal rat brain. (A) RT-PCR was conducted on the cDNA of the right hippocampus 
from a normal rat with specific primers to LCN2 transcript. (B) 60 μg of right 
hippocampus lysate from three individual normal animals were loaded for western 
blot analysis and probed with anti-LCN2. 
 
2.3.2. Expression of LCN2 in Kainate-lesioned brain 
2.3.2.1. Changes in LCN2 mRNA and protein expression in the rat 
hippocampus after LPS and KA treatment 
As a preliminary study, icv injection of lipopolysaccharide (LPS) was 
performed on the animals. In LPS-treated animals, LCN2 mRNA in the right 
hippocampus was 20.8-fold (p < 0.01) relative to the saline controls (Fig. 2.5A). 
Denser bands were observed for LPS-treated right hippocampi relative to the saline 
injected-controls (Fig. 2.5B, top panel), indicating a 19.8 (p < 0.01) times increase in 
LCN2 protein levels by densitometric analysis (Fig. 2.5B, bottom panel).  
Chapter 2: Distribution and expression of LCN2 in normal and KA-lesioned brain 
 



































































Fig. 2.5. LCN2 mRNA and protein upregulated after LPS treatment. (A) Real-time 
RT-PCR analysis on LCN2 mRNA expression changes of the right hippocampus 24 
hours after icv LPS and saline administration. LCN2 mRNA levels increase significantly 
after LPS treatment. Data are expressed as mean ± SEM, n = 4 per treatment group. 
(B) Western blot analysis of LCN2 expression in LPS vs. saline injected animals (top 
panel) and densitometric analysis of western blot (bottom panel). LCN2 protein 
increased after LPS treatment. Data are expressed as mean ± SEM, n = 3 per 
treatment group. Analysed by Student’s t-test, asterisks indicate significant difference 
(*p < 0.05, **p < 0.01, ***p < 0.001). 
 
Kainate was administered via icv injection to induce neural injury. To 
understand the expression of LCN2 in acute and chronic conditions of neural injury-
such as in kainate injury, three different timepoints were performed. 
At 1 day, 3 days and 2 weeks post-KA injection, LCN2 mRNA expression was 
5.6- (p < 0.01), 8.6- (p < 0.001) and 14.2- (p < 0.01) fold relative to their saline-
injected controls, respectively (Fig. 2.6). Only the right hippocampus was studied 
because the unilateral icv injection was done at the right ventricle. A consistent 
increase in LCN2 mRNA expression was detected at all timepoints.  
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Fig. 2.6. LCN2 mRNA expression upregulated after KA injury. Real-time RT-PCR 
analysis on LCN2 mRNA expression changes of the right hippocampus at 1 day, 3 
days and 2 weeks post-KA injection. LCN2 mRNA levels were increased in all 
timepoints. Data are expressed as mean ± SEM, n = 4 per treatment group. Analysed 
by Student’s t-test, asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p 
< 0.001). 
The increase of LCN2 in KA-treated animals at 1 day, 3 days and 2 weeks 
post-KA treatment was further validated by western blot analysis (Fig. 2.7). 3 days 
(Fig. 2.7B) and 2 weeks (Fig. 2.7C) post-KA injection hippocampi samples had 
greater band intensities than 1 day post-KA injection samples (Fig. 2.7A). From 
densitometric analysis, LCN2 protein levels were significantly upregulated at all three 
timepoints; 1 day, 3 days and 2 weeks post-KA injection samples had 2.7 (p < 0.01), 
13.2 (p < 0.001) and 31.2 (p < 0.01) times increase in LCN2 protein respectively in 
comparison to their corresponding saline-injected controls (Fig. 2.7E).  
This trend corresponded with the upregulation of LCN2 mRNA expression 
observed earlier. Therefore, the 2 weeks post-KA injection samples had the highest 
upregulation of LCN2 mRNA and protein expression compared to its saline controls, 
followed by 3 days post-KA injection samples, and lastly, the 1 day post-KA injection 
samples with the smallest upregulation in LCN2.  
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LCN2 protein expression after KA injury






























































Fig. 2.7. LCN2 protein expression upregulated after KA injury. Western blot 
analysis of LCN2 in the right hippocampus at (A) 1 day, (B) 3 days and (C) 2 weeks 
post-KA injection, n = 3 per treatment group. (D) 2 weeks post-KA treatment 
hippocampi lysates, R6 and R4 were used for control experiments. First two lanes on 
the left: incubated with LCN2 antibody at 1 µg/ml, produced specific bands for LCN2. 
Next two lanes: LCN2 antibody pre-incubated with 10 µg/ml of blocking peptide, 
resulted in reduced intensity of the bands. Last two lanes: LCN2 antibody pre-
incubated with 20 µg/ml of rLCN2, resulted in the absence of the LCN2 band, 
indicating specificity of the LCN2 antibody. (E) Densitometric analysis of LCN2 
protein expression in KA-treated vs. saline-injected controls. Values are normalised 
with the saline-injected controls at the respective timepoints. Analysed by Student’s t-
test, asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). 
Data are expressed as mean ± SEM , n = 3 per treatment group. 
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Control experiments were performed with the antigen, recombinant LCN2 
protein, as the blocking solution. Western blots incubated with the LCN2 antibody 
produced a single band at 25kDa. Blots incubated with 10 µg/ml antigen-absorbed 
LCN2 antibody, showed reduced intensity of the band at 25kDa; and blots incubated 
with 20 µg/ml antigen-absorbed LCN2 antibody showed absence of bands, indicating 
the specificity of the LCN2 antibody (Fig. 2.7D).  
 
2.3.2.2. Changes in LCN2 immunoreactivity in the rat hippocampus after KA 
injury 
Nissl staining was performed to observe the extent of neuronal damage at the 
1 day, 3 days and 2 weeks post-KA injection. Hippocampal lesions were observed 
from the Nissl-stained sections at CA3 region at 1 day post-KA injection (Fig. 2.8B); 
and at CA1 and CA3 regions at 3 days (Fig. 2.8D) and 2 weeks post-KA injection 
(Fig. 2.8F). All saline-injected control sections showed absence of lesions (Fig. 2.8A, 
C and E).  
LCN2 immunostaining was done to investigate the distribution and 
localisation of LCN2 in the lesioned hippocampus. At 3 days post-KA injection, LCN2 
expression was regulated in the lesioned CA1 region (Fig. 2.8G). At 2 weeks post-KA 
injection, higher LCN2 immunoreactivity was observed in both the lesioned CA1 and 
CA3 regions (Fig. 2.8H) compared to 3 days post-KA injection sections. This 
correlated with the high LCN2 mRNA and protein levels at 2 weeks post-KA injection. 
The localisation of LCN2 in the hippocampal lesioned areas suggested that they may 
be expressed in glia, and not neuronal cells.  
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Fig. 2.8. LCN2 upregulation in hippocampal lesioned areas after KA injury. Light 
micrographs of Nissl-stained sections of the right hippocampus at 1 day, 3 days and 
2 weeks post-KA/saline injection. Intact hippocampi were observed from (A) 1 day, 
(C) 3 days and (E) 2 weeks post-saline injection controls. In (B) 1 day post-KA 
injection animals, lesions are observed in the CA3 region, while in both (D) 3 days 
and (F) 2 weeks post-KA injection animals, lesions are observed in the CA1 and CA3 
regions (indicated by black arrows). Scale=500 μm. (G, H) Fluorescence 
micrographs of LCN2 (red) upregulation in the hippocampal lesioned regions 
(indicated by white arrows). Scale=500 μm. At higher magnification shown in the 
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Immunoperoxidase staining was performed to confirm the LCN2 
immunoreactivity at 2 weeks post-KA injection. No obvious immunoperoxidase 
staining was detected at the CA3 hippocampal region of saline-injected control 
animals (Fig 2.9A, C), consistent with a low level of LCN2 mRNA and protein in the 
normal hippocampus. In contrast, intense staining was observed in glial-like cells in 
the lesioned CA3 region of the 2 weeks post-KA injection sections (Fig. 2.9B, D). The 
labelled cells had large cell bodies and thick processes characteristic of astrocytes. 
Immunofluorescence also showed LCN2 upregulation in cells with characteristics of 
astrocytes (Fig. 2.9E). Sections incubated with the rLCN2-absorbed antibody showed 
absence of staining (Fig. 2.9F), indicating the specificity of the antibody. 
Since at 2 weeks post-KA injection, the right hippocampus had high LCN2 
mRNA and protein expression, double immunolabelling was performed to determine 
the identity of the immunopositive LCN2 cells. As LCN2 was upregulated in the 
lesioned areas of the hippocampus, LCN2 may be localised in glial cells, as reactive 
gliosis (activation of astrocytes and microglia) was often observed after KA injury. 
The reactive astrocytes were characterised by hypertrophic processes and increased 
expression of GFAP (a marker for astrocytes), while activated microglia were 
characterised by amoeboid morphology. The majority of the GFAP positive cells were 
double-labelled with LCN2 (Fig. 2.10A) and z-series reconstruction of cells showed 
the colocalisation of LCN2 with GFAP-positive cells (Fig. 2.10B). This indicates that 
LCN2 is expressed in the astrocytes. At higher magnification, LCN2 staining 
comprises of intense dots, which could represent vesicles or other intracellular 
organelles or inclusions (Fig. 2.10C). LCN2 did not colocalise with OX-42, a marker 
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Fig. 2.9. Micrographs of LCN2 staining at 2 weeks post-KA injection. (A,B) Light 
micrographs of Nissl stained sections at 2 weeks post-KA (KA 2wk) and post-saline 
(Sal 2wk) injections (identical to Fig. 2.8E and 2.8F). Scale=500 μm. (C-D) Light 
micrographs of immunoperoxidase staining of the CA3 region of the right 
hippocampus as indicated by the square boxes in (A) and (B) at (C) 2 weeks post-
saline and (D) 2 weeks post-KA injection. LCN2 was upregulated in CA3 region of 
the KA-treated animals. Scale=100 μm. (E) Confocal micrographs of CA1 field of the 
right hippocampus at 2 weeks post-KA injection indicating upregulation of LCN2-
positive cells. (F) LCN2 antibody was pre-incubated with 20 µg/ml rLCN2 (Bp) for 
blocking study. LCN2 positive staining (red) was blocked, indicating specificity of the 
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With the knowledge that LCN2 was expressed in the astrocytes of 2 weeks 
post-KA injection samples, double immunolabelling of LCN2 and GFAP was 
performed at other timepoints to examine the changes in LCN2 immunoreactivity in 
the lesioned hippocampus from 1 day to 3 days to 2 weeks post-KA injury.  
In saline-injected control sections, negligible LCN2 staining was detected at 
both CA1 (Fig. 2.11A) and CA3 (Fig. 2.11B) hippocampal regions. Instead, LCN2 
was upregulated in the GFAP-positive cells at 1 day (Fig. 2.11C, D), 3 days (Fig. 
2.11E, F) and 2 weeks (Fig. 2.11G, H) post-KA injection in the CA1 and CA3 
lesioned regions of the hippocampus.  
LCN2 had high immunoreactivity at 2 weeks post-KA injection, correlating 
with the high LCN2 mRNA and protein levels detected. Furthermore, at 2 weeks 
post-KA injection, reactive astrocytes were more pronounced compared to earlier 
timepoints, characterised by the large cell bodies, thick hypertrophic processes and 
increased expression of GFAP. 
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Fig. 2.10 Confocal micrographs of colocalisation of LCN2 with GFAP-positive 
cells. Right hippocampus at 2 weeks post-KA injection was double-labelled with 
LCN2 (red) and GFAP (green), a marker for astrocytes. (A) 40x magnification 
showed majority of the GFAP-positive cells were LCN2-positive. (B) z-series 
reconstruction of the cells indicated by the white arrows in (A) at 63x magnification, 
indicating LCN2 was expressed in the astrocytes. (C) Orthogonal projections through 
CA1 lesioned region at higher magnification demonstrate that LCN2 staining 
comprised of intense dots. LCN2 is present in astrocytes. (D) No colocalisation was 
observed between LCN2 and OX-42, a marker for microglia, indicates that LCN2 is 
not present in microglia. Scale=20 μm. 
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Fig. 2.11. Changes in LCN2 expression with GFAP-positive cells after KA injury. 
Negligible LCN2 staining was observed in (A) CA1 and (B) CA3 in 2 weeks post-saline 
injection hippocampus. Immunofluorescence staining for LCN2 (red) colocalised with 
GFAP (green) at (C,D) 1 day (E,F) 3 days and (G,H) 2 weeks post-KA injection and was 
upregulated in CA1 and CA3 lesioned regions. Scale=100 μm. 
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2.3.3. Changes in mRNA expression of other lipocalins in the rat hippocampus 
after KA injury 
The mRNA expression of other lipocalins together with LCN2 was surveyed 
by real-time RT-PCR after KA injury in order to determine if the upregulation is 
specific to LCN2. The other lipocalins included apolipoprotein D (apoD), 
prostaglandin D2 synthase (PGDS), retinol binding protein 4 (Rbp4) and lipocalin 5 
(LCN5).  
At 3 days post-KA injection, LCN2 mRNA levels were 9.7- (p < 0.001) and 
8.4- (p < 0.01) fold relative to the saline-injected controls in the right (Fig. 2.12A) and 
left (Fig. 2.12B) hippocampus, respectively. At 2 weeks post-KA injection, LCN2 
mRNA levels continued to rise to 16.3- (p < 0.01) and 8.5- (p < 0.01) fold relative to 
the saline-injected controls, in the right (Fig. 2.12C) and left (Fig. 2.12D) 
hippocampus, respectively. 
At 3 days post-KA injection, apoD mRNA expression was 1.6-fold (p < 0.001) 
in the right hippocampus relative to the saline-injected controls (Fig. 2.12A). In 
contrast, significant decreases in mRNA levels were observed with Rbp4 (0.43 fold, p 
< 0.01), LCN5 (0.23 fold, p < 0.01) and PGDS (0.34 fold, p < 0.001) relative to saline-
injected controls at this timepoint (Fig. 2.12A). The left hippocampus showed a 
similar trend as the right hippocampus. PGDS mRNA levels decreased (0.49 fold, p < 
0.01) relative to saline-injected controls (Fig. 2.12B). At 2 weeks post-KA injection, 
other than LCN2, the other lipocalins had no significant differences in the right or left 




Chapter 2: Distribution and expression of LCN2 in normal and KA-lesioned brain 
 



























































































Fig. 2.12. Changes in mRNA expression of LCN2 and other lipocalins in the rat 
hippocampus after KA injury. Real-time RT-PCR analysis of the lipocalins of the 
right hippocampus: LCN2, apoD, Rbp4, LCN5 and PDGS at (A, B) 3 days and (C, D) 
2 weeks post-KA injection. LCN2 mRNA levels changed from 9.7-fold (***p < 0.001) 
at 3 days post-KA injection to 16.3-fold (**p < 0.01) at 2 weeks post-KA injection of 
the right hippocampus, relative to their respective saline-injected controls. The 
increase in mRNA expression was specific to LCN2 as the significant changes in 
apoD, Rbp4, LCN5 and PDGS mRNA levels observed at 3 days post-KA injection 
returned to normal baseline at 2 weeks post-KA injection. Analysed by Student’s t-
test, asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). 
Data are expressed as mean ± SEM, n = 4 per treatment group. 
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2.4. DISCUSSION 
The present study aimed to bridge the knowledge gap between 
understanding of LCN2 in the periphery and in the CNS by examining the distribution 
and expression of LCN2 among different brain parts in normal rat brain and analysing 
changes in expression in the KA-lesioned hippocampus. The distribution of LCN2 
was surveyed across various parts of the brain in both the left and right hemispheres. 
Since LCN2 is known as a bacteriostatic agent, and often upregulated during 
infections (Flo et al., 2004), it may be expressed in those areas of the brain that 
bacteria can access easily. Interestingly, the hippocampus has the lowest expression 
of LCN2, possibly because it is folded deep in the temporal lobe and more 
inaccessible to bacterial infections. The low basal expression of LCN2 in the 
hippocampus was also confirmed with RT-PCR and western blot analysis. The 
olfactory bulb expressed the highest level of LCN2 mRNA, followed by the 
cerebellum, brainstem, thalamus and hypothalamus, consistent with the trend 
observed in protein expression.  
The olfactory bulb and the brainstem are connected to the olfactory, 
respiratory and oral mucosa by the olfactory and trigeminal nerves, and there is 
evidence that these could be entry portals for microorganisms (Thorne et al., 2004). 
The vestibulocochlear nerve not only projects to the brainstem but axons of the 
vestibular nerve also terminate in the cerebellum. Hence, it is possible that the high 
basal expression of LCN2 in the olfactory bulb, brainstem and cerebellum may help 
the CNS defend against pathogens by sequestering iron and bacterial siderophores. 
These high LCN2-expressing regions were then investigated for LCN2’s cellular 
localisation. In the olfactory bulb, cerebellum and brainstem, colocalisation of LCN2 
with GFAP, a marker of astrocytes, was observed, thus it can be concluded that 
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LCN2 is expressed in the astrocytes. This is consistent with the study in which LCN2 
is expressed by primary astrocytes in vitro (Lee et al., 2009).  
The expression of LCN2 was suggested to be an innate immune response to 
prevent bloodborne bacteria from disseminating into the CSF and brain as 
intraperitoneal injection of lipopolysaccharide (LPS) resulted in the increase in LCN2 
protein in the choroidal epithelia and endothelial cells of blood vessels in the brain 
parenchyma (Marques et al., 2008). LPS is a component of the outer membrane of 
Gram negative bacteria and is commonly used to induce inflammation in the CNS 
and periphery (Block et al., 2007; Choi et al., 2008; Gibbons and Dragunow, 2006; Ip 
et al., 2011). Previously, microarray analysis showed upregulation of LCN2 mRNA in 
the hippocampus after icv injection of lipopolysaccharide (LPS) in C57BL/6 mice 
(Bonow et al., 2009). In view of the potential differences between LCN2 orthologues 
(Kjeldsen et al., 2000), icv LPS injections were performed on rats. Similar to the 
mouse models, LCN2 mRNA and protein levels increase significantly in the LPS-
treated hippocampi by 20 times compared to saline-injected controls. The elevation 
of LCN2 may be dependent on Toll-like receptor 4 (TLR4), as TLR4-deficient mice 
had low levels of LCN2 expression relative to the C57BL/6 wild-type, with a 200-fold 
and a 20-fold increase in LCN2 mRNA and protein expression, respectively, after 
LPS intraperitoneal administration (Flo et al., 2004).  
To induce neurodegeneration, KA icv injection was performed and LCN2’s 
mRNA and protein expression increased steadily from earlier timepoints - 1 day and 
3 days and peaked at the later timepoint, 2 weeks post-KA injection. Since LCN2 
expression was highly upregulated at 2 weeks post-KA injection, which has 
pronounced reactive gliosis occurring, suggests that the elevation of LCN2 may be 
associated with reactive gliosis as LCN2 was demonstrated to induce reactive 
astrocytosis in primary astrocytes in vitro (Lee et al., 2009) 
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This inference about LCN2 and reactive gliosis was further confirmed with low 
magnification of LCN2 immunofluorescence at the degenerating hippocampus. LCN2 
upregulation was only observed in lesioned areas visualised with Nissl staining. Nissl 
staining was performed for KA/saline-treated sections to ensure the icv KA injection 
was effective in inducing neurodegeneration prior to any further analysis. In 3 days 
and 2 weeks post-KA injection samples, hippocampal lesions were observed in CA1 
and CA3 regions. In contrast, at 1 day post-KA injection, hippocampal lesions were 
only observed in the CA3 region. There may be delayed onset of neuronal death, 
therefore neurodegeneration may not have been completed by 1 day post-KA 
injection. Hence the most vulnerable region, CA3, was first affected due to high 
density of KA receptors localised at that region (Nadler et al., 1980a; Patel et al., 
1986). The CA2 hippocampal region was mostly unaffected at all timepoints similar to 
previous KA lesioning studies (McGeer and McGeer, 1982; Sperk et al., 1983). 
Hence, the upregulation of LCN2 in the CA1 and CA3 hippocampal lesions further 
suggests its expression in glial cells, which are known to be upregulated in the 
lesioned areas during neurodegeneration (Wang et al., 2005; Zheng et al., 2011). 
Furthermore, immunoperoxidase staining of 2 weeks post-KA injection 
sections also showed intense LCN2 immunoreactivity in cells with large cell bodies, 
thick processes which are characteristic of astrocytes at the lesion sites (CA1 and 
CA3 regions) of the hippocampus. Thus, double immunolabelling was performed to 
determine the cellular localisation of LCN2 using sections from 2 weeks post-KA 
injection since they have high LCN2 expression. As speculated, LCN2 colocalised 
with GFAP, but not other glia markers, such OX-42 (marker for microglia). Therefore, 
LCN2 is expressed in astrocytes, but not microglia. This is consistent with the 
enhanced secretion of LCN2 by primary astrocytes into culture media with LPS 
treatment in vitro (Lee et al., 2009), indicating expression of LCN2 from astrocytes 
upon insult. Since LCN2 was secreted by primary astrocytes (Lee et al., 2009), the 
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LCN2 staining of round intense dots from the high magnifications of the orthogonal 
projections could be vesicles or other intracellular organelles for transport of LCN2 to 
the cell surface to be secreted out, either to act on itself (autocrine function) or other 
cells, depending on the localisation of the LCN2 receptors. Furthermore, LCN2 was 
reported to be expressed in primary microglial cultures and BV-2 microglial cell line in 
vitro (Lee et al., 2007) and we likewise found LCN2 mRNA to be expressed in BV-2 
microglial cells by RT-PCR (in Appendix 1A), but LCN2 was not detected in microglia 
in vivo. The discrepancies may be due to differences between in vitro and in vivo 
conditions.  
With the knowledge that LCN2 is expressed in the reactive astrocytes, the 
expression changes of LCN2 throughout the different timepoints were studied with 
double immunolabelling of LCN2 and GFAP. In all saline-injected controls at all 
timepoints, negligible LCN2 staining was observed, again correlating with the low 
LCN2 expression physiologically. Upregulation of LCN2 in the astrocytes was 
observed in the lesioned areas as early as at 1 day post-KA injection. Corresponding 
to the LCN2 mRNA and protein expression levels, LCN2 staining was most intense at 
2 weeks post-KA injection, likely due to the increase of reactive astrocytosis. 
Hyperproliferation of glia usually occurs after neuronal death (Wang et al., 2005). 
Expression of GFAP, a marker for astrogliosis, was shown to increase steadily, even 
at one day after intrahippocampal injection of KA (Bendotti et al., 2000; Zheng et al., 
2011), and upregulation of reactive astrocytes was observed to peak at 1 month 
post-KA icv injection (Mitchell et al., 1993).  
Since LCN2 is a member of the lipocalin family, it would be valid to question 
whether this distinct upregulation was only specific to LCN2 or to other lipocalins as 
well. Four more well-studied lipocalins were examined, which are apolipoprotein D 
(apoD), prostaglandin D2 synthase (PGDS), retinol binding protein 4 (Rbp4) and 
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lipocalin 5 (LCN5). ApoD binds arachidonic acid (Morais Cabral et al., 1995), 
cholesterol (Patel et al., 1997), pregnenolone and progesterone (Vogt and Skerra, 
2001). PGDS is a PGD2-producing enzyme as well as a binding protein for biliverdin, 
bilirubin, retinaldehyde and retinoic acid (Urade and Hayaishi, 2000). Rbp4 is a 
binding protein for all-trans retinoic acid and is elevated in patients with Type 2 
diabetes (Graham et al., 2006). Lipocalin 5 is a binding protein for retinoic acid and is 
a major secreted protein in the epididymis (Ong et al., 2000).  
Although at 3 days post-KA injection, there was a significant increase in apoD 
and decreases in Rbp4, LCN5 and PGDS mRNA levels relative to saline-injected 
controls, these changes did not persist till 2 weeks. An interesting point to note is the 
changes in apoD mRNA levels were consistent with a previous study that showed 
apoD immunoreactivity to peak at 3 days after KA injection but return to baseline 
levels by 7 days post-injection (Ong et al., 1997). Of the lipocalins, only LCN2 mRNA 
expression continued to increase from 3 days to 2 weeks post-KA injection in the 
right hippocampus. The increase of LCN2 mRNA expression in the left hippocampus 
could be due to diffusion of KA from the right to the left lateral ventricle after icv 
injection.  
From the data presented in this chapter, the pronounced upregulation was 
found to be unique to LCN2, but not other lipocalins. Also, it is possible to speculate 
that if the CNS is threatened by bacterial infections, LCN2 will be greatly expressed 
by the astrocytes in the olfactory bulb, cerebellum and brainstem as a CNS defence 
response. This is the same context as the upregulation of LCN2 with the 
administration of LPS. Due to the bacterial origin of LPS, the mammalian host 
release LCN2 as an innate immune response to scavenge iron from bacteria, 
protecting the host from “bacterial infection”. Like LCN2, lactoferrin, another 
mammalian iron-binding protein, is a bacteriostatic agent which binds iron directly to 
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inhibit bacterial growth (Ellison, 1994). In the mammalian host, LCN2 complements 
the activity of lactoferrin by binding ferric siderophore complexes rather than free 
iron, targeting the iron that has been earmarked for bacterial use (Clifton et al., 2009; 
Goetz et al., 2002). Therefore, LCN2-deficient mice were reported to have increased 
susceptibility to bacterial infections (Berger et al., 2006; Flo et al., 2004). The 
bacteriostatic property of LCN2 demonstrated by NGAL’s dramatic 20-fold inhibition 
on E.coli growth was negated with the addition of iron to saturate NGAL. This 
indicates that the main function of LCN2 in the anti-bacterial innate immune response 
is to limit iron by sequestering ferric siderophores (Berger et al., 2006; Goetz et al., 
2002). 
However, these are the roles of LCN2 in conditions of bacterial infections. 
How about in non-bacterial infection conditions? Unlike LPS, KA does not have 
bacterial origin. Since previously lipocalins were classified primarily as transport 
proteins (Flower, 1996), could LCN2 transport iron or an unknown endogenous 
ligand? Thus, other than its bacteriostatic property, it would be interesting to know if 
LCN2 has any involvement in neurodegeneration, in order to substantiate its 
pronounced upregulation after KA injury. Therefore, in the next chapter, the 
expression of LCN2 receptors will be investigated after KA injury, as the cellular 
localisation of these receptors will be pertinent to postulate the role of LCN2 in KA-
induced neurodegeneration.  
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3.1. INTRODUCTION 
With the discovery that LCN2 is expressed in the astrocytes in the brain, the 
next question is – what does LCN2 bind to in the hippocampus? Recently, two 
cellular receptors for LCN2 have been identified - megalin and 24p3R (Devireddy et 
al., 2005; Hvidberg et al., 2005). 
Megalin, a multi-ligand receptor, was shown to bind NGAL with high affinity by 
surface plasmon resonance analysis and mediates NGAL’s cellular uptake. Megalin 
was also detected to bind siderophore-NGAL with similar affinity (Hvidberg et al., 
2005). Other than binding NGAL/LCN2, megalin binds lactoferrin, another iron-
binding protein secreted from human neutrophils (Willnow et al., 1992). Megalin is 
not new to the CNS as its involvement in CNS development and Alzheimer’s disease 
(AD) has been well-studied. It is expressed early in the development (McCarthy et 
al., 2002) and involved in the formation of brain structures (Spoelgen et al., 2005; 
Willnow et al., 1996). In the adult, megalin is only expressed at the choroid plexus 
(Carro et al., 2005), the ependymal cells of the lateral ventricles (Gajera et al., 2010) 
and in the spinal cord (Wicher et al., 2006). Megalin-deficient mice have a low 
survival rate (1 in 50) and die immediately after birth from respiratory insufficiency, 
exhibiting brain malformations (Marzolo and Farfan, 2011; Willnow et al., 1996). 
Megalin is also implicated in neurodegenerative conditions such as 
Alzheimer's disease (AD). It is involved in the endocytic uptake of numerous ligands, 
including many known carriers of amyloid beta (Aβ) (Christensen and Birn, 2002) and 
participates in Aβ clearance (Carro et al., 2005; Deane et al., 2004; Hammad et al., 
1997; Zlokovic, 1996). In AD patients and the elderly, a reduced level of megalin 
expression was reported (Dietrich et al., 2008), suggesting a reduction of protective 
effects of megalin on the brain. 
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The other LCN2 receptor, 24p3R, was cloned by Green and colleagues for 
24p3 (murine orthologue of LCN2) (Devireddy et al., 2005). Ligand-cell binding 
experiments and internalisation assays showed that only 24p3R-expressing HeLa 
cells could bind to 32P-labelled 24p3 and internalise it into the cells. This was not 
observed in HeLa cells, which do not express 24p3R (Devireddy et al., 2005). 
Therefore, 24p3R/LCN2R is necessary for binding and internalisation of 24p3/LCN2. 
In addition, 24p3R-expressing HeLa cells internalise apo-24p3 to export intracellular 
55Fe into the extracellular medium, decreasing intracellular iron levels. The low 
intracellular iron level was suggested to trigger Bim-dependent apoptosis in the 
24p3R-expressing cells (Devireddy et al., 2005). Following the discovery of 24p3R, 
the Bim-dependent apoptotic function of LCN2 mediated by 24p3R was also 
observed in primary astrocytes and C6 glioma cells (Devireddy et al., 2005; Lee et 
al., 2009). Although it has been established that 24p3R binds both apo-24p3 (iron-
free) and holo-24p3 (iron-loaded), the affinity of 24p3R for neither was measured.  
LCN2R is widely expressed in many organs (such as kidney, liver, testes and 
heart), but its mRNA expression is highest in the brain. It is noteworthy that among 
brain-derived cells surveyed, primary neurons have higher LCN2R mRNA expression 
than the primary astrocytes or C6 glioma cells (Bennett et al., 2011).  
Suk and colleagues (2009) have detected both megalin and 24p3R (murine 
orthologue of LCN2R) in brain-derived cells. LCN2 was reported to sensitise primary 
astrocytes and C6 glioma cells to apoptotic stimuli. Since 24p3R mRNA expression 
was detected in both cell types, while megalin was only expressed in the primary 
astrocytes, this suggests that the pro-apoptotic effect of LCN2 was mediated by 
24p3R. In addition, 24p3R was also expressed in primary microglia, BV-2 cells, 
primary cortical neurons and B35 neuroblastoma (Lee et al., 2007; 2011). 
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In this thesis, the focus will be placed on the rat orthologue of 24p3R, LCN2R, 
rather than megalin. This is firstly because LCN2R has been well-characterised with 
LCN2, as compared to the interaction of megalin with LCN2, especially in iron 
transport and apoptosis. Secondly, being a promiscuous receptor with many ligands, 
it would be difficult to distinguish LCN2’s effect through megalin without interference 
from the effects of other ligands. Although megalin’s protective effect on AD suggests 
a possible role in KA-induced neurodegeneration, in view of the potential 
confounding factors and the unavailability of a specific antibody for megalin, cellular 
localisation studies were focused on LCN2R instead. 
Since little is known about LCN2R physiologically and in conditions of 
neurodegeneration, this chapter will examine if LCN2R is present in vivo and more 
importantly - its cellular localisation. The effect of LCN2, mediated by LCN2R would 
be different depending on the cellular localisation of LCN2R in the hippocampus. For 
instance, if LCN2R was expressed on astrocytes, the LCN2 produced could bind to 
the LCN2R expressed on the same cells to mediate an autoregulatory function as 
suggested by Lee et al. (2009). On the other hand, if LCN2 receptors were 
expressed on neurons or microglia, the function of LCN2 may be different. These 
results would be important in postulating the possible mechanism or function of LCN2 
in KA-induced neurodegeneration.  
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3.2. MATERIALS AND METHODS 
3.2.1. Animals and kainate (KA) injections 
Male Wistar rats weighing approximately 200 g each were anaesthetised by 
intraperitoneal injection of ketamine (75 mg/kg) and xylazine (10 mg/kg). KA (1.2 µl 
of 1 mg/ml) was stereotaxically injected into the right lateral ventricle (coordinates: 
1.0 mm caudal to bregma, 1.5 mm lateral to the midline, 4.5 mm from the surface of 
the cortex) using a microlitre syringe (5 μl Hamilton syringe, Model no.: 88000, 24 
gauge needle, outer diameter of needle: 0.57 mm, inner diameter of needle: 0.31 
mm). Experimental control rats were injected with 1.2 µl of normal saline instead of 
KA. All procedures involving animals were approved by the Institutional Animal Care 
and Use Committee, NUS. 
 
3.2.2. Real-time RT-PCR 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals were sacrificed at 1 day, 3 days and 2 weeks after injection. 
Three animals were also sacrificed to study LCN2R in the normal hippocampus. 
Tissues were freshly dissected from the brain and immersed into RNAlater (Ambicon, 
CA, USA), flash frozen and kept at -80°C until analysis. Total RNA was isolated using 
TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s protocol, and 
RNeasy Mini Kit (Qiagen Inc., CA, USA) was used to purify the RNA. The samples 
were reverse transcribed using High-Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, CA, USA). The reaction conditions were 25°C for 10 min, 37°C 
for 120 min and 85°C for 5 min. Real-time PCR amplification was carried out using 
the 7500 Real-time PCR system (Applied Biosystems, CA, USA) with Taq-Man 
Universal PCR Master Mix (Applied Biosystems, CA, USA) and gene-specific primers 
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and probes according to manufacturer’s protocols (Assay ID: Slc22A17/LCN2R 
(Rn00598583_m1)). β-actin (Part no: 4352340E) was used as an internal control. All 
primers and probes were synthesised by Applied Biosystems. The PCR conditions 
were: an initial incubation of 50°C for 2 min and 95°C for 10 min followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min. All reactions were carried out in 
triplicates. The threshold cycle, CT, which correlates inversely with the levels of 
target mRNA, was measured as the number of cycles at which the reporter 
fluorescence emission exceeds the preset threshold level. The amplified transcripts 
were quantified using the comparative CT method (Livak and Schmittgen, 2001), with 
the formula for relative fold change = 2–∆∆CT. The mean was calculated, and possible 
significant differences were analysed using Student’s t-test. p < 0.05 was considered 
significant. RT-PCR was conducted on rat hippocampal tissues using specific 
primers to Slc22A17/LCN2R transcript (Applied Biosystems, Assay ID: 
Rn00598583_m1). DNA gel electrophoresis was performed to separate the PCR 
products in a 1.5% agarose gel. The DNA bands were stained with ethidium bromide 
and visualised under UV irradiation.  
 
3.2.3. Western blotting 
Three KA-injected rats and three saline-injected control animals were 
sacrificed at 1 day, 3 days and 2 weeks after injection. Three normal rats were also 
sacrificed to analyse LCN2R protein levels in the untreated rat brain. The rats were 
anaesthetised by intraperitoneal injection of ketamine and xylazine and decapitated. 
The tissues were quickly removed and homogenised in cold lysis buffer containing 
Tris–HCl, pH 7.4, 10 mM EDTA, 150 mM NaCl, 0.5% Triton X-100 with protease 
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and placed on the 
shaker for 1 hr at 4°C. After centrifugation at 12,000g for 30 min, the supernatant was 
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collected, and protein concentration was determined using the BCA protein assay kit 
(Pierce Biotechnology, Rockford, IL, USA). Prior to gel electrophoresis, the protein 
lysates were denatured by heating the sample in the presence of SDS and DTT for 
10 min at 95-100°C.  
Total protein (60 µg) was resolved in 12% SDS-polyacrylamide gel under 
reducing conditions and electro-transferred to a nitrocellulose membrane (Biorad, 
CA, USA). Non-specific binding sites on the membrane were blocked by incubation 
with 5% non-fat milk for 1 hr. The membrane was then incubated overnight with 
polyclonal rabbit anti-Slc22A17/LCN2R antibody at 1:2000 (Cat no. 4651, Prosci 
Incorporated, Poway, CA, USA). After washing with 0.1% Tween-20 in TBS, the 
membrane was incubated with horseradish peroxidase-conjugated goat anti-rabbit 
immunoglobulin lgG (1:10,000; Thermo Fisher Scientific, Rockford, IL, USA) for 1 hr 
at room temperature. The protein was visualised with SuperSignal West Pico 
chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL, USA) according 
to the manufacturer’s instructions. Blots were treated with stripping buffer (Restore 
Western Blot Stripping Buffer, Thermo Fisher Scientific, Rockford, IL, USA) at room 
temperature for 10 min before reprobing of membrane with antibody to β-actin 
(Sigma, St. Louis, MO, USA). Exposed films were scanned with at least 300 dpi and 
the mean optical density of the protein bands of LCN2R was analysed by 
densitometry using ImageJ (NIH, Maryland, USA), and normalised to β-actin.  The 
mean was calculated, and possible significant differences were analysed using 
Student’s t-test. p < 0.05 was considered significant. 
 
3.2.4. Double immunofluorescence labelling 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals were sacrificed at 1 day, 3 days and 2 weeks after injection 
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to study the effect of KA lesions. Three untreated rats were used to study the cellular 
localisation of LCN2R in the normal hippocampus. The rats were anaesthetised by 
intraperitoneal injection of anaesthetic comprising ketamine and xylazine and 
transcardially perfused with Ringer solution, followed by 4% paraformaldehyde in 
0.1M phosphate buffer (pH 7.4). The brains were dissected out, and blocks 
containing the hippocampus were sectioned coronally at 20 µm using a freezing 
microtome. Sections were soaked in phosphate buffered saline (PBS) for 30 min to 
remove traces of sucrose and permeabilised with PBS-0.3% Triton X-100 for 10 min. 
They were then blocked with 5% donkey/goat serum in PBS-0.3% Triton X-100 for 1 
hr, followed by incubation with rabbit polyclonal antibody to Slc22A17/LCN2R at 
1:500 (Cat no. 4651, Prosci Incorporated, Poway, CA, USA) and mouse monoclonal 
antibody to OX-42 (1:200, Chemicon, Temecula, CA, USA) or mouse monoclonal 
MAP2a (1:200, Sigma-Aldrich, MO, USA) or goat polyclonal antibody to LCN2 at 
1:200 (AF3508, R&D systems, MN, USA) overnight at 4°C. Specificity of the 
Slc22A17/LCN2R antibody was verified by pre-incubating 10 µg/ml (5x) and 20 µg/ml 
(10x) of Slc22A17 peptide (Prosci Incorporated, Poway, CA, USA) with 2 µg/ml of 
Slc22A17/LCN2R antibody overnight. The sections were washed in PBS, and 
incubated for 1 hr at room temperature in 1:200 dilution of donkey anti-goat lgG 
(H+L) Alexa Fluor 488 and donkey anti-rabbit lgG (H+L) Alexa Fluor 555 or goat anti-
rabbit IgG (H+L) Alexa Fluor 555 and goat anti-mouse IgG (H+L) Alexa Fluor 488 
(Invitrogen, CA, USA). The sections were then washed and mounted with ProLong® 
Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA, USA) and captured using 
a fluorescence microscope (Olympus BX51; Olympus Corporation, Tokyo, Japan) 
and a laser scanning confocal microscope (LSM 510, Carl Zeiss Göttingen, 
Germany). Colocalisation was established by analysing the overlap between the 
different labels by orthogonal reconstruction throughout the entire z-stack (LSM 510, 
Carl Zeiss Göttingen, Germany). 
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3.3. RESULTS 
3.3.1. Expression of LCN2R in the normal hippocampus 
3.3.1.1. LCN2R mRNA and protein expression in the hippocampus  
To investigate if LCN2R is present in the normal hippocampus, RT-PCR and 
western blot analysis were conducted. In the right hippocampus, RT-PCR revealed a 
PCR product of 98bp (Fig. 3.1A). Western blot analysis of the right hippocampi of 
three normal rats showed discrete bands slightly under the 75kDa ladder, due to 
glycosylation of LCN2R. This indicates that LCN2R mRNA and protein were present 













Fig. 3.1. LCN2R mRNA and protein expression in the right hippocampus of 
normal rat brain. (A) RT-PCR was conducted on the cDNA of the right hippocampus 
from a normal rat with specific primers to LCN2R transcript. (B) 60 μg of right 
hippocampus lysate from three individual normal animals were loaded for western 
blot analysis and probed with anti-LCN2R. 
 
3.3.1.2. Cellular expression of LCN2R in the hippocampus  
LCN2R labelling was observed in neuronal-like cells of the normal rat 
hippocampal sections, in the CA hippocampal regions (from CA1, CA2, CA3 to CA4) 
(Fig. 3.2A, D, G, J) and the cells of the dentate gyrus (Fig. 3.2.M). Colocalisation of 
LCN2R with MAP2a (Fig. 3.2B, E) indicates that it was localised in the neurons (Fig. 
3.2C, F). Control experiments were performed by incubating the LCN2R antibody  
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Fig. 3.2. Cellular expression of LCN2R in normal hippocampus. Hippocampal 
sections are double-labelled with (A, D) LCN2R and (B, E) MAP2a, indicating 
colocalisation at both (C) CA1 and (F) CA3 regions of the hippocampus. Scale=20 
μm. Sections are pre-incubated with LCN2R antibody with (H, K and N) 5x and (I, L 
and O) 10x excess of blocking peptide, blocking LCN2R positive staining at (G) CA1, 
(J) CA3 hippocampal regions and (M) the dentate gyrus, indicating the specificity of 
the antibody. G-L: scale=200 μm; M-O: scale=500 μm. 
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together with its blocking peptide in 5x and 10x excess. The antigen-absorbed 
LCN2R antibody showed absence of staining for the normal rat hippocampal 
sections, in the CA1 (Fig. 3.2H and I), CA3 (Fig. 3.2K and L) hippocampal regions 
and dentate gyrus (Fig. 3.2N and O). This indicates the specificity of the LCN2R 
antibody in the neurons.  
 
 3.3.2. Expression of LCN2R in the Kainate-lesioned brain 
3.3.2.1. mRNA expression changes of LCN2 receptors after LPS and KA 
treatment 
Previously in Chapter 2, LCN2 mRNA and protein expression was greatly 
upregulated by 20-fold in LPS-treated hippocampi (Fig. 2.5). Since LCN2 has two 
known receptors, real-time RT-PCR was performed to examine any mRNA 
expression changes in LCN2R and megalin. In LPS-treated right hippocampi, LCN2R 
and megalin mRNA expression was 0.68- (p < 0.01) and 0.74- (p < 0.01) fold relative 
to the saline-injected controls, respectively (Fig. 3.3A).  
As a comparison to LPS-treatment, mRNA expression of the LCN2 receptors 
was also studied at 2 weeks post-KA injection, which had the highest upregulation of 
LCN2 (relative to controls) among all timepoints. In KA-treated hippocampi, mRNA 
levels of LCN2R and megalin were 0.32- (p < 0.01) and 0.50- (p < 0.001) fold relative 
to the saline-injected controls in the right hippocampi, respectively (Fig. 3.3B). 
In both KA and LPS treatment, the downregulation of the LCN2 receptors 
could be attributed to loss of neurons after treatment. Since LCN2R had the greatest 
decrease in mRNA expression after KA injury, further studies will be done on 
different timepoints of KA injection in the next section (Section 3.3.2.2.) to understand 
the expression changes of LCN2R. 
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Fig. 3.3. mRNA expression changes of LCN2 receptors, LCN2R and megalin, 
after LPS and KA treatment. (A) Real-time RT-PCR analysis on mRNA changes of 
LCN2R and megalin at 24 hrs post-LPS and -saline injection. (B) Real-time RT-PCR 
analysis on mRNA changes of LCN2R and megalin at 2 weeks post-KA and –saline 
injection. The right hippocampus of each animal was analysed. Analysed by 
Student’s t-test, asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 
0.001). Data are expressed as mean ± SEM, n = 4 per treatment group. 
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3.3.2.2. Changes in LCN2R mRNA and protein expression in the rat 
hippocampus after KA injury 
Real-time RT-PCR indicated that LCN2R mRNA expression was 0.28- (p < 
0.001), 0.22- (p < 0.001) and 0.30- (p < 0.001) fold at 1 day, 3 days and 2 weeks 
























Fig. 3.4. LCN2R mRNA expression downregulated after KA injury. Real-time RT-
PCR analysis of LCN2R mRNA expression in the right hippocampus at 1 day, 3 days 
and 2 weeks post-KA and -saline injection. Analysed by Student’s t-test, asterisks 
indicate significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). Data are 
expressed as mean ± SEM, n = 4 per treatment group. 
 
The decrease in LCN2R in KA-treated animals was further validated by 
western blot analysis (Fig. 3.5). All KA-treated samples had lighter bands than their 
respective saline-injected controls (Figure 3.5A-C). Decrease in LCN2R protein 
expression was revealed to be significant at all timepoints by densitometric analysis. 
LCN2R protein expression was 0.53 times (p < 0.001) lower at 1 day post-KA 
injection compared to the saline-injected controls. At 3 days and 2 weeks post-KA 
injection, LCN2R protein expression further decreased to 0.13 (p < 0.01) and 0.18 (p 
< 0.05) times relative to their saline-injected controls, respectively. Densitometric 
analysis of the LCN2R protein bands were normalised to β-actin (identical to the β-
Chapter 3: Expression of LCN2R in normal and KA-lesioned hippocampus  
 
   82 
 
actin bands from Fig. 2.7A-C). Hence, after KA injury, LCN2R mRNA and protein 













LCN2R protein expression after KA injury










































Fig. 3.5. LCN2R protein expression downregulated after KA injury. Western blot 
analysis of LCN2R protein expression in the right hippocampus at (A) 1 day, (B) 3 
days and (C) 2 weeks post-KA vs -saline icv injection. n = 3 per treatment group. (D) 
Densitometric analysis of LCN2R protein expression. LCN2R was downregulated 
after KA injury. Values are normalised with the saline-injected controls of the 
respective timepoints. Analysed by Student’s t-test, asterisks indicate significant 
difference (*p < 0.05, **p < 0.01, ***p < 0.001). Data are expressed as mean ± SEM, 
n = 3 per treatment group. 
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3.3.2.3. Changes in LCN2R immunoreactivity in the rat hippocampus after KA 
injury 
 Immunofluorescence staining of LCN2R was detected on the neurons of the 
hippocampus in the saline-injected controls (Fig. 3.6A, B), similar to the staining 
observed in the normal (untreated) hippocampus (Fig. 3.2). After KA injury, LCN2R 
staining was reduced in the neurons, but upregulated in other cell types in the 
lesioned areas. To identify the cell type, sections were colabelled with LCN2R and 
OX-42 (marker for microglia). 
Immunostaining for OX-42 (as shown in the inserts in their respective 
timepoints) illustrates the change in morphology of the microglia. With time, the 
morphology of the microglia transformed from that of ramified microglia to activated 
and reactive microglia. In the hippocampus of normal (untreated) and saline-injected 
control animals, the ramified cells possess a small oval cell body and numerous 
processes of small diameter radiating from the soma. With KA insult, activated 
microglia were observed with larger cell bodies and with shorter and stouter 
processes (Davis et al., 1994; Stoll and Jander, 1999; Streit et al., 1999; 2000) (Fig. 
3.6). 
At 1 day post-KA injection, LCN2R was localised at the pyramidal neurons of 
the intact CA1 region and did not colocalise with the ramified microglia (Fig. 3.6C). 
The microglia had similar morphology to those observed in the 2 weeks post-saline 
injection controls. In contrast, at the CA3 region, sparse LCN2R staining colocalised 
with OX-42 in the hippocampal lesioned area (Figure 3.6D). At 3 days post-KA 
injection, LCN2R was upregulated together with OX-42 in both CA1 and CA3 
lesioned areas (Figure 3.6 E-F). Intense upregulation of LCN2R and OX-42 was also 
observed in the lesioned areas of 2 weeks post-KA injection sections (Figure 3.6G-
H). Among the three timepoints, the upregulation of LCN2R and OX-42 positive cells 
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was the greatest at 2 weeks post-KA injection. At all timepoints, LCN2R colocalised 
with OX-42 in the lesioned areas. 
Forty times magnifications of the CA1 hippocampal region of 3 days (Fig. 
3.7A) and 2 weeks (Fig. 3.7C) post-KA injection samples indicate that majority of the 
LCN2R positive cells were immunolabelled with OX-42. Orthogonal projections 
through CA1 lesioned region at higher magnification demonstrate that LCN2R was 
present in the OX-42-positive cells at both timepoints (Fig. 3.7B, D), confirming 
LCN2R’s upregulation in the microglia after KA injury. 
 
3.3.2.4. Immunoreactivity at CA1-CA2 region in KA-treated sections 
In the previous section, LCN2R was shown to be expressed in neurons in 
normal/saline conditions and upregulated in microglia in lesioned areas. Hence, the 
immunoreactivity of LCN2R was examined at higher magnifications at the CA1 to 
CA2 region to further confirm the change in cellular localisation after KA injury. As 
observed previously, in the CA1 hippocampal lesioned area of 2 weeks post-KA 
injection samples, LCN2R positive cells colocalised with the OX-42 positive microglia 
cells (Fig. 3.8A). Interestingly, in the non-lesioned CA2 hippocampal region, LCN2R 
was expressed in the intact pyramidal neurons instead (Fig. 3.8A). This confirms that 
LCN2R is expressed in the microglia in lesioned areas, and remained localised in the 
intact neurons after KA injury.  
At 2 weeks post-KA injection, LCN2 was highly upregulated in the astrocytes 
(Chapter 2) and its receptor, LCN2R, was also greatly upregulated in microglia at this 
timepoint. Hence, to examine the relationship between LCN2 and LCN2R, double 
immunolabelling was performed on 2 weeks post-KA injection sections.  
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Similar to Figure 3.8A, LCN2R was present in neurons of the CA2 region, and 
had lower expression in the lesioned area, while LCN2 was upregulated in the 
astrocytes of the lesioned CA1 region (Fig. 3.8B).  
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Fig. 3.6. Changes in cellular localisation of LCN2R in the rat hippocampus after 
KA injury. Hippocampal sections were double-labelled with LCN2R (green) and OX-
42 (red), a marker for microglia. (A, B) In 2 weeks post-saline injection samples, 
immunostaining of LCN2R at the neurons in CA1 and CA3 regions and did not 
colocalise with OX-42. (C) LCN2R was expressed at the pyramidal neurons at CA1, 
but (D) colocalised with OX-42 at CA3 in 1 day post-KA injection samples. LCN2R 
colocalise with OX-42 in the CA1 and CA3 regions in (E, F) 3 days and (G, H) 2 
weeks post-KA injection samples. Scale=100 μm, Inserts in A-H shows morphology of 
microglia labelled with OX-42 at the timepoint. Scale in inserts=10 μm.  
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Fig. 3.7. Confocal micrographs of colocalisation of LCN2R with OX-42 positive 
cells. Right hippocampus at (A, B) 3 days and (C, D) 2 weeks post-KA injection was 
double-labelled with LCN2R (green) and OX-42 (red), a marker for microglia. (A, C) 
40x magnification showed LCN2R positive cells are OX-42 positive. (B, D) 63x 
magnifications of orthogonal projections through CA1 lesioned region of the cells 
indicated by the white arrows in (A) and (C). LCN2R is present in microglia. Scale=20 
μm. 
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Fig. 3.8. Immunoreactivity at CA1-CA2 region in KA-treated sections. (A) 
Colocalisation studies of LCN2R (red) and OX-42 (green). LCN2R was localised at 
intact pyramidal neurons (CA2 region) and upregulated in the microglia of the CA1 
lesioned area. (B) Colocalisation studies of LCN2 (green) and LCN2R (red). LCN2R 
was predominantly expressed in the intact neurons at CA2 region, while LCN2 was 
upregulated in the astrocytes at CA1. Scale=50 μm. 
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3. 4. DISCUSSION  
The present study was carried out to examine the expression and cellular 
localisation of LCN2R physiologically and after KA injury to help investigate a 
possible function of LCN2 in KA-induced neurodegeneration. For the first time, the 
two known LCN2 receptors, LCN2R and megalin, were detected in the intact 
hippocampus and LCN2R was observed to have changes in cellular localisation after 
KA injury.  
In Chapter 2, a tremendous upregulation (20-fold increase) of LCN2 mRNA 
and protein expression were observed after LPS treatment. As a preliminary finding, 
real-time RT-PCR was performed to detect the difference in LPS and KA treatments 
on the LCN2 receptors. With LPS treatment, megalin and LCN2R mRNA expression 
decreased significantly by 26% and 32% respectively. At 2 weeks post-KA injection, 
the significant downregulation of both receptors were even more pronounced; 
megalin’s mRNA expression decreased by 50% while LCN2R’s mRNA expression 
decreased by almost 70%.  
In both treatments, LCN2 receptors were significantly downregulated and the 
decrease in LCN2R was more pronounced than megalin, suggesting that LCN2R 
could be more sensitive to insults. In the normal rat, LCN2R was detected in neurons 
as it colocalised with MAP2a at the hippocampal formation and at the dentate gyrus. 
The staining of LCN2R was specific as it was abolished with the addition of blocking 
peptide. Since LCN2R was localised at the neurons, the decrease in expression is 
likely due to neuronal loss after KA-induced neurodegeneration. Furthermore, KA-
treated samples have a greater decrease of LCN2 receptors compared to the LPS-
treated samples because in the KA-induced neurodegeneration model, excitotoxicity 
causes neuronal loss either through necrosis or apoptosis (Nishiyama et al., 1996; 
Pollard et al., 1994b; Portera-Cailliau et al., 1997; Wang et al., 2005), while LPS-
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induced inflammatory mediators indirectly cause neuronal damage (Boje and Arora, 
1992; Choi et al., 2008; Jeohn et al., 1998). Therefore, the neuronal loss sustained 
due to KA injury is expected to be greater than in LPS treatment. These results 
further strengthen the evidence for LCN2R localisation on neurons physiologically. 
 With this preliminary understanding, we next investigated LCN2R at 1 day, 3 
days and 2 weeks post-KA injection to understand the progression of its possible 
expression changes at different phases of neurodegeneration. After KA injury, 
LCN2R mRNA expression decreased significantly by 70-80%, likely due to neuronal 
damage. Similarly, LCN2R protein levels also decreased significantly by 47% in 1 
day post-KA injection hippocampi and 87% and 82% in 3 days and 2 weeks post-KA 
injection hippocampi respectively. Higher LCN2R protein levels were observed 1 day 
post-KA injection, likely due to the delayed onset of neurodegeneration after KA 
injection (Sperk et al., 1983; Tokuhara et al., 2007). Thus at later timepoints, most 
neurons have undergone degeneration. Hence, LCN2R protein levels were similar at 
3 days and 2 weeks post-KA injection. 
Interestingly, although mRNA and protein levels of LCN2R were reduced 
significantly after KA injury, intense immunoreactivity for LCN2R was observed in 
OX-42 positive microglial cells in lesioned areas of KA-treated sections. Although 
OX-42 labels all types of microglia, LCN2R colocalised only with activated microglia 
characterised by its amoeboid morphology, which is different from its resting, ramified 
form. This is evident from the double immunofluorescence staining of LCN2R with 
OX-42 at 1 day post-KA injection samples: Only the CA3 hippocampal subfield was 
lesioned, as shown in the Nissl staining in Figure 2.8B (Chapter 2). Hence, 
upregulation and colocalisation of OX-42 and LCN2R was observed in the lesioned 
area. In contrast, the CA1 hippocampal region was intact, hence LCN2R staining was 
localised at the pyramidal neurons and did not colocalise with the ramified microglia. 
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This resembles the neuronal expression of LCN2R at the neurons and ramified 
microglia in saline-injected controls. Expression of LCN2R and OX-42 increase 
steadily at the lesioned sites from 1 day to 3 days and peaked at 2 weeks post-KA 
injection. The morphological and expression changes of microglia observed in the 
present study corresponds with previous studies which shown upregulation of 
activated microglia at 1 day after icv KA injection, increasing in number gradually to 
peak at 1 month before declining (Jorgensen et al., 1993; Mitchell et al., 1993). Thus, 
it is possible that LCN2R expression may even be more highly upregulated in the 
activated microglia at 1 month post-KA injection. 
The cellular localisation of LCN2R was further confirmed by examining the 
intersection between the lesioned CA1 region and the intact CA2 hippocampal 
regions of 2 weeks post-KA injection sections at high magnifications. LCN2R was 
expressed at the neurons in the intact CA2 region and at the activated microglia in 
the lesioned CA1 region, further confirming the decrease of LCN2R in neurons to the 
upregulation in activated microglia after KA injury. The punctate staining of LCN2R 
observed here is also congruent with localisation of LCN2R in a punctate distribution 
in LCN2R stable HEK cell lines (Bennett et al., 2011). 
The expression of LCN2R in the neurons and microglia observed here is 
consistent with the previous studies reporting the expression of LCN2R in primary 
microglia, BV-2 microglial cells, primary cortical neurons and B35 neuroblastoma 
cells (Lee et al., 2007; 2011). Although, LCN2R was also expressed in murine 
primary astrocytes and C6 glioma cells (Lee et al., 2009), the same was not 
observed in the astrocytes in vivo. This discrepancy could be due to differences in 
species (in orthologues) or in vitro and in vivo differences. LCN2R neuronal staining 
also corresponded with the high LCN2R mRNA expression detected in primary 
neurons (Bennett et al., 2011).  
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It is noteworthy to point out that despite the pronounced increase of LCN2R 
immunoreactivity in the activated microglia after KA injury, especially at 2 weeks 
post-KA injection, the overall LCN2R mRNA and protein expression still decreased. 
This phenomenon indicates that LCN2R is highly expressed in the neurons and the 
decrease in expression could not be compensated by the further upregulation of 
LCN2R in the activated microglia. The abundant expression of LCN2R in the neurons 
suggests its involvement in physiological conditions. 
Taken together, during KA-induced neurodegeneration, upregulation of LCN2 
in the astrocytes may result in the secretion of LCN2 into the extracellular 
environment as LCN2 was reported to be secreted by primary astrocytes into the 
culture media (Lee et al., 2009). The released LCN2 could bind the receptors on the 
neighbouring effector cells, in this case, either the LCN2R expressing-activated 
microglia or -intact neurons. LCN2-induced apoptosis mediated by LCN2R had been 
reported in mouse primary microglia, cortical neurons, BV-2 microglial cells, B35 
neuroblastoma and 24p3R-expressing HeLa cells (Devireddy et al., 2005; Lee et al., 
2007; 2011). Could the same be observed in vivo? For the first time, the cellular 
localisation of both LCN2 and LCN2R were elucidated in the hippocampus. 
Nonetheless, the effect of the astrocytic expression of LCN2 on the LCN2R-
expressing neurons and activated microglia are still unknown and will be examined in 
Chapters 4 and 5.  
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4.1. INTRODUCTION 
In the previous chapters (Chapter 2 and 3), it was established that after KA-
induced injury, LCN2R expression was decreased in the neurons, but upregulated in 
the activated microglia, at the lesioned site. This was accompanied by an 
upregulation of LCN2 in the astrocytes.  
Recent studies have suggested LCN2 and LCN2R to have a role in 
apoptosis. Addition of LCN2/24p3 (murine orthologue of LCN2) was internalised by 
24p3R-expressing cells, resulting in apoptosis (Devireddy et al., 2005). In most 
neurodegenerative diseases, and in the KA-induced neurodegeneration model, 
neuronal loss is often associated with apoptosis, together with other types of 
neuronal death, such as necrosis, and more recently autophagy (Jellinger, 2010; 
Pollard et al., 1994b; Przedborski et al., 2003). 
Furthermore, the pro-apoptotic effect of 24p3/LCN2 was shown to be 
associated with Bim as Bim was increased with 24p3/LCN2 treatment in 24p2R-
expressing HeLa cells, primary astrocytes, C6 glioma cells and B35 neuroblastoma 
(Devireddy et al., 2005; Lee et al., 2009; 2011). The pro-apoptotic effect of 
24p3/LCN2 was abolished by stable knockdown of Bim. This confirms that LCN2’s 
pro-apoptotic effect on cells was Bim-dependent. Nonetheless, the same was not 
observed in primary microglia and BV-2 microglial cells, indicating LCN2’s apoptotic 
role may have other pathways (Lee et al., 2007). Although it appears that the Bim-
dependent apoptotic effect of LCN2 may be dependent on cell type, it is still intriguing 
to investigate whether LCN2 and LCN2R have an effect on apoptosis in KA-induced 
neurodegeneration via Bim. 
Bim is a pro-apoptotic member of the Bcl-2 homology domain 3 (BH3) 
subfamily of the Bcl-2 family. The Bcl-2 family consists of both anti- and pro-apoptotic 
Chapter 4: Expression of Bim in KA-lesioned hippocampus 
 
   95 
 
proteins, which share sequence homology with the conserved region known as the 
Bcl-2 homology (BH) domains (Danial, 2007; Youle and Strasser, 2008). The anti-
apoptotic members are Bcl-2, Bcl-XL and Bcl-w proteins, while the pro-apoptotic 
members are categorised into multidomain proteins, such as Bax and Bak; and the 
BH3-only proteins, including Bim, Bid and Puma (Danial, 2007). The members of 
BH3 subfamily are important initiators of the intrinsic (mitochondrial) pathway, by 
activating Bax/Bak either through direct or indirect binding to anti-apoptotic Bcl-2 
members (Cheng et al., 2001; Wei et al., 2001). As it can bind all anti-apoptotic Bcl-2 
members, Bim is known as one of the potent members in the BH-3 subfamily 
(O'Connor et al., 1998). Bim has three major isoforms generated by alternative 
splicing, namely the BimEL (extra-long), BimL (long) and BimS (short) (O'Connor et al., 
1998). The BimEL form is detected in the rat brain and is most common in neurons 
(Shibata et al., 2002; Whitfield et al., 2001), unlike BimL and BimS, which are detected 
in rat C6 glioma cells but not in rat brain (Shinoda et al., 2004). Bim is usually 
sequestered to the microtubule-associated dynein motor complex and when 
released, it associates with 14-3-3 to be translocated to the mitochondria to promote 
activation of Bax/Bak-dependent apoptosis via neutralisation of anti-apoptotic 
proteins (Puthalakath et al., 1999; Shinoda et al., 2004).  
Furthermore, Bim has been demonstrated to promote neurodegeneration in 
various experimental paradigms. Upregulation of Bim was observed in hippocampal 
injury in seizure models induced by intra-amygdala KA injection (Murphy et al., 2010; 
Shinoda et al., 2004). Bim was also reported to be induced in growth factor (NGF) 
withdrawal-induced apoptosis in sympathetic neurons (Putcha et al., 2001). In trophic 
factor deprivation (TFD), c-Jun N-terminal kinases (JNKs) caused induction and 
phosphorylation of Bim to induce a Bim-dependent cell death (Putcha et al., 2003).  
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In KA-induced excitotoxicity, triggers from the intrinsic pathway were evident, 
such as the release of cytochrome-c and disruption of mitochondrial membrane 
potential (Wang et al., 2005). Therefore, together with the previous studies on the 
pro-apoptotic effect of Bim in various neurodegeneration models, LCN2 and LCN2R 
may have an effect on apoptosis in KA-induced neurodegeneration via Bim, a pro-
apoptotic protein in the intrinsic pathway. This chapter will examine Bim expression 
changes and especially its cellular localisation after KA injury to determine if it has 
any association with LCN2R-expressing microglia and neuronal cells. 
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4.2. MATERIALS AND METHODS  
4.2.1. Animals and kainate (KA) injections 
Male Wistar rats weighing approximately 200 g each were anaesthetised with 
intraperitoneal injection of ketamine (75 mg/kg) and xylazine (10 mg/kg). KA (1.2 µl 
of 1 mg/ml) was stereotaxically injected into the right lateral ventricle (coordinates: 
1.0 mm caudal to bregma, 1.5 mm lateral to the midline, 4.5 mm from the surface of 
the cortex) using a microlitre syringe (5 μl Hamilton syringe, Model no.: 88000, 24 
gauge needle, outer diameter of needle: 0.57 mm, inner diameter of needle: 0.31 
mm). Experimental control rats were injected with 1.2 µl of normal saline instead of 
KA. All procedures involving animals were approved by the Institutional Animal Care 
and Use Committee, NUS 
 
4.2.2. Real-time RT-PCR 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals were sacrificed at 1 day, 3 days and 2 weeks after injection. 
Tissues were freshly dissected from the brain and immersed into RNAlater (Ambicon, 
CA, USA), flash frozen and kept at -80°C until analysis. Total RNA was isolated using 
TRIzol reagent (Invitrogen, CA, USA) according to the manufacturer’s protocol, and 
RNeasy Mini Kit (Qiagen Inc., CA, USA) was used to purify the RNA. The samples 
were reverse transcribed using High-Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems, CA, USA). The reaction conditions were 25°C for 10 min, 37°C 
for 120 min and 85°C for 5 min. Real-time PCR amplification was carried out using 
the 7500 Real-time PCR system (Applied Biosystems, CA, USA) with Taq-Man 
Universal PCR Master Mix (Applied Biosystems, CA, USA) and gene-specific primers 
and probes according to manufacturer’s protocols (Assay ID: Bim 
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(Rn00674175_m1)). β-actin (Part no: 4352340E) was used as an internal control. All 
primers and probes were synthesised by Applied Biosystems. The PCR conditions 
were: an initial incubation of 50°C for 2 min and 95°C for 10 min followed by 40 
cycles of 95°C for 15 s and 60°C for 1 min. All reactions were carried out in 
triplicates. The threshold cycle, CT, which correlates inversely with the levels of 
target mRNA, was measured as the number of cycles at which the reporter 
fluorescence emission exceeds the preset threshold level. The amplified transcripts 
were quantified using the comparative CT method (Livak and Schmittgen, 2001), with 
the formula for relative fold change = 2–∆∆CT. The mean was calculated, and possible 
significant differences were analysed using Student’s t-test. p < 0.05 was considered 
significant.  
 
4.2.3. Western blotting 
Three KA-injected rats and three saline-injected control animals were 
sacrificed at 1 day, 3 days and 2 weeks after injection. The rats were anaesthetised 
by intraperitoneal injection of ketamine and xylazine and decapitated. The right 
hippocampi were quickly removed and homogenised in cold lysis buffer containing 
Tris–HCl, pH 7.4, 10 mM EDTA, 150 mM NaCl, 0.5% Triton X-100 with protease 
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA) and placed on the 
shaker for 1 hr at 4°C. After centrifugation at 12,000g for 30 min, the supernatant was 
collected, and protein concentration was determined using the BCA protein assay kit 
(Pierce Biotechnology, Rockford, IL, USA). Prior to gel electrophoresis, the protein 
lysates were denatured by heating the sample in the presence of SDS and DTT for 
10 min at 95-100°C. 
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Total protein (60 µg) was resolved in 12% SDS-polyacrylamide gel under 
reducing conditions and electro-transferred to a nitrocellulose membrane (Biorad, 
CA, USA). Non-specific binding sites on the membrane were blocked by incubation 
with 5% non-fat milk for 1 hr. The membrane was then incubated overnight with 
monoclonal rabbit goat anti-Bim antibody at 1:1000 (Cell Signaling Technology, MA, 
USA). Specificity of the Bim antibody was verified by pre-incubating 230 ng/ml (10x) 
and 460 ng/ml (20x) of recombinant Bim peptide (Cell Signaling Technology, MA, 
USA) with 23 ng/ml Bim antibody overnight. After washing with 0.1% Tween-20 in 
TBS, the membrane was incubated with horseradish peroxidase-conjugated goat 
anti-rabbit immunoglobulin lgG (1:10,000; Thermo Fisher Scientific, Rockford, IL, 
USA) for 1 hr at room temperature. The protein was visualised with SuperSignal 
West Pico chemiluminescent substrate (Thermo Fisher Scientific, Rockford, IL, USA) 
according to the manufacturer’s instructions. Blots were treated with stripping buffer 
(Restore Western Blot Stripping Buffer, Thermo Fisher Scientific, Rockford, IL, USA) 
at room temperature for 10 min before reprobing of membrane with antibody to β-
actin (Sigma, St. Louis, MO, USA). Exposed films were scanned with at least 300 dpi 
and the mean optical density of the protein bands of LCN2R was analysed by 
densitometry using ImageJ (NIH, Maryland, USA), and normalised to β-actin.  The 
mean was calculated, and possible significant differences were analysed using 
Student’s t-test. p < 0.05 was considered significant. 
 
4.2.4. Double immunofluorescence labelling 
A total of 24 animals were used, four KA-injected animals versus four saline-
injected control animals were sacrificed at 1 day, 3 days and 2 weeks after injection 
to study the effect of KA lesions. The rats were anaesthetised by intraperitoneal 
injection of anaesthetic comprising ketamine and xylazine and transcardially perfused 
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with Ringer solution, followed by 4% paraformaldehyde in 0.1M phosphate buffer (pH 
7.4). The brains were dissected out, and blocks containing the hippocampus were 
sectioned coronally at 20 µm using a freezing microtome. Sections were soaked in 
phosphate buffered saline (PBS) for 30 min to remove traces of sucrose and 
permeabilised with PBS-0.3% Triton X-100 for 10 min. Antigen retrieval was 
performed by incubating the sections in 1% sodium dodecyl sulfate (SDS) for 5 min, 
followed by PBS washes. They were then blocked with 5% goat serum in PBS-0.3% 
Triton X-100 for 1 hr, followed by incubation with rabbit monoclonal antibody to Bim 
at 1:100 (Cell Signaling Technology, MA, USA) and/or mouse monoclonal antibody to 
OX-42 (1:200, Chemicon, Temecula, CA, USA) or mouse monoclonal antibody to 
NeuN (1:200, Millipore, MA, USA) overnight at 4°C. Specificity of the Bim antibody 
was verified by pre-incubating 2.3 μg/ml (10x) of recombinant Bim peptide (Cell 
Signaling Technology, MA, USA) with 0.23 μg/ml Bim antibody overnight. The 
sections were washed in PBS, and incubated for 1 hr at room temperature in 1:200 
dilution of goat anti-rabbit lgG (H+L) Alexa Fluor 555 and/or goat anti-mouse IgG 
(H+L) Alexa Fluor 488 (Invitrogen, CA, USA). The sections were then washed and 
mounted with ProLong® Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA, 
USA) and captured using a fluorescence microscope (Olympus BX51; Olympus 
Corporation, Tokyo, Japan) and a laser scanning confocal microscope (LSM 510, 
Carl Zeiss Göttingen, Germany). Colocalisation was established by analysing the 
overlap between the different labels by orthogonal reconstruction throughout the 
entire z-stack (LSM 510, Carl Zeiss Göttingen, Germany). 
 
4.2.5. In situ cell death detection (TUNEL assay) 
TUNEL assay was performed on tissues from 1 day, 3 days and 2 weeks 
post-kainate treated animals in accordance with the manufacturer’s instructions for 
the in situ cell death detection kit, Fluorescein (Roche, Mannheim, Germany). 
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Colocalisation of Bim and TUNEL assay was done by performing 
immunofluorescence staining of Bim before performing TUNEL assay. Sections were 
incubated with rabbit anti-Bim monoclonal antibody overnight at 4°C, then incubated 
for 1 hr at room temperature in 1:200 dilution of goat anti-rabbit lgG (H+L) Alexa 
Fluor 555 (Invitrogen, CA, USA). After PBS-0.1% Triton-X washes, sections were 
incubated with Proteinase K (10 µg/ml in 10 mM Tris/HCI, pH 7.4) at 37°C for 30 min. 
Sections were washed twice with PBS. For positive controls, DNAse I recombinant 
was added at (30U/ml) at 37°C for 30 min to induce DNA strand breaks. Sections 
were then incubated with TUNEL reaction mixture with 40 μl/section, at 37°C for 1 hr. 
Negative controls were incubated with label solution without the enzyme solution. 
The sections were then washed and mounted with ProLong® Gold antifade reagent 
with DAPI (Invitrogen, Carlsbad, CA, USA) and captured using a fluorescence 
microscope (Olympus BX51; Olympus Corporation, Tokyo, Japan). Colocalisation 
was established using a laser scanning confocal microscope (LSM 510, Carl Zeiss 
Göttingen, Germany) to analyse the overlap between the different labels by 
orthogonal reconstruction throughout the entire z-stack (LSM 510, Carl Zeiss 
Göttingen, Germany). 
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4.3. RESULTS 
4.3.1. mRNA expression of Bim in kainate-lesioned hippocampus 
At 1 day post-KA injection, real-time RT-PCR showed that there is no 
significant difference between KA- and saline-injected hippocampus in Bim mRNA 
expression. In contrast, Bim mRNA expression was 1.4- (p < 0.01) and 2.1- (p < 
0.01) fold in the right hippocampus at 3 days and 2 weeks post-KA injury relative to 
























Fig. 4.1. Bim mRNA expression upregulated after KA injury. Real-time RT-PCR 
analysis of Bim mRNA expression at the right hippocampi at 1 day, 3 days and 2 
weeks post-KA injection, relative to their saline-injected controls. Bim mRNA levels 
increased significantly at 3 days and 2 weeks post-KA injection. Analysed by 
Student’s t-test, asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 
0.001). Data are expressed as mean ± SEM, n = 4 per treatment group. 
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4.3.2. Protein expression of Bim in kainate-lesioned hippocampus 
To validate the mRNA changes in Bim expression, western blot analysis was 
performed with hippocampal lysate from the right side of the brain, i.e. site of icv 
injection. At 1 day post-KA injection, there is no obvious difference in intensity of the 
bands between treated and saline-injected animals (Fig. 4.2A). At 3 days post-KA 
injection, denser bands at 23kDa were observed for KA-treated samples relative to 
the saline-injected controls (Fig. 4.2B). The increase in band intensity was even more 
pronounced in 2 weeks post-KA injection hippocampi (Fig. 4.2C). Densitometric 
analysis revealed no significant differences between 1 day post-KA and saline 
injection samples. In contrast, significant increases in Bim protein levels were 
detected at 3 days and 2 weeks post-KA injection with 2.5- (p < 0.01) and 5.0- (p < 
0.01) fold in KA-treated samples relative to the saline controls, respectively (Fig. 
4.2E).  
This upregulation of Bim protein levels validates the increase in mRNA levels 
from real-time RT-PCR results. Control experiments performed by incubating blots 
with 10x and 20x antigen-absorbed Bim antibody showed absence of bands for 2 
weeks post-KA injection hippocampal lysates, indicating specificity of the Bim 
antibody (Fig. 4.2D).  
 
4.3.3. Regional expression of Bim in kainate-lesioned hippocampus 
Since Bim mRNA and protein expression were greatly expressed at 2 weeks 
post-KA injection, sections from this timepoint were used to perform the control 
experiments. Upregulation of Bim was detected at the subiculum (Fig. 4.3A), CA1 
(Fig. 4.3C) and CA3 (Fig. 4.3E) lesioned areas of the right hippocampus. Sections 
incubated with pre-incubated Bim antibody with 10x excess blocking peptide (2.3 
µg/ml) showed an absence of staining at the subiculum (Fig. 4.3B), CA1 (Fig. 4.3D),  
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Bim protein expression after KA injury
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Fig. 4.2. Bim protein expression changes after KA injury. Western blot analysis 
of Bim protein expression in the right hippocampi at (A) 1 day, (B) 3 days and (C) 2 
weeks post-KA vs. -saline icv injection. (D) 2 weeks post-KA treated hippocampi 
lysates, R4 and R6 were used for three sets of incubation conditions for the blocking 
experiments. Lane 1 and 2 from the left: Incubated with 23 ng/ml of Bim antibody. 
Lane 3 and 4: Incubated with Bim antibody pre-absorbed with 230 ng/ml of blocking 
peptide. Lane 5 and 6: Incubated with Bim antibody pre-absorbed with 460 ng/ml of 
blocking peptide. (E) Densitometric analysis of Bim protein expression in (A-C) 1 day, 
3 days and 2 weeks post-KA vs. saline-injected controls. Values are normalised with 
the saline-injected controls at the respective timepoints. Analysed by Student’s t-test, 
asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). Data are 
expressed as mean ± SEM, n = 3 per treatment group. 
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Fig. 4.3. Regional expression of Bim in 2 weeks post-KA injection lesioned 
hippocampus. Immunoreactivity of Bim (red) was upregulated at (A) subiculum/CA1, 
(C) CA1 and (E) CA3 regions of the right hippocampus. (B, D and F) Sections 
incubated with pre-absorbed Bim antibody with 10x excess blocking peptide showed 
absence of positive Bim staining. Scale=500 μm. 
 
and the CA3 (Fig. 4.3F) hippocampal regions. This indicates the specificity of the Bim 
antibody. Immunoreactivity of Bim in the lesioned area suggests that the upregulated 
Bim could be localised in glial cells since gliosis are usually observed in the lesioned 
areas where neurons are damaged. Next, double immunofluorescence was 
performed to identify the localisation of Bim.  
 
4.3.4. Cellular expression of Bim in kainate-lesioned hippocampus 
Double immunofluorescence was carried out to identify the cellular 
localisation of Bim after KA injury. Negligible Bim staining was observed in all the 
saline-injected controls, as represented by 2 weeks post-saline injection 
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hippocampus (Fig. 4.4A). In contrast, 1 day (Fig. 4.4B), 3 days (Fig. 4.4C) and 2 
weeks (Fig. 4.4D) post-KA injection hippocampal sections had increased Bim 
immunoreactivity and colocalisation of Bim and OX-42, a marker for microglia. After 
KA injury, OX-42 positive cells had an amoeboid morphology unlike the ramified cells 
observed in saline controls, indicating activation of microglia (as described in Chapter 
3, Results, Section 3.3.2.3). The 2 weeks post-KA injection sections had the greatest 
upregulation of Bim and OX-42 positive cells in the lesioned hippocampal regions. 
Orthogonal projections through CA1 lesioned region at a higher magnification 
demonstrate that Bim was present in the OX-42-positive activated microglia (Fig. 
4.4E). 
Only in 1 day post-KA injection sections, upregulation of Bim was also 
observed in neuronal-like cells in addition to the OX-42 immunopositive cells. Hence, 
double immunofluorescence of Bim and NeuN (marker for neurons) was performed. 
In 1 day post-saline injection controls, no Bim was detected (Fig. 4.5A-C), but it was 
upregulated in NeuN positive cells in KA-treated sections in the CA1 (Fig. 4.5D-F) 
and CA3 (Fig. 4.5G-I) hippocampal regions. Orthogonal projections through the CA1 
lesioned region at higher magnification demonstrate that upregulated Bim was 
localised in the NeuN positive pyramidal neurons at the CA1 and CA3 hippocampal 
regions of 1 day post-KA injection hippocampal sections (Fig. 4.5J).  
Therefore upregulated Bim was detected in the activated microglia of the CA1 
and CA3 hippocampal lesioned areas at all timepoints after KA injury; and detected 
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Fig. 4.4. Confocal micrographs of upregulation of Bim in activated microglia 
after KA injury. (A) In 2 weeks post-saline injection controls, negligible Bim staining 
was observed. At (B) 1 day, (C) 3 days and (D) 2 weeks post-KA injection, 
upregulated Bim (red) colocalised with OX-42 (green). (E) Orthogonal projections 
through CA1 lesioned region at higher magnification demonstrate that Bim was 
upregulated in the OX-42-positive cells. Confocal micrographs were taken from CA1 
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Fig. 4.5. Confocal micrographs of upregulation of Bim in neurons at 1 day post-
KA injury. Hippocampal sections were incubated with anti-Bim (red) and anti-NeuN 
(green) antibody. (A-C) No Bim staining detected in the CA1 region of a 1 day post-
saline injection sample. In KA-treated sections, Bim staining colocalised with NeuN in 
(D-F) CA1 and (G-I) CA3 regions of the hippocampus. (J) Orthogonal projections 
through CA1 lesioned region at higher magnification demonstrate that Bim is present 
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4.3.5. Apoptotic condition in hippocampus after KA injury 
 Since Bim is a pro-apoptotic protein, TUNEL assay was performed to 
determine if the upregulation of Bim in the activated microglia and neurons would 
lead to apoptosis. There was an absence of TUNEL positive cells at 2 weeks post-KA 
injection (Fig. 4.6E and F). In 3 days post-KA injection samples, some TUNEL 
staining was observed at the pyramidal neurons in the CA1 and CA3 regions (Fig. 
4.6C and D) and was more pronounced in 1 day post-KA injection samples (Fig. 4.6A 
and B). Orthogonal projections through CA1 lesioned region in 1 day post-KA 
injected samples demonstrate that TUNEL positive cells were Bim positive, indicating 















Fig. 4.6. Fluorescent micrographs of TUNEL assay of the lesioned 
hippocampus after KA injury. In situ cell death detection kit was applied to right 
hippocampal sections to indicate the apoptotic status. Positive TUNEL staining 
(green) is an indication of apoptosis. CA1 and CA3 regions in (A, B) 1 day post-KA 
injection, (C, D) 3 day post-KA injection and (E, F) 2 weeks post-KA injection 
sections. 1 day and 3 days post-KA injection sections have TUNEL positive cells, 
while 2 weeks post-KA injection sections have no TUNEL staining. Scale=500 μm. 
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Fig. 4.7. Confocal micrograph of colocalisation of Bim with TUNEL staining in 1 
day post-KA injection sections. 1 day post-KA injection hippocampal sections were 
stained with (B) TUNEL assay (green) and double-labelled with (A) anti-Bim antibody 
(red). (C) Orthogonal projections through CA3 lesioned region demonstrate that Bim 
was present in the TUNEL-positive cells. Scale=20 μm.  
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4.4. DISCUSSION  
The present study was carried out to examine the expression and cellular 
localisation of Bim after KA injury. In this chapter, an association was made between 
Bim and the LCN2R-expressing cells, which is in line with this thesis’s hypothesis 
that LCN2 and LCN2R may have an effect on Bim-mediated apoptosis in KA-induced 
neurodegeneration.  
Although Bim has three major isoforms generated by alternative splicing, 
namely BimEL (extra-long), BimL (long) and BimS (short) (O'Connor et al., 1998), only 
BimEL can be detected in the rat hippocampus, while the other two were absent, 
consistent with the single band at 23kDa detected in the present study, similar to the 
observations made by Shinoda and colleagues (2004). Significant upregulation of 
mRNA and protein levels of Bim were detected at 3 days and 2 weeks post-KA injury, 
while no obvious change was detected at 1 day post-KA injury. Another study on icv 
KA injection in rats showed downregulation of Bim immunopositive cells at 6, 12 
hours, and the highest at 24 hours, which coincide with the greatest increase in 
Fluoro-Jade-stained cells (indicator of neurodegeneration) (Korhonen et al., 2003). 
The reduction of Bim expression before 24 hours could be attributed to neuronal loss 
as Bim was detected in hippocampal neurons (O'Reilly et al., 2000). 
In saline-injected control sections, low levels of expression of Bim were 
observed, consistent with reports of low Bim expression in normal physiological 
conditions (Murphy et al., 2010; O'Reilly et al., 2000). In contrast, upregulation of Bim 
was observed in all KA-treated sections, with intense immunoreactivity at 2 weeks 
post-KA injection when there was a 5.0 times increase in protein expression. Proteins 
upregulated at later timepoints after KA injury were often associated with gliosis 
(Zagulska-Szymczak et al., 2001) and indeed Bim was upregulated in activated 
microglia, characterised by their amoeboid morphology, in the lesioned areas of the 
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hippocampus at all timepoints after KA injury. In addition, at 1 day post-KA injection, 
other than in the activated microglia, upregulated Bim was also observed in the NeuN 
immunopositive neurons. Taken together, increased Bim expression was observed in 
the activated microglia and neurons. Interestingly, the cellular localisation of Bim 
coincided with the LCN2R-expressing cells, i.e. the activated microglia and neurons. 
Since the elevation of Bim expression was observed in the LCN2R-expressing cells, 
upregulation of Bim could be a downstream effect of the interaction between LCN2 
and LCN2R.  
To examine if the upregulated Bim had any apoptotic effect on the expressing 
cells, TUNEL assay was performed. Negative TUNEL staining was observed at 2 
weeks post-KA injection. Despite having the highest Bim mRNA and protein 
expression, the Bim expressing-activated microglia were not apoptotic. The 
upregulation of Bim in activated microglia might be a pro-apoptotic signal to clear the 
microglia as a self-regulatory mechanism in the inflammatory site after KA injury. 
Bim’s gradual increase in expression from 1 day to 2 weeks post-KA injection 
indicates that it may increase further at later timepoints. Therefore, at 2 weeks post-
KA injection, it might be too early to detect clearing or apoptosis of activated 
microglia as they have been shown to peak in numbers at one month post-KA 
injection before declining (Jorgensen et al., 1993; Mitchell et al., 1993). Alternatively, 
Bim may have other unknown functions in the activated microglia other than 
mediating apoptosis in the intrinsic pathway.  
In contrast, the TUNEL positive cells observed at 1 day and 3 days post-KA 
injection outlined the pyramidal neurons from CA1 to CA3 region, indicating the 
apoptotic cells were likely to be neuronal cells. Many studies have shown great 
increases in the number of Fluoro-Jade positive cells and TUNEL positive cells 
among the pyramidal neurons 1 day post-KA administration (Korhonen et al., 2003; 
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Shinoda et al., 2004) and detection of activated caspase 3 in the CA1 lesioned 
hippocampus 12 hours after excitotoxic injury in mice, which later peaked at 24 hours 
(Theofilas et al., 2009). This evidence further supports the present TUNEL positive 
staining at 1 day post-KA injection, indicating apoptosis was present. Furthermore, 
the majority of these apoptotic cells were Bim immunopositive, indicating that Bim-
expressing neurons were apoptotic. Upregulation of neuronal Bim was only detected 
at 1 day, but not 3 days or 2 weeks post-KA injection possibly because the Bim-
expressing neurons would have undergone apoptosis and could not be detected at 
later timepoints. Although LCN2R was expressed in both activated microglia and 
neurons, upregulation of Bim may have differential effects on them; Bim-expressing 
neurons were apoptotic, but not Bim-expressing activated microglia. 
It is interesting to note that although upregulation of Bim was observed in the 
activated microglia and neurons at 1 day post-KA injection, the upregulation was not 
reflected in the mRNA and protein expression, i.e. there was no significant difference 
between KA-treated and saline controls. As mentioned in previous studies, Bim could 
be downregulated due to neuronal damage, but its significance could have been 
negated by the increase in expression in the activated microglia and surviving 
neurons.  
In the present study, the increase in Bim mRNA and protein expression 
observed after KA injury is consistent with upregulation of Bim after intra-amygdala 
KA injection and KA treatment on hippocampal cultures (Murphy et al., 2010; 
Shinoda et al., 2004). However, no difference was detected between Bim-deficient 
and wild-type control mice after intrahippocampal KA injection (Theofilas et al., 
2009), which contradicted with another group that showed decreased hippocampal 
cell death from Fluoro-Jade staining of Bim-deficient mice compared to the wild-type 
controls (Murphy et al., 2010). Furthermore, Bim knockdown protected mouse 
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organotypic hippocampal cultures after KA-induced cell death (Murphy et al., 2010). 
Since neurodegeneration was still observed in the Bim-deficient mice despite lacking 
Bim expression, this indicates that other BH3-only proteins could compensate for 
Bim’s absence or the involvement of other mechanisms in contributing to the intrinsic 
and/or extrinsic pathway, leading to apoptosis. 
In this chapter, through the expression and localisation of Bim, LCN2R and 
Bim were found to be upregulated in the same cell types. Also, the LCN2R-
expressing neurons with upregulated Bim were found to be apoptotic. It is tempting to 
conclude that, at 1 day post-KA injection, LCN2 released by the astrocytes could 
interact with the LCN2R-expressing neurons to upregulate Bim, to trigger apoptosis. 
Unfortunately, such a conclusion would be premature as it is unclear if the 
upregulation of Bim is a downstream effect of LCN2 and LCN2R’s interaction. The 
increase in Bim could be due to other pro-apoptotic triggers downstream of KA-
induced excitotoxicity. Therefore, it is important to investigate the effect of LCN2 on 
Bim-dependent apoptosis, mediated by the receptor LCN2R, which will be examined 
in the following chapter, Chapter 5.  
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5.1. INTRODUCTION  
In the previous chapters we have seen that Bim was significantly upregulated 
at 3 days and 2 weeks post-KA injection, and coincidentally was localised in the 
LCN2R-expressing neurons and activated microglia. Also, the LCN2R-expressing 
neurons with upregulated Bim were found to be apoptotic. Yet it is unclear if the 
apoptosis and upregulation of Bim in the neurons was a consequence of LCN2 and 
LCN2R’s interaction. Therefore, this chapter aims to examine if LCN2 and LCN2R 
interact at the hippocampal neurons, and if they do, then to examine their 
localisation. The pertinent question of whether LCN2 has a direct role in upregulating 
Bim expression to trigger apoptosis in the neurons (Bim-dependent apoptosis) will 
also be addressed in this chapter. 
Besides mediating apoptosis, LCN2 is well-known as an iron-trafficking 
protein. Other than its role in sequestering iron-bacterial siderophore complexes to 
limit iron availability to the pathogen, LCN2 could bind iron and deliver it into the 
mammalian cells via endocytosis (Mori et al., 2005; Yang et al., 2002b). NGAL 
(human orthologue of LCN2):enterochelin can capture 55Fe and deliver it to the 
mouse kidney’s proximal tubule in vivo, whereas without NGAL, 55Fe was detected at 
the liver instead (Schmidt-Ott et al., 2006). Furthermore, the import of iron into the 
cells could regulate iron-responsive genes, such as the upregulation of ferritin and 
downregulation of transferrin receptor 1 (Devireddy et al., 2005; Yang et al., 2002b) 
and decreased levels of iron-regulatory protein IRP2 and conversion of IRP1 to 
cytosolic aconitase (Devireddy et al., 2010).  
Recently, a link was established between apoptosis and intracellular iron 
levels: Iron-loaded LCN2 (holo-LCN2) could import iron into the cell, increasing 
intracellular iron and thus inhibiting apoptosis. Iron-free LCN2 (apo-LCN2) could 
cause iron export via binding with intracellular endogenous mammalian 
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siderophore(s) complexed with intracellular iron (Richardson, 2005). The decrease in 
intracellular iron activates Bim, the pro-apoptotic protein, to stimulate apoptosis 
(Devireddy et al., 2005). Therefore, the iron status of LCN2 affects the intracellular 
iron level, which in turn determines the apoptotic status of the cell, i.e. the iron status 
of LCN2 accounts for the distinct biological effects on the cell. For instance, holo-
NGAL was more effective than apo-NGAL in inducing epithelial characteristics in 
4T1-Ras-transformed mesenchymal tumour cells (Hanai et al., 2005); and holo-
NGAL upregulated the expression of the iron-dependent reporter construct, but 
inhibited the iron-repressed genes while apo-NGAL resulted in an opposite effect (Li 
et al., 2004).  
Furthermore, LCN2-induced cell death sensitisation in B35 neuroblastoma, 
C6 glioma and BV-2 microglial cells was abolished upon the addition of the 
siderophore:iron complex (Lee et al., 2007; 2009; 2011). The siderophore:iron 
complex can associate with apo-LCN2 to form holo-LCN2 to import iron into the cells. 
Thus, by increasing intracellular iron levels, holo-LCN2 inhibits apoptosis. This 
indicates that the pro-apoptotic effect of LCN2 could be affected by the iron status of 
LCN2, which is consistent with the mechanism proposed by Green, Devireddy and 
colleagues (2005). Therefore, the effect of LCN2:Fe:siderophore (holo-LCN2) should 
be studied in comparison with LCN2 (apo-LCN2) to detect if they exert different or 
opposite effects on the cells as suggested by many studies. 
Due to the possible interactions that can occur among different cell types, to 
isolate the effect of LCN2 on neurons among all the other cell types, primary 
hippocampal neurons were cultured. This chapter aims to investigate the effect of 
iron on Bim-dependent apoptosis on the neurons by comparing apo-LCN2 and holo-
LCN2 conditions. 
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5.2. MATERIALS AND METHODS 
5.2.1. Primary hippocampal neuronal culture 
Primary neuronal cultures were obtained from hippocampi of newborn Wistar 
pups, by procedures approved by the Institutional Animal Care and Use Committee, 
NUS. Each set of primary hippocampal neuron isolation consisted of 6 hippocampi 
from 3 newborn pups. In all, 3 sets of cells were obtained from 9 newborn pups, n= 3. 
Brains were removed and placed in Dissection Medium (Hank’s balanced salts 
solution (HBSS, 0.01 M HEPES/NaOH). The hippocampi were dissected, cut into 
halves, and digested with papain in HBSS (1.5 mM CaCl2, 0.2 ug/ul of L-cysteine, 0.5 
mM EDTA, 20 units/ml DNase I, 15 units/ml papain) at 37°C for 30 min followed by 
mechanical trituration using a 1 ml pipette tip. Tubes were then clapped twice 
between hands to provide additional mechanical force for cell dissociation. 
Dissociated cells were harvested by centrifugation and resuspended in Neurobasal-A 
medium (supplemented with B27, 2 mM GlutaMAX-1 and 1% penicillin-streptomycin) 
for plating. 
Cells were seeded at 20,000 cells/coverslip in 24-well plates for Duolink 
assays; 160,000 cells/well in 12-well plates for RNA extraction for real-time RT-PCR 
analysis; 28,750 cells/well in 96-well plates for cell survival assays and were cultured 
at 37°C in a humidified 5% CO2 incubator. Plates were coated with 0.01% poly-L-
lysine solution (Sigma, St. Louis, MO, USA) at 37°C overnight and washed with cell 
culture grade PBS and water and left to dry before plating of cells. The primary 
cultures were used on days in vitro (DIV) 10 for immunocytostaining of LCN2R and 
treatment for Duolink assays, real-time RT-PCR analysis and cell survival assays. 
HBSS, HEPES/NaOH, penicillin/streptomycin, GlutaMAX-1, sodium pyruvate, B27 
supplement, and Neurobasal-A were from Invitrogen (Carlsbad, CA, USA); DNase I 
was from Roche (Roche Diagnostic GmbH, Mannheim, Germany); papain and 
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Immunocytochemistry for LCN2R was performed on primary hippocampal 
neurons on DIV 10. The cells on the coverslips were fixed with 4% paraformaldehyde 
for 10 min, followed by permeabilisation with PBS-01% Triton X-100 for 5 min. Cells 
were then blocked with 3% BSA in PBS for 1 hr at room temperature, followed by 
incubation with rabbit polyclonal antibody to Slc22A17/LCN2R at 1:2000 (Cell 
Signaling Technology, MA, USA) and mouse monoclonal MAP2a (1:200, Sigma-
Aldrich, MO, USA) overnight at 4°C. The cells were washed in PBS, and incubated 
for 1 hr at room temperature in 1:200 dilution of goat anti-rabbit lgG (H+L) Alexa 
Fluor 555 and goat anti-mouse IgG (H+L) Alexa Fluor 488 (Invitrogen, CA, USA). 
The cells were washed with PBS and mounted with ProLong® Gold antifade reagent 
with DAPI (Invitrogen, Carlsbad, CA, USA). Colocalisation was examined using a 
laser scanning confocal microscope by analysing the overlap between the different 
labels by orthogonal reconstruction throughout the entire z-stack (LSM 510, Carl 
Zeiss, Göttingen, Germany). 
 
5.2.3. Treatment of primary hippocampal neurons 
Primary hippocampal neurons were treated on DIV 10 for Duolink assays, 
real-time RT-PCR analysis and cell survival assays. Recombinant rat LCN2 (rLCN2) 
used for treatment was purchased from R&D systems (Minneapolis, MN, USA). To 
obtain the tricomplex, rLCN2:Fe:Ent, five-fold molar excess of ferric enterochelin (0.7 
kDa) (EMC Microcollections, Tϋbingen, Germany) was pre-incubated with rLCN2 
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protein as suggested by Lee and colleagues (2007, 2009) for 1 hr at 4°C. Different 
incubation times 30 min, 1 hr, 2 hr and overnight at 4°C all showed presence of 
LCN2:Fe:Ent complex as detected by native polyacrylamide gel electrophoresis. The 
MES buffer (25 mM MES and 150 mM NaCl, pH 6.5) used to reconstitute the 
lyophilised rLCN2 protein was used as the vehicle for controls. 
 
5.2.4. Native polyacrylamide gel electrophoresis  
500 ng of recombinant rat LCN2 (rLCN2) (Minneapolis, MN, USA) and rLCN2 
preincubated with five-fold molar excess of ferric enterochelin (0.7 kDa) (EMC 
Microcollections, Tϋbingen, Germany) were loaded for native gel electrophoresis. 
Bromophenol blue was added to the proteins to facilitate loading of the proteins into 
10% polyacrylamide gels (without SDS). Tris-glycine buffer without SDS, at pH 7.4 
and pH > 8.0 were used as the running and transfer buffer respectively. Post-transfer 
denaturation of the electro-transferred proteins was done with 10% SDS in TBS 
buffer at 70°C for 10 min. Reducing agents were avoided in the procedures prior to 
the post-transfer denaturation. Blocking of the membrane was performed with 5% 
non-fat milk for 1 hr. The membrane was then incubated overnight with polyclonal 
goat anti-LCN2 antibody at 1:200 (AF3508, R&D systems, Minneapolis, MN, USA). 
After washing with 0.1% Tween-20 in TBS, the membrane was incubated with 
horseradish peroxidase-conjugated mouse anti-goat immunoglobulin lgG (1:10,000; 
Thermo Fisher Scientific, Rockford, IL, USA) for 1 hr at room temperature. The 
protein was visualised with SuperSignal West Pico chemiluminescent substrate 
(Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s 
instructions.  
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5.2.5. Duolink in situ proximity ligation assay (PLA) 
On DIV 10, primary hippocampal neurons plated 20,000 cells/coverslip were 
treated with 20 µg/ml rLCN2, rLCN2:Fe:Ent or MES buffer as vehicle control for 24 
hrs. On DIV 11, they were fixed with 4% paraformaldehyde for 10 min, followed by 
permeabilisation with PBS-01% Triton X-100 for 5 min. Cells were then blocked with 
3% BSA in PBS for 1 hr at room temperature, followed by incubation with rabbit 
polyclonal antibody to Slc22A17/LCN2R at 1:2000 (Cell Signaling Technology, MA, 
USA) and goat polyclonal antibody to LCN2 at 1:200 (AF3508, R&D systems, MN, 
USA) overnight at 4°C. After PBS washes, cells were incubated with secondary 
antibodies conjugated with oligonucleotides (PLA probes MINUS and PLA probe 
PLUS) and incubated for 1 hr at 37°C. The PLA probe anti-rabbit MINUS binds to the 
rabbit LCN2R antibody, while the PLA probe anti-goat PLUS binds to the goat LCN2 
antibody. After several washes, the ligation solution was added to the cells for 30 min 
at 37°C which consists of ligase and two oligonucleotides which hybridised the two 
PLA probes and joined them to a closed circle if they are in close proximity (less than 
40 nm apart) which was amplified via rolling circle amplification (RCA) using a 
polymerase with the addition of the amplification solution for 100 min at 37°C. The 
RCA product hybridised to the fluorescently labelled oligonucleotides produced a 
distinct fluorescent spot. In situ PLA was performed according to the instructions 
provided by the manufacturer (OLINK Bioscience, Uppsala, Sweden).  
After performing the Duolink assay, cells were incubated with mouse 
monoclonal MAP2a (1:200, Sigma-Aldrich, MO, USA) for 1 hr at room temperature. 
After several PBS washes, cells were incubated for 1 hr at room temperature in 
1:200 dilution of goat anti-mouse IgG (H+L) Alexa Fluor 488 (Invitrogen, CA, USA). 
The cells were then washed and mounted with Duolink mounting medium (OLINK 
Bioscience, Uppsala, Sweden). Duolink and MAP2a colocalisation were examined 
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using a laser scanning confocal microscope, by analysing the overlap between the 
different labels by orthogonal reconstruction throughout the entire z-stack (LSM 510, 
Carl Zeiss, Göttingen, Germany). 
 
5.2.6. Real-time RT-PCR analysis 
Primary hippocampal neurons plated (160,000 cells/well) on 12-well plates 
were treated with rLCN2, rLCN2:Fe:Ent or vehicle control (MES buffer) on DIV 10 for 
24, 48 or 72 hrs. Total RNA was isolated using PureLink™ RNA Mini Kit (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s protocol, with DNaseI treatment 
(Roche Diagnostic GmbH, Mannheim, Germany). Quantitation of RNA was 
performed with the NanoDrop. The samples were reverse transcribed using High-
Capacity cDNA Reverse Transcription Kits (Applied Biosystems, CA, USA). The 
reaction conditions were 25°C for 10 min, 37°C for 120 min and 85°C for 5 min. Real-
time RT-PCR amplification was carried out using the 7500 Real-time PCR system 
(Applied Biosystems, CA, USA) with Taq-Man Universal PCR Master Mix (Applied 
Biosystems, CA, USA) and gene-specific primers and probes according to 
manufacturer’s protocols (Assay ID: Bim (Rn00674175_m1)). β-actin (Part no.: 
4352340E) was used as an internal control. All primers and probes were synthesised 
by Applied Biosystems. The PCR conditions were: an initial incubation of 50°C for 2 
min and 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. 
All reactions were carried out in triplicates. The threshold cycle, CT, which correlates 
inversely with the levels of target mRNA, was measured as the number of cycles at 
which the reporter fluorescence emission exceeds the preset threshold level. The 
amplified transcripts were quantified using the comparative CT method (Livak and 
Schmittgen, 2001), with the formula for relative fold change = 2–∆∆CT. Fold change 
was normalised to untreated cells (added with media) of each set of hippocampal 
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neurons. The mean was calculated from 3 sets of neurons and possible significant 
differences with treatment and time effects were analysed by two-way ANOVA using 
SPSS version 12 (SPSS Inc., Chicago, IL, USA). Since the effect of time on 
treatment effects was not the aim of the study, to examine the effect of different 
treatments at a particular timepoint, different treatments at 24, 48 and 72 hrs were 
further investigated by three separate one-way ANOVAs and were followed-up by 
Tukey’s HSD post-hoc comparisons. p < 0.05 was considered significant. 
 
5.2.7. Cell survival assay: MTS assay 
Primary hippocampal neurons plated (28,750 cells/well) in 96-well plates were 
pre-treated with rLCN2, rLCN2:Fe:Ent or MES buffer (vehicle) on DIV 10 for 48 hrs. 
20 and 50 µg/ml of rLCN2 were used in both rLCN2 and rLCN2:Fe:Ent treatments. 
Cells were then post-treated with 2 µg/ml tunicamycin (Sigma-Aldrich MO, USA) or 
PBS (vehicle) for 24 hrs (Table 1).  
 
Table 1. Treatment groups to investigate the effect of LCN2 and LCN2:Fe:Ent 
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The cell survival assay was performed on DIV 13 with CellTiter 96® Aqueous 
Non-Radioactive Cell Proliferation Assay (MTS assay) (Promega, WI, USA). Since 
primary hippocampal neurons are non-dividing, the cell proliferation assay was 
utilised as a cell survival assay instead. CellTiter 96® AQueous One Solution reagent 
was added according to manufacturer’s instructions and incubated at 37ºC. Using a 
spectrophotometric plate reader (Infinite M200, Tecan), readings were recorded at 1, 
2, 3 and 4 hours after incubation at 490 nm with reference wavelength at 630 nm. 
Absorbance values were normalised to vehicle controls of each set of hippocampal 
neurons and the mean was calculated from 3 sets of neurons. To investigate the 
effect of the different pre-treatments (i.e. effect of different pre-treatments on the 
same dose of rLCN2 and same post-treatment), four separate one-way ANOVAs 
were performed using SPSS version 12 (SPSS Inc., Chicago, IL, USA), followed-up 
by Tukey’s HSD post-hoc comparisons. p < 0.05 was considered significant. 
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5.3. RESULTS 
5.3.1. LCN2R expression in the primary hippocampal neurons 
LCN2R staining was observed in primary hippocampal neurons (Fig. 5.1A). 
Colocalisation of LCN2R with MAP2a (Fig. 5.1B) indicates that LCN2R was localised 
at the neurons (Fig. 5.1C), similar to observations made in the hippocampus of 
normal animals (Chapter 3, Fig. 3.2). At higher magnification, orthogonal projections 
demonstrate that the punctate staining of LCN2R was mostly present on the 
projections and on the surface of the MAP2a-positive cells (Figure 5.1D).  
 
5.3.2. Interaction of LCN2 with LCN2R  
Duolink assay was performed firstly, to investigate if the two proteins, LCN2 
and its receptor, LCN2R, interact and secondly, if they interact, the localisation of the 
interaction. In vehicle (MES)-treated cells (Fig. 5.2A), Duolink signals were not 
obvious. In rLCN2-treated (Fig. 5.2B) and rLCN2:iron:enterochelin (rLCN2:Fe:Ent)-
treated (Fig. 5.2C) primary neurons, Duolink signals were present and colocalised 
with MAP2a staining. Thus, Duolink assay illustrates the presence of interaction 
between exogenous rLCN2 and endogenous LCN2R receptor expressed on the 
neurons in vitro when either rLCN2 or rLCN2:Fe:Ent was applied.  
A native gel electrophoresis was carried out to examine the ability of the 
exogenous iron:enterochelin (Fe:Ent) to bind the recombinant LCN2 (rLCN2). The 
lane loaded with rLCN2:Fe:Ent has a shift in weight compared to the lane loaded with 
rLCN2 (Fig. 5.2D). The shift in the weight is due to the formation of the complex of 
rLCN2 with iron enterochelin (719 Da), an indication that the commercial rLCN2 is 
capable of binding to the iron:bacterial siderophore. 
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Fig. 5.1. LCN2R is present in the primary hippocampal neurons. Primary 
hippocampal neurons were cultured till DIV 10, fixed and double-labelled with LCN2R 
(red) and MAP2a (green). (A-C) Fluorescence micrographs of colocalisation of LCN2R 
with MAP2a under 20x low magnification. Scale=100 μm. (D) Confocal micrographs 
were taken at 40x magnification, and 63x for orthogonal projections in the insert, 
demonstrating that LCN2R was mostly present on the surface of the cell body and on 
the projections of the MAP2a-positive cells. Scale=20 μm. Scale in insert=20 μm. 
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Fig. 5.2. Interaction of LCN2 with LCN2R in primary hippocampal neurons. 
Primary hippocampal neurons were cultured and treated on DIV 10 with (A) vehicle 
(MES buffer), (B) rLCN2, (C) rLCN2:iron:enterochelin (rLCN2:Fe:Ent) for 24 hrs. 
Cells were fixed and Duolink (red) was performed followed by MAP2a 
immunostaining (green). Confocal micrographs were taken at 40x magnification, 
while 63x magnification was used for orthogonal projections shown in the inserts. (A) 
Duolink signals were not obvious in vehicle (MES)-treated control cells, but were 
present and colocalised with MAP2a staining in (B) rLCN2-treated and (C) 
rLCN2:Fe:Ent-treated primary neurons. Scale=20 μm. Scale in inserts=20 μm. (D) 
Native gel loaded with rLCN2 protein and rLCN2:Fe:Ent (pre-incubated together for 1 
hr prior to loading), probed with anti-LCN2 antibody. Upwards shift of weight 
(increase in weight) in the lane loaded with rLCN2:Fe:Ent, indicates the ability of 
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5.3.3. Effect of rLCN2 and rLCN2:Fe:Ent treatment on Bim mRNA expression 
Primary hippocampal neurons at DIV 10 were treated with rLCN2 to mimic the 
effect of the LCN2 release in the lesioned hippocampus. Other than rLCN2, 
rLCN2:iron:enterochelin (rLCN2:Fe:Ent) was also used to investigate how the effect 
of LCN2:iron:siderophore would differ from that of LCN2. Bim mRNA expression 
changes were detected using real-time RT-PCR. 
Two-way ANOVA revealed significant effects of the treatment [treatment: 
F(2,18)=10.65, p<0.001], the duration of treatment [time: F(2,18)=8.08, p<0.01] and a 
significant interaction between these effects [treatment x time: F(4,18)=13.57, 
p<0.001].  
Follow-up one-way ANOVA for the effect of treatment at each treatment 
duration confirmed significant treatment effects on the changes in Bim mRNA levels 
at 24 hrs [treatment: F(2,6)=33.10, p<0.001], 48 hrs [treatment: F(2,6)=5.69, p<0.05], 
and 72 hrs [treatment: F(2,6)=10.591, p<0.05]. Follow-up one-way ANOVA for the 
effect of duration of treatment within each treatment group was not performed 
because the time course study of the various treatments was not the aim of the 
study.  
Post-hoc Tukey’s HSD tests confirmed that at 24 hrs of treatment, there were 
significant differences between rLCN2 and rLCN2:Fe:Ent (p < 0.01) and between 
rLCN2:Fe:Ent and vehicle control (p < 0.001). Bim mRNA expression was 1.3-fold in 
rLCN2:Fe:Ent-treated neurons relative to the vehicle controls. Similarly, at 48 hrs of 
treatment, post-hoc Tukey’s HSD comparisons revealed that Bim mRNA levels 
increased significantly, being 1.2-fold (p < 0.05) relative to the vehicle controls, in 
rLCN2:Fe:Ent-treated neurons. Furthermore, at 72 hrs of treatment, significant 
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difference was only observed between rLCN2 and rLCN2:Fe:Ent (p < 0.01) as 
confirmed by post-hoc Tukey’s HSD. 
On the whole, no significant differences in Bim expression were observed 
between rLCN2-treated neurons with the vehicle controls at all timepoints. Instead, 
Bim mRNA levels were significantly increased at 24 and 48 hrs of rLCN2:Fe:Ent 
treatment (Fig. 5.3). 
rLCN2 and rLCN2:Fe:Ent treatment


































Fig. 5.3. Effect of rLCN2 and rLCN2:Fe:Ent treatment on Bim mRNA levels in 
primary hippocampal neurons. Primary hippocampal neurons were cultured and 
treated on DIV 10 with either media (untreated cells), vehicle (MES buffer), rLCN2, or 
rLCN2:Fe:Ent for 24, 48 or 72 hrs. Cells were harvested for RNA and real-time RT-
PCR analysis was performed to determine the effect of treatment on Bim mRNA 
expression. Values are normalised with the untreated cells (Fold change= 1.0) at the 
respective timepoints to obtain the relative fold change. Analysed by 2-way ANOVA, 
follow-up one-way ANOVA for the effect of treatment at each timepoint. Tukey’s HSD 
post-hoc comparisons at each timepoint revealed significant differences, indicated by 
(*p < 0.05, **p < 0.01, ***p < 0.001). Data are expressed as mean ± SEM, n = 3 per 
treatment group. 
 
5.3.4. Effect of rLCN2 and rLCN2:Fe:Ent treatment on cell survival 
In Section 5.3.3 above, upregulation of Bim mRNA expression was observed 
in 24 and 48 hrs of rLCN2:Fe:Ent-treated neurons. Hence, a cell survival assay was 
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performed to determine if cell viability was affected. In addition, to examine if 
rLCN2:Fe:Ent (tricomplex) treatment has the ability to potentiate or desensitise 
neurons to apoptosis stress, an cytotoxic agent that triggers Bim-induced apoptosis 
was selected - tunicamycin. It is an ER-stress inducing agent known to upregulate 
Bim expression (Morishima et al., 2004; Puthalakath et al., 2007). Preliminary 
tunicamycin treatment was performed on primary hippocampal neurons. Bim mRNA 
levels were 2.7-fold (p < 0.05) with 24 hours of tunicamycin relative to untreated cells 
(Fig. 5.4A). MES-PBS-treated neurons had 93.2% of cell survival while MES-
tunicamycin-treated neurons had 63.8% relative to the untreated cells. Hence, cell 









Fig. 5.4. Effect of tunicamycin on Bim mRNA levels and cell survival in primary 
hippocampal neurons. Primary neuronal cells were treated with 48 hrs of MES 
(vehicle) before 24 hrs of tunicamycin or PBS treatment. (A) Real-time RT-PCR 
analysis on primary neurons on the mRNA expression of Bim after tunicamycin (Tun) 
treatment, relative to untreated cells (Fold change=1.0). Upregulation of Bim mRNA 
expression was observed after tunicamycin treatment. (B) Cell survival assay (MTS 
assay) was performed on neurons. Tunicamycin caused decrease in cell survival. 
Cell survival was normalised to untreated cells (100%). Analysed by Student’s t-test, 
asterisks indicate significant difference (*p < 0.05, **p < 0.01, ***p < 0.001). Data are 






































































After establishing that tunicamycin could upregulate Bim mRNA expression 
and cause decrease in cell survival, neurons were pre-treated with rLCN2 or 
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rLCN2:Fe:Ent (48hrs), and post-treated with tunicamycin (24hrs). Significant 
differences in cell survival were confirmed by performing four separate one-way 
ANOVA (Table 2): 
 Pre-treatment Post-treatment One-way ANOVA Post-hoc Tukey’s HSD 





rLCN2 vs. rLCN2:Fe:Ent 
(p<0.05) 
rLCN2:Fe:Ent vs. vehicle 
control (p<0.01) 
rLCN2:Fe:Ent-treated 
neurons had decreased 
cell survival of 83.3% 
compared to the vehicle 
control (100%) 
2. Vehicle or 
20µg/ml rLCN2 
or rLCN2:Fe:Ent 
Tunicamycin Not significant 
F(2,6)=0.67, n.s. 
- 





rLCN2 vs. rLCN2:Fe:Ent 
(p<0.05) 
rLCN2:Fe:Ent vs. vehicle 
control (p<0.05) 
rLCN2:Fe:Ent-treated 
neurons had decreased 
cell survival of 69.5% 
compared to the vehicle 
control (87.7%) 





rLCN2 vs. rLCN2:Fe:Ent 
(p<0.05) 
Table 2. Statistical analysis of the effect of different treatments on cell 
survival. 
 
One-way ANOVA indicated that the 1) pre-treatment (20 µg/ml of rLCN2 or 
tricomplex) had significant effects on cell survival with PBS post-treatment [pre-
treatment: F(2,6)=14.20, p<0.01] and 2) no significant differences with tunicamycin 
post-treatment [pre-treatment: F(2,6)=0.67, n.s.]. For 50 µg/ml of rLCN2 and 
rLCN2:Fe:Ent, one-way ANOVA confirmed significant pre-treatment effects on cell 
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survival with 3) PBS post-treatment [pre-treatment: F(2,6)=7.34, p<0.05], and 4) 
tunicamycin post-treatment [pre-treatment: F(2,6)=6.663, p<0.05]. 
Post-hoc Tukey’s HSD tests confirmed that there were significant differences 
in cell survival between 20 µg/ml of rLCN2 and rLCN2:Fe:Ent (p < 0.05); and 
between rLCN2:Fe:Ent with the vehicle control (p < 0.01). Neurons treated with 
rLCN2:Fe:Ent had lower cell survival of 83.3% compared to the vehicle controls 
(100%).  
Similar to the trend observed in 20 µg/ml, when 50 µg/ml of rLCN2 and 
rLCN2:Fe:Ent were used, post-hoc Tukey’s HSD tests confirmed that there were 
significant differences in cell survival between rLCN2 and rLCN2:Fe:Ent (p < 0.05); 
and between rLCN2:Fe:Ent with the vehicle control (p < 0.05). Neurons treated with 
rLCN2:Fe:Ent, had lower cell survival of 69.5% compared to the vehicle control 
(87.7%).  
Post-hoc Tukey’s HSD tests also confirmed that cell survival decreased 
significantly (p < 0.05) in the 50 µg/ml rLCN2:Fe:Ent-treated neurons in comparison 
to LCN2-treated neurons with tunicamycin post-treatment (Fig. 5.5). 
On the whole, rLCN2:Fe:Ent-treated (and PBS post-treated) neurons 
decreased significantly in cell survival as compared to their vehicle controls. 
Treatment groups 1 and 3 (with PBS post-treatment) is comparable with the 
experimental conditions in Section 5.3.3 which describes the upregulation of Bim 
mRNA expression after rLCN2:Fe:Ent treatment (Fig. 5.3). Furthermore, no 
significant changes were observed in tunicamycin-treated cells as compared to their 
vehicle (MES) controls, indicating that rLCN2:Fe:Ent treatment does not potentiate or 
desensitise cell survival under ER stress-induced apoptosis.  
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Fig. 5.5. Effect of rLCN2 and rLCN2:Fe:Ent treatment on primary hippocampal 
neurons on cell survival. Primary hippocampal neurons were plated on 96-well 
plates, cultured and pre-treated on DIV 10 with either media (untreated cells), vehicle 
(MES buffer), 20 µg/ml rLCN2, 50 µg/ml rLCN2, 20 µg/ml rLCN2:Fe:Ent or 50 µg/ml 
rLCN2:Fe:Ent, for 48 hrs. Cells were then treated with tunicamycin or vehicle (PBS) 
for 24 hrs. MTS assay was performed on DIV 13. Absorbance values are normalised 
with the untreated cells of its own set, and normalised values from three sets of cells 
were again normalised to the vehicle controls to 20 µg/ml of rLCN2/rLCN2:Fe:Ent 
(first bar from the left in the graph). Statistical analysis was performed with four 
separate 1-way ANOVA for each experimental setup to determine the effect of the 
pre-treatment on cell survival. Tukey’s HSD post-hoc comparisons at each condition 
revealed significant differences, indicated by (*p < 0.05, **p < 0.01, ***p < 0.001). 
Data are expressed as mean ± SEM, n = 3 per treatment group. 
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5.4. DISCUSSION 
In the previous chapters, upregulation of Bim was associated with apoptosis 
in the LCN2R-expressing neurons. However the link between LCN2, Bim and 
apoptosis is still unclear. Thus, in this chapter, the effect of LCN2 and iron-loaded 
LCN2 on Bim-dependent apoptosis on neurons was elucidated with in vitro assays. 
After KA injury, Bim was upregulated in both the LCN2R-expressing activated 
microglia and neurons, which could potentially give identical or different responses 
upon LCN2 release. Therefore, in order to isolate the effect of LCN2 on the neurons, 
rat hippocampal neurons were cultured. Colocalisation of LCN2R with MAP2a 
indicated that the primary hippocampal neurons expressed LCN2R, identical to the 
neurons in vivo (Chapter 3, Fig. 3.2). High magnification orthologonal projections of 
primary neurons revealed that LCN2R was mostly localised on the surface of the 
neurons and had punctate staining which was commonly observed for receptor 
proteins, such as GluR1-4 subunits of AMPA receptors, NR1 subunit of NMDA 
receptors, α2 and γ2 subunits of GABAA receptors (Andras et al., 2007; Kneussel et 
al., 1999; Mokin and Keifer, 2006; Nagy et al., 2004). LCN2R was also localised in a 
punctate distribution in LCN2R stable expressing HEK cell line (Bennett et al., 2011). 
Since LCN2R was expressed on the primary neurons, cells were treated with 
recombinant LCN2 (rLCN2) and rLCN2:Fe:Ent to detect for protein interaction using 
the Duolink assay. The Duolink assay uses the in situ PLA technology which enables 
the detection, visualisation of protein interactions in cell samples. Primary antibodies 
raised in different species bind to the species-specific secondary antibodies, which 
are attached with a unique short DNA strand, also known as PLA probes. Only when 
the PLA probes are in close proximity (less than 40nm), the DNA strands interact and 
with ligation are amplified via rolling circle amplification with polymerase. The signal 
from the detected pair of PLA probes is visualised as an individual fluorescent dot. 
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Therefore, the Duolink provides insight to the presence of in situ protein interactions, 
the localisation of the interactions and quantity of interaction since each discrete dot 
represents a single interaction (Gullberg et al., 2004; Gustafsdottir et al., 2005; 
Weibrecht et al., 2010).  
Interaction was detected between endogenous LCN2R and exogenous 
rLCN2 when applied in either rLCN2 or rLCN2:Fe:Ent and colocalised with MAP2a 
on the projections and surface of the neuron, and within the neuron. Here, the results 
illustrate the ability of LCN2R to bind and internalise LCN2, applied both as apo-
LCN2 and as holo-LCN2, into the neurons, which is consistent with the receptor-
mediated endocytosis proposed by others (Devireddy et al., 2005; Mori et al., 2005; 
Yang et al., 2002b). 
LCN2 has been reported to colocalise with the divalent metal transporter 
(DMT1) which is found in late endosomes (Abergel et al., 2008; Yang et al., 2002b), 
and with Rab11, a well-established recycling endosome marker (Devireddy et al., 
2005). Although these studies revealed LCN2 to be transported intracellularly via late 
endosomes or recycling endosomes, it is unclear in the present context and 
colocalisation studies could be done with late or recycling endosomal markers 
(Devireddy et al., 2005; Yang et al., 2002b). Vesicular intracellular staining observed 
in clones with highest expression of LCN2R among many LCN2R stable expressing 
HEK clones also supports the notion that LCN2R is internalised into the cytoplasm 
via vesicular or endosomal trafficking (Bennett et al., 2011). Furthermore, the 
absence of Duolink signals in vehicle-treated neurons indicates the absence of 
endogenous LCN2 in the neurons. This corresponds to the in vivo findings (Chapter 
2) of the absence of LCN2 expression in other cell types, except in astrocytes. This 
also helps to confirm that the protein-to-protein interaction detected using Duolink 
was between the exogenous rLCN2 or rLCN2:Fe:Ent with the endogenous LCN2R.  
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To date, the extracellular mammalian siderophore has not been fully identified 
in the CNS, hence the bacterial siderophore, enterochelin, was used instead to act as 
a chaperone for iron to bind LCN2 so as to compare between apo-LCN2 (iron-free) 
and holo-LCN2 (iron-loaded). Various durations of incubation of rLCN2 with Fe:Ent 
were examined from 30 min to overnight. All durations produced a heavier band 
when compared to rLCN2 suggesting that LCN2 binds Fe:Ent readily due to the high 
affinity that LCN2 has for enterochelin (Abergel et al., 2008; Yang et al., 2002b). 
Therefore, primary neurons were treated with pre-incubated rLCN2 and Fe:Ent, and 
rLCN2 in order to see their effect on Bim expression and cell survival. 
Devireddy et al. (2005) reported that the treatment of apo-24p3 (murine 
orthologue of LCN2) caused Bim-mediated apoptosis in 24p3R-expressing HeLa 
cells. Interestingly, the same was not observed in the rat hippocampal neurons. No 
significant differences in Bim expression was observed in rLCN2 (apo-LCN2)-treated 
neurons regardless of the duration of incubation of the recombinant protein in the 
culture media. Instead, holo-LCN2 (LCN2:Fe:Ent) resulted in significant increases in 
Bim mRNA levels at 24 and 48 hours (1.2- to 1.3-folds relative to vehicle controls) 
after treatment. At 72 hours after holo-LCN2 treatment, instead of upregulation of 
Bim mRNA as detected in earlier timepoints, there were no significant differences 
between holo-LCN2 and vehicle treated cells. By 72 hours, the effectiveness of 
rLCN2:Fe:Ent could be compromised. This is firstly because LCN2 was supplied as 
recombinant proteins which may be degraded by proteases from the cells after time. 
Secondly, the neurons with upregulated Bim mRNA expression at 24 and 48 hours 
could have already undergone apoptosis by 72 hours. Lastly, LCN2 was reported to 
traffic iron in acidic vesicles/endosomes and the low pH results in the dissociation of 
iron and degradation of enterochelin (Abergel et al., 2008). LCN2 has been shown to 
be non-degraded, suggesting its ability to be recycled (Yang et al., 2002b). 
Therefore, if the imported iron (from rLCN2:Fe:Ent complex) remained in the cells 
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earmarked for Bim-mediated apoptosis and with the availability of rLCN2 without 
enterochelin, import of iron will be discontinuous, resulting in the apo-LCN2 condition, 
instead of holo-LCN2 (Fig. 5.6). This speculation of the conversion of holo-LCN2 
treatment to apo-LCN2 implies the absence of endogenous extracellular 
siderophores. Despite new progress in elucidation of mammalian siderophores (Bao 
et al., 2010; Devireddy et al., 2010), their existence in the primary neurons is still 
unknown. These plausible reasons may explain why Bim was not upregulated at 72 
hours of holo-LCN2 treatment. Despite the anomaly observed at 72 hours, the trend 
observed at 24 and 48 hours of holo-LCN2 was consistent, indicating holo-LCN2 


















72 hrs of rLCN2:Fe:Ent treatment on primary hippocampal neurons
?
Fig. 5.6. Possible effects on Bim mRNA expression after 72 hours of 
rLCN2:Fe:Ent treatment on primary hippocampal neurons. With the degradation 
of enterochelin due to low pH in the endosomes, only rLCN2 is recycled. Since iron is 
imported into cells earmarked for apoptosis (depicted by the dotted cell membrane), 
this would result in an apo-LCN2 situation. The mechanism of apo-LCN2 remains 
unclear at this stage due to the insignificant effects on Bim. Hence, the possible 
effects of holo-LCN2 may be masked. 
Chapter 5: Expression of LCN2 and LCN2R in Primary Hippocampal Neurons 
 
   138 
 
Significant decreases in cell survival were observed in cells treated with 20 
µg/ml (16.8% decrease) and 50 µg/ml (18.2% decrease) of holo-LCN2 relative to 
vehicle controls. The decrease in cell survival was more pronounced at the higher 
dose of LCN2. Taken together with the previous result, holo-LCN2 leads to 
upregulation of Bim mRNA expression which stimulates apoptosis, resulting in 
decrease in cell survival. Since LCN2 was present in both apo- and holo-LCN2 
treatment conditions, the pro-apoptotic effect of holo-LCN2 is likely to be attributed to 
the iron:enterochelin (Fe:Ent) complex as the critical factor to induce apoptosis in 
neurons. 
 Contrary to the present findings, LCN2 has been reported to sensitise 
microglia and astrocytes to cytotoxic agents, and the cell death sensitisation effect 
was abolished with the addition of iron:siderophore complex (Lee et al., 2007; 2009). 
This pro-apoptotic function of apo-LCN2 and anti-apoptotic function of holo-LCN2 in 
vitro is in line with the mechanism of holo-LCN2 increasing intracellular iron levels 
and inhibiting apoptosis as proposed by Devireddy et al. (2005). Yet, the present 
results show otherwise. This pro-apoptotic effect of holo-LCN2 may be specific to 
neurons, as previous studies have suggested LCN2 to have different biological 
effects depending on the cell type (Lee et al., 2009; Mori et al., 2005).  
With the knowledge that holo-LCN2 is pro-apoptotic, how does holo-LCN2 
induce apoptosis? Holo-LCN2 may deliver iron into the neurons and increase 
intracellular iron levels. This influx of iron may contribute to the pro-apoptotic effect of 
holo-LCN2. Iron is a strong promoter of free radical damage and thus most iron in the 
brain is sequestered by ferritin to keep intracellular iron levels in check (Thomas and 
Jankovic, 2004; Zecca et al., 2004). Damage to brain tissue releases iron which is 
capable of catalysing the generation of ROS, lipid peroxidation and autooxidation of 
neurotransmitters (Braughler et al., 1986; Halliwell and Gutteridge, 1985). In many 
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neurodegenerative diseases, iron homeostasis is often disrupted, which has been 
suggested to be a precursor of AD and iron accumulation has been found in regions 
affected by AD and PD in aged brains (McNeill and Chinnery, 2011). Therefore, if the 
excess iron imported by LCN2 is not sequestered by sufficient intracellular ferritin or 
regulated by iron regulatory mechanisms, free iron can cause cellular damage, 
upregulate Bim expression, stimulate apoptosis and decrease cell survival. 
If holo-LCN2 delivers iron into the neurons to upregulate Bim, with a pro-
apoptotic effect, it would be reasonable to postulate that apo-LCN2 might produce 
the opposite phenomenon, i.e. an anti-apoptotic effect, since studies have shown 
apo-LCN2 and holo-LCN2 to have opposite effects on apoptosis (Devireddy et al., 
2005; Lee et al., 2007; 2009; 2011). Similar to the effect on Bim mRNA expression, 
no significant differences on cell survival was observed in apo-LCN2 treated neurons. 
There are a few possible explanations. Firstly, the effect of apo- and holo-LCN2 
might not be opposite. In holo-LCN2, the presence of iron could enhance the effect of 
apo-LCN2. For instance, holo-LCN2 protected kidneys from ischaemia-reperfusion 
injury while apo-LCN2 only protected the injured kidneys partially (Mori et al., 2005). 
Also, holo-NGAL was more effective than apo-NGAL in inducing epithelial 
characteristics in 4T1-Ras-transformed mesenchymal tumour cells (Hanai et al., 
2005). Secondly, the primary neurons were in physiological conditions with no 
apoptotic trigger. Hence if apo-LCN2 had any anti-apoptotic effect, it would not be 
significant.  
Therefore, to examine if apo- and holo-LCN2 could potentiate or desensitise 
apoptotic effects, the cytotoxic agent used must induce apoptosis via activation of 
Bim. Since at 48 hours of holo-LCN2, Bim mRNA levels were elevated, primary 
neurons were pre-treated with 48 hours of apo-LCN2 or holo-LCN2, followed by post-
treatment with tunicamycin or PBS for 24 hours. Tunicamycin is an antibiotic that 
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inhibits protein glycosylation and has been used in many studies to induce Bim-
mediated ER stress-induced apoptosis (Chung et al., 2011; Han et al., 2008; 
Szegezdi et al., 2006). Upregulation of Bim expression was shown to be essential for 
ER stress-induced apoptosis (Morishima et al., 2004; Puthalakath et al., 2007). In the 
present study, preliminary studies on tunicamycin treatment on the primary 
hippocampal neurons showed upregulation of Bim mRNA and decrease in cell 
survival which were consistent with previous studies (Morishima et al., 2004; 
Puthalakath et al., 2007). However, even with tunicamycin post-treatment, no 
significant differences were observed between apo-LCN2 and vehicle treated primary 
neurons, regardless of the dosage of rLCN2. Apo-LCN2 did not desensitise the 
apoptotic effect of tunicamycin. Hence, apo-LCN2 is unlikely to have any anti-
apoptotic/ protective effect on neurons, even though holo-LCN2 is pro-apoptotic. 
When pre-treated with a lower dose of rLCN2, the cell survival of the primary 
neurons was similar after tunicamycin post-treatment regardless of apo- or holo-
rLCN2 pre-treatment. This could be because the effect of tunicamycin on Bim-
mediated apoptosis may have outweighed the effects of holo-LCN2 (Fig. 5.7). In 
contrast, a higher dose of holo-LCN2 (50 µg/ml) caused a further decrease in cell 
survival compared to apo-LCN2 (50 µg/ml) after tunicamycin treatment. This implies 
that a higher dose of holo-LCN2 may exert greater effects on Bim than tunicamycin 
(Fig. 5.7). It may be tempting to conclude that holo-LCN2 can potentiate the effect of 
tunicamycin-induced apoptosis, but since cell survival of holo-LCN2-treated neurons 
was not significantly different from vehicle-treated neurons, it would be premature. It 
is possible that with higher doses of holo-LCN2, the cell death potentiating effect may 
be more pronounced. 
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Fig. 5.7. Proposed effects of tunicamycin and different doses of holo-LCN2 on 
Bim mRNA expression. At lower dose of holo-LCN2, effect of tunicamycin on Bim 
expression outweighs its effect (as depicted by the thicker arrow). Higher dose of 
holo-LCN2 has a greater effect on Bim expression than tunicamycin (as depicted with 
the thickest arrow). Arrow indicates activation. Other pro-apoptotic triggers may exist 
other than Bim, but the amount of contribution to apoptosis is unknown (as 
represented by ‘?’ in the figure) to decrease cell survival. 
 
In the cell survival assay, neurons were treated 48 hours with apo- and holo-
LCN2 and 24 hours with tunicamycin. Hence apo- and holo-LCN2 were present in 
the culture media for 72 hours in total. From the real-time RT-PCR analysis, neurons 
treated with 72 hours of holo-LCN2 had no significant difference in Bim mRNA levels 
compared to vehicle controls. However, in the cell survival assay, regardless of dose 
of holo-LCN2, decrease in cell survival was observed. This could be due to the delay 
in the onset of cell death. At 48 hours, Bim mRNA levels were increased, but time is 
required for protein translation, activation and localisation changes in other pro-
apoptotic proteins, such as BAX/BAK, activation of caspases and caspase cascade, 
dysfunction of mitochondria and finally cell demise (Borner, 2003; Danial, 2007; Willis 
et al., 2003). Therefore, in consideration of the delay of onset of apoptosis, it could 
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explain the significant decrease in cell survival at 72 hours after holo-LCN2 
treatment. 
In summary, this chapter showed the interaction between LCN2R and LCN2 
when applied in either apo- or holo-LCN2 treatment and the Bim-mediated apoptotic 
effect of holo-LCN2 on the primary neurons for the first time. Based on the present 
results, a mechanism for Bim-mediated apoptosis in neurons is proposed: Holo-
LCN2 interacts with LCN2R (expressed on the hippocampal primary neuron) to be 
internalised with the import of iron into the cell. As a result of the iron influx, Bim is 
upregulated, stimulating apoptosis and causing a decrease in cell survival (Fig. 5.8). 
This phenomenon is parallel to the in vivo upregulation of Bim in apoptotic LCN2R-
expressing neurons after KA-induced neurodegeneration. Thus, the in vitro results 
suggest that the import of iron assisted by an endogenous extracellular mammalian 
siderophore complex (holo-LCN2) into the neurons may be attributed to the apoptotic 
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Fig. 5.8. Proposed mechanism of the pro-apoptotic effect of holo-LCN2 on 
primary hippocampal neurons. (1) Holo-LCN2 (LCN2:Fe:siderophore) interacts 
with LCN2R to be internalised into the neurons. (2) Due to the low pH, iron is 
dissociated from the tricomplex, increasing intracellular iron concentrations. Iron 
regulatory genes/proteins are activated to decrease the iron levels. (3) High iron 
levels induce upregulation of Bim. (4) Decrease in cell survival is observed as a 
result of holo-LCN2 treatment. Modified from Richardson (2005). Diagram not drawn 
to scale. 
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6.1. GENERAL DICUSSION 
 Despite being well-studied in the periphery, little was known about LCN2 in 
the brain. Previously, LCN2 had only been detected in the CNS via microarray in 
several studies (Bonow et al., 2009; MacManus et al., 2004) and the most relevant 
studies related to the CNS were on the brain-derived cells, in the murine primary 
microglia, astrocytes, neurons and glioblastoma cells (Lee et al., 2007; 2009; 2011; 
Zheng et al., 2009), and at the choroid plexus in vivo (Marques et al., 2008). 
Therefore, this thesis started off by examining if those roles postulated in the 
periphery could be relevant in hypothesising LCN2’s role in the CNS. In 
neurodegeneration, excess iron is often detected, along with generation of ROS, and 
neuronal loss via apoptosis. Hence, LCN2’s ability to bind iron (via siderophore) and 
involvement in apoptosis led to the hypothesis that LCN2 may have a role in KA-
induced neurodegeneration. This thesis have found an association between LCN2, 
LCN2R and Bim-mediated apoptosis; and postulated a likely mechanism for LCN2’s 
role in Bim-mediated apoptosis in the neurons during KA-induced 
neurodegeneration. 
In this thesis, the role of LCN2 in KA-induced neurodegeneration was covered 
in four chapters: (1) LCN2 expression physiologically and after KA injury, (2) LCN2R 
expression, (3) Bim expression after KA injury and (4) association of LCN2, LCN2R 
and Bim in vitro.  
This study shows for the first time the localisation of LCN2 and its receptor 
LCN2R in the hippocampus. After KA injury, LCN2 was upregulated in the reactive 
astrocytes, while its receptor, LCN2R, was upregulated in the activated microglia, 
and expressed in the neurons physiologically. Upregulation of Bim in the LCN2R 
expressing-activated microglia did not lead to apoptosis, unlike in the LCN2R 
expressing-neurons at 1 day post-KA injection. The effect of LCN2 on apoptosis in 
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the neurons was studied with the treatment of apo-LCN2 and holo-LCN2 as iron was 
reported to confer LCN2 to have different effects on cells. Interaction between holo-
LCN2 and LCN2R resulted in Bim-mediated apoptosis and decrease in cell survival 




















































 of the effects of LCN2 in KA-induced neurodegeneration. 
In KA-induced neurodegeneration, LCN2 secreted by the reactive astrocytes 
ould act on either the LCN2R–expressing neurons or activated microglia. At 1 day 
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etected in apoptotic neurons. This appears to support the proposed mechanism by 
evireddy and colleagues (2005) that apo-LCN2 induces apoptosis. LCN2 released 
om astrocytes (apo-LCN2) could interact with LCN2R and induce upregulation of 
im in neurons, resulting in apoptosis. 
However, the in vitro studies discussed in Chapter 5 show otherwise as apo-
CN2 had no effect on the Bim mRNA expression or cell survival on primary 
ippocampal neurons. Also, apo-LCN2 neither sensitise nor desensitise neurons to 
ro-
poptotic nor an anti-apoptotic effect, even when apoptotic triggers are present. 
Instead, treatment of holo-LCN2 increased Bim mRNA expression and decreased 
cell survival, indicating holo-LCN2 is pro-apoptotic. This is different from the 
proposed mechanism by Devireddy et al. (2005) as apo-LCN2 was proposed to be 
pro-apoptotic and holo-LCN2 to be anti-apoptotic. Devireddy et al. (2005) used 
24p3R-overexpressing HeLa cells, which could possibly give different effects from 
naturally occurring LCN2R-expressing neurons. Also in support of Devireddy and 
colleagues’ mechanism, LCN2-induced cell death sensitisation was abolished with 
the addition of iron:siderophore complex in C6 glioma and BV-2 microglial cells (Lee 
Although it was not investigated in this thesis how holo-LCN2 treatment leads 
to upregulation of Bim and decrease in cell survival, it is not far-fetched to postulate 
that holo-LCN2 delivers iron into the neurons to increase intracellular iron 
concentration. Increased intracellular iron, if not kept in check (sequestered by 
ferritin), will generate ROS, increasing vulnerability of neurons to oxidative stress 








tunicamycin-induced cell death further supports that apo-LCN2 has neither a p
a
et al., 2007; 2009), indicating that holo-LCN2 is anti-apoptotic, which is opposite from 
our analysis. This discrepancy could be due to difference in cell types, as neurons 
and glial cells have very different functions.  
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 intracellular iron concentration can lead 
to compensatory changes in the iron regulatory proteins/genes, such as ferritin, 
transferrin receptor 1 and other proteins of iron metabolism (Rouault, 2001; Zecca et 
present in the neurons to sequester iron, but it may not be sufficient to cope with 
sudden import of iron. Each ferritin molecule can store up to 4,500 iron atoms, but it 
(Joshi et al., 1995). Neurons express mostly H-ferritin, which is associated with 
responses to stress unlike microglia which express mostly L-ferritin, which is 
associated with iron storage (Connor et al., 1994). 
also did not produce an opposite effect from holo-LCN2. Elucidated in recent studies 
(Bao et al., 2010; Devireddy et al., 2010), endogenous mammalian siderophores may 
the cells or from the culture media, and with the great affinity of siderophores to iron, 
induce apoptosis, decreasing cell survival (Simon et al., 2000). This fits well into the 
paradigm in which increasing iron is thought to be detrimental to the CNS (Halliwell, 
1992; Thomas and Jankovic, 2004). Iron accumulation in specific brain regions 
affected by AD and PD in aged brains and defects in iron homeostasis are often 
observed in many neurodegenerative diseases (Zecca et al., 2004). Therefore, to 
keep iron homeostasis in check, changes in
al., 2004). Compensatory mechanisms, such as upregulation of ferritin, may be 
contains variable amounts of two types of polypeptide chains, heavy (H) and light (L) 
Therefore, based on the present results, a mechanism for Bim-mediated 
apoptosis in neurons is proposed: Holo-LCN2 interacts with LCN2R expressed on 
the hippocampal primary neuron to be internalised to import iron into the cell. Due to 
accumulation of iron, free radicals are generated, increasing oxidative stress in the 
cells. As a result, Bim is upregulated, stimulating apoptosis and causing decrease in 
cell survival (Fig. 6.2).  
Unexpectedly, apo-LCN2 has no significant effect on primary neurons and 
be present in the primary hippocampal neurons. Together with availability of iron in 
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apo-LCN2 treatment may well be converted to “holo-LCN2” treatment despite the 
addition of rLCN2 only. With the endogenous amount of iron and siderophore, the 
amount of tricomplex formed would be far lesser than the tricomplex present in the 
holo-LCN2 treatment, which has 5x molar excess of Fe:Ent than rLCN2 supplied. 
Therefore, apo-LCN2 could not produce a significant pro-apoptotic effect like holo-
LCN2, or the opposite, i.e. anti-apoptotic effect. This is akin to the observations made 






















Fig. 6.2. Proposed mechanism of pro-apoptotic effect of holo-LCN2 on primary 
hippocampal neurons. (1) Holo-LCN2 (LCN2:Fe:siderophore) interacts with LCN2R 
to be internalised into the neurons. (2) Due to the low pH, iron is dissociated from the 
tricomplex, increasing intracellular iron concentrations. Iron regulatory genes/proteins 
are activated to decrease the iron levels. If free iron remains in excess, ROS are 
generated, increasing oxidative stress. (3) As a result, Bim is upregulated. (4) 
Decrease in cell survival is observed as a result of holo-LCN2 treatment. Modified 
from Richardson (2005). Diagram not drawn to scale. 
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component of holo-NGAL (NGAL:enterochelin:Fe) that delivers iron into the kidney. 
They found NGAL:enterochelin was as effective as NGAL:enterochelin:Fe in 
delivering iron to the kidney because of the strong affinity of the enterochelin for iron 
strips iron from transferrin to form NGAL:enterochelin:Fe (Mori et al., 2005). 
Therefore, if mammalian siderophores were present in the primary neurons, they 
would have strong affinity to bind any existing iron to form holo-LCN2. Thus, the 
chances of having a real “apo-LCN2” condition would be slim. Further studies would 
have to be performed to identify whether the primary neurons have endogenous 
mammalian siderophore(s) present.  
Having established that holo-LCN2 is pro-apoptotic, holo-LCN2-treated 
primary neurons have many points in common with the neurons at 1 day post-KA 
injection. In both in vitro and in vivo treatments, Bim was upregulated in the LCN2R-
expressing neurons and cell survival was compromised with decreased cell survival 
in vitro, and apoptosis of neurons in vivo (refer to Fig. 6.1). Increase in iron was also 
 
bacterial enterochelin was used as the siderophore in many experimental setups as 
the presence of mammalian siderophore was still unclear despite many speculations.  
siderophore, RT-PCR and western blot analysis show the presence of BDH2 mRNA 
observed after KA injury (Ong et al., 1999), a phenomenon common to other types of 
neuronal injuries or neurodegenerative diseases (Thomas and Jankovic, 2004; Zecca 
et al., 2004). Thus, the accumulation of free iron and the rapid upregulation of LCN2 
help to promote the formation of holo-LCN2. Therefore, this suggests the presence of 
an extracellular mammalian siderophore in the hippocampus. In many studies,
Finally in 2010, the enzyme, BDH2, that synthesise the iron moiety (2,5-
dihydroxybenzoic, 2,5-DHBA) of the mammalian siderophore was elucidated and 
required for 24p3-mediated iron transport and apoptosis (Devireddy et al., 2010). 
BDH2 mRNA expression was also detected in the brain from adult mice (Devireddy 
et al., 2010). In a preliminary attempt to examine the presence of mammalian 
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mouse urine and that the LCN2:Fe:catechol complex could deliver iron to the 
proximal tubule of the kidney (Bao et al., 2010). Interestingly, the CNS has high 
norepinephrine and epinephrine. These neurotransmitters could be potential 
candidates as mammalian siderophores, and their abundance in the CNS would 
and oligodendrocytes in KA-lesioned hippocampus (Huang and Ong, 2005). Since 
the microglia express mostly L-ferritin, which 
et al., 1994), the iron delivered into the activated microglia by holo-LCN2 may be 
effectively sequestered by the upregulated ferritin. Since iron homeostasis is not 
Alternatively, at 2 weeks post-KA injection, it might be too early to detect apoptosis of 
and protein expression in the rat hippocampus (Appendix 1B and C). Although the 
detection of BDH2 does not equate to the detection of the mammalian siderophore, it 
gives a strong indication that the hippocampus has endogenous siderophore(s) 
because silencing of BDH2 resulted in siderophore depletion (Devireddy et al., 2010). 
Also, another group found catechols to bind LCN2:iron complex in human and 
levels of catechols in the form of catecholamine neurotransmitters: dopamine, 
possibly offer an alternative route of iron trafficking other than transferrin.  
Bim-mediated apoptosis was only detected in neurons at 1 day post-KA 
injection, but not at later timepoints because the neurons with upregulated Bim would 
have undergone apoptosis by then. At 2 weeks post-KA injection, Bim and LCN2R 
were highly upregulated in the activated microglia. However, the activated microglia 
were not apoptotic even though 2 weeks post-KA injection samples had the highest 
Bim mRNA and protein expression. There could be a number of plausible reasons. 
Firstly, upregulation of Bim may have other unknown functions in activated microglia. 
Secondly, the absence of apoptosis may be due to the tolerance of microglia to the 
excess iron influx. Increase expression of ferritin was detected mostly in microglia 
is associated with iron storage (Connor 
disrupted with free, labile iron to create havoc, apoptosis is not triggered. 
Chapter 6: General Discussion and Conclusion 
 
   152 
 
areas. The apoptotic status of the cells may be very dependent on the stage of 
at 1 day post-KA injection in the present study.  It is therefore possible that the 
appropriate timepoint for the activated microglia to apoptose has yet to be identified. 
erophore) 
with unknown extracellular siderophore(s) to induce Bim-mediated apoptosis at the 
neurons after KA-induced neurodegeneration. Furthermore, LCN2-deficient mice 
showed no defects in apoptosis, iron metabolism, kidney development and 
reproduction (Berger et al., 2006; Flo et al., 2004), suggesting that LCN2 does not 
mind that LCN2-induced Bim-mediated apoptosis does not account for all cell demise 
during KA-induced neurodegeneration, and possibly only a population of cells 
than Bim and other than apoptosis, necrosis and other forms of neuronal damage are 
also involved in neurodegeneration. Nevertheless, since Bim-mediated apoptosis is 
activated microglia as they peak one month post-KA injection before declining 
(Jorgensen et al., 1993; Mitchell et al., 1993). Furthermore, Bim’s gradual increase in 
expression from 1 day to 2 weeks post-KA injection indicates that it may increase 
further at later timepoints to signal clearing of activated microglia in the lesioned 
neurodegeneration, as apoptotic neurons with upregulated Bim were only observed 
In summary, the data in this thesis shows that iron-loaded LCN2 is pro-
apoptotic in vitro. Also, the great elevation of LCN2 together with accumulated iron in 
the lesioned area may promote the formation of holo-LCN2 (LCN2:Fe:sid
have an obligatory role in these biological processes. Thus it is important to keep in 
undergo Bim-mediated apoptosis. There are also other pro-apoptotic factors other 
specific to LCN2R-expressing neurons, interventions can target the pathway to 
ameliorate the neuronal loss in neurodegeneration. 
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 Having established that holo-LCN2 induces Bim-mediated apoptosis, more 
work has to be done to provide more evidence for this proposed mechanism. Firstly, 
siRNA-mediated silencing of LCN2R in the primary hippocampal neurons will help to 
also required for the receptor-mediated endocytosis and exocytosis of LCN2 by using 
AlexaFluor-labelled LCN2 to treat the primary neurons, together with immunolabelling 
sugges
Furthermore, to validate the cellular localisation of Bim and LCN2R after KA 
done. Although apo- and holo-LCN2 was detected to interact with LCN2R expressed 
on the primary neurons, it would be useful to demonstrate that LCN2 interacts with 
 More importantly, further investigations have to be done to elucidate the 
presence of mammalian siderophore(s) in the hippocampus. Catechols have been 
elucidated as possible mammalian siderophores with the ability to deliver iron to the 
kidneys (Bao et al., 2010). Catechols are present in the CNS in the form of 
6. 2. Future studies 
verify if the effect of holo-LCN2 on neurons is mediated by LCN2R. More evidence is 
of late/recycling endosomes markers, such as DMT1 and Rab11. Since holo-LCN2 is 
ted to induce Bim-mediated apoptosis due to influx of intracellular iron, 
intracellular iron levels could be measured using calcein assay (a cell permeable dye; 
its emission is quenched by iron binding) or deduced from the expression levels of 
iron-regulatory proteins, such as transferrin receptor 1, ferritin, and iron-regulatory 
protein 1 and 2. To examine if the increase of intracellular iron led to generation of 
ROS, ROS levels can be measured using fluorometric analysis by preloading cells 
with the non-fluorescent probe CDDHCF-DA, which is rapidly converted to the highly 
fluorescent compound CDCF-DA by ROS (Devireddy et al., 2010).  
injury, triple immunostaining of Bim, LCN2R and neuronal/microglial marker can be 
LCN2R in vivo using the Duolink assay on hippocampal sections as Duolink provides 
insights to the localisation of the interactions.  
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mine, norepinephrine and epinephrine (for chemical structures 
Appendix 1D and E
catecholamine synthesis from the conversion of tyrosine to dihydroxyphenylalanine 
(DOPA), which is the rate limiting step for catecholamine synthesis (Appendix 1E). 
TH has been shown to be expressed on hippocampal neurons in vitro (Aubert et al., 
on the primary neurons, followed by treatment of rLCN2:Fe and rLCN2. Without the 
endogenous siderophore, both treatments should produce the same effect (no 
synthesis of the iron moiety (2,5 DHBA, for chemical structure see Appendix IF) of 
the intracellular mammalian siderophore, it would be interesting if it functions as an 
same knockdown experiment can be performed for BDH2. With the elucidation of 
extracellular mammalian siderophore in vitro, more studies can be performed in vivo. 
essing activated 
microglia had the highest Bim expression but were not apoptotic. Since activated 
microglia were suggested to peak at 1 month (Jorgensen et al., 1993; Mitchell et al., 
followed by triple immunostaining of Bim, LCN2R and OX-42 at 1 month post-KA 
injection. TUNEL assay could be done to examine whether LCN2 has a Bim-
 no apoptosis is observed, the 
upregulation of Bim may have other functions in the activated microglia. 
 
catecholamines: dopa
see ). Tyrosine hydroxylase (TH) catalyses the first step in 
2001; Frotscher and Leranth, 1988). Thus, TH knockdown experiments can be done 
apoptosis). Although BDH2 has been identified as the enzyme responsible for the 
extracellular siderophore to import iron-loaded LCN2 into the neurons. Thus the 
In the present study, the effect of LCN2 on the LCN2R-expressing microglia 
was not examined. At 2 weeks post-KA injection, LCN2R-expr
1993), mRNA and protein expression of LCN2 and Bim could be investigated, 
mediated apoptotic effect on the activated microglia. If
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In conclusion, this thesis has addressed the expression and localisation of 
LCN2 and its receptor, LCN2R, after KA injury, and associated the interaction of 
LCN2 and LCN2R with Bim-mediated apoptosis. Iron status of LCN2 was shown to 
mediated apoptosis in primary neurons, which was not observed for iron-lacking 
LCN2. The pro-apoptotic effect of iron-loaded LCN2 may account for a population of 
presence of extracellular mammalian siderophore(s) in the hippocampus to assist 
LCN2 to import iron into the neurons to induce apoptosis. The understanding of the 




affect its function as interaction between iron-loaded LCN2 and LCN2R led to Bim-
cell demise in KA-induced neurodegeneration. The present study also suggests the 
role of LCN2 in the KA model could be a stepping stone to investigate the role of 
LCN2 in other neurodegenerative diseases as interventions can be targeted at the 
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-PCR analysis shows that LC(A) RT N2 mRNA expression is present in BV-2 
icroglial cell line. Reverse transcribed BV-2 cDNA was used as a template for 
CR using Go Taq Master Mix (Promega). RT-PCR was conducted with specific 
primers for the LCN2 mouse transcript (forward: 5'-ATG TCA CCT CCA TCC TGG 
TC-3', reverse: 5’-CAC ACT CAC CAC CCA TTC AG-3').  
(B) RT-PCR analysis shows that BDH2 mRNA expression is present in the right 
hippocampus of 3 individual normal animals. Rat hippocampal cDNA was used 
as a template for PCR using Go Taq Master Mix (Promega). RT-PCR was conducted 
with specific primers for the BDH2 rat transcript (forward: 5’-GAG AAC AGA TGT 
GTG TAC AGT GCA ACC-3’, reverse: 5’-CT AGG GAG GGC CTG TCT TCC AGC-
3’).  
(C) Western blot analysis indicates that BDH2 protein is present in 2 weeks 
post-KA injection hippocampal samples (R4 and R6). Membrane was probed with 
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(D) Chemical structure of catechol. 
(E) Catechols in the CNS in the form of catecholamines. Tyrosine hydroxylase 
(TH) catalyses the rate limiting step of catecholamines in their biosynthesis. Modified 
from (Siegel, 1999). 
(F) Chemical structure of 2,5-dihydroxybenzoic acid (2,5-DHBA), the iron-binding 
moiety of the mammalian siderophore identified. BDH2 catalyses the production of 
2,5-DHBA (Devireddy et al., 2010). 
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